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MI Myocardial infarction 
mmHg Millimetres of mercury 
NICE National Institute for Health and Clinical Excellence 
NO Nitric oxide 
NOS Nitric oxide synthase 
RAIx Radial augmentation index 
PDE  Phosphodiesterase 
PED Penile erectile dysfunction 
 xvi 
PKG  cGMP-dependent protein kinase 
PP Pulse pressure 
PAH  Pulmonary arterial hypertension 
PWA Pulse wave analysis 
PWV Pulse wave velocity 
SD Standard deviation 
SEM Standard error of the mean 
sGC  Soluble guanylate cyclase 
t-PA  Tissue plasminogen activator 
TRH  Treatment-resistant hypertension 
VTI Velocity time integral 




Nitric oxide is released from the endothelium and causes relaxation of vascular 
smooth muscle by stimulating guanylate cyclase to produce guanosine 3’,5’-cyclic 
monophosphate (cGMP) which, in turn, is degraded by phosphodiesterase type 5 
(PDE5). Inhibition of PDE5, with drugs like sildenafil citrate, promotes NO-
stimulated relaxation of vascular smooth muscle. The overall aim of the work 
contained within this thesis was to further characterise the systemic vascular effects 
of PDE5 inhibition. Four clinical studies were performed.  
 
The aims of the first study were to investigate in healthy men the effect of smoking 
on endothelium-dependent vasomotor function measured as the change in peripheral 
arterial wave reflection with inhaled salbutamol, and the effect of acute sildenafil 
100 mg on this response. Smokers (n=12) exhibited a reduced response to inhaled 
salbutamol compared to non-smokers (n=11) [mean(standard deviation) area under 
the curve of the change in central augmentation index following salbutamol 400 µg: 
-29(143) AU in smokers vs -159(124) AU in non-smokers, P=0.03]. In the smokers, 
there was a trend to an improvement in the response to salbutamol following 
sildenafil [-96(266) AU vs -29(143) AU with matched placebo; P=0.2].  
 
The co-administration of glyceryl trinitrate (GTN) and sildenafil is absolutely 
contraindicated because of the potential for profound hypotension. The aim of the 
second study was to characterise the time course of this interaction. Twenty men 
with stable angina, maintained on their usual medicines, were administered 
sublingual GTN 400 µg 1, 4, 6 and 8 hours after sildenafil 100 mg or matched 
placebo. Compared to the combination of GTN and placebo, the combination of 
GTN and sildenafil resulted in greater mean maximum reductions from baseline in 
sitting systolic blood pressure (BP) at 1, 4 and 8 hours, and in sitting diastolic BP at 
all time points (all P<0.05). Compared to placebo, sildenafil alone reduced systolic 
BP at 1, 4, 6 and 8 hours (P<0.01 at 1 hour and P<0.05 at 4, 6, and 8 hours) and 
diastolic BP at 4, 6, and 8 hours (all P<0.01). Analysis of the change in BP from the 
measures taken before each GTN challenge suggested that the interaction on BP 
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might be synergistic at 1 hour after sildenafil, but no more than additive at 6 and 8 
hours after sildenafil. Symptoms consistent with hypotension occurred following 
GTN in 6 subjects at 1 hour and 3 subjects at 4 hours after sildenafil, but in no 
subjects at 6 and 8 hours after sildenafil or at any time after placebo. 
 
In the third study, 25 otherwise untreated hypertensives were given sildenafil 50 mg 
or matched placebo three times daily for 16 days and the effects on ambulatory BP, 
clinic BP, arterial wave reflection, carotid-femoral pulse wave velocity and brachial 
artery flow-mediated dilatation were measured. Three subjects were withdrawn 
because of side effects and the data from the remaining 22 subjects were analysed. 
Sildenafil reduced ambulatory BP [change from baseline in average daytime BP: 
systolic -8(9) mmHg vs 2(9) mmHg with placebo, P<0.01; diastolic -6(5) mmHg vs 
0(6) mmHg, P<0.01] and clinic BP [change from baseline to 1 hour after drug 
administration on day 16: systolic -5(11) mmHg vs 4(10) mmHg, P<0.01; diastolic 
-5(5) mmHg vs 2(7) mmHg, P<0.01]. Sildenafil, but not placebo, reduced arterial 
wave reflection [central augmentation index from 32(9)% at baseline to 30(10)% at 1 
hour after administration on day 16, P<0.05; radial augmentation index from 
88(13)% to 84(13)%, P<0.01], but the change in arterial wave reflection was not 
statistically significant compared to the change with placebo. Sildenafil did not affect 
pulse wave velocity or flow-mediated dilatation. 
 
The fourth study investigated the potential of combined PDE5 inhibition and organic 
nitrate for the management of treatment-resistant hypertension (TRH). In 6 patients 
with TRH, maintained on their usual antihypertensives sildenafil 50 mg alone, 
isosorbide mononitrate (ISMN) 10 mg alone and co-administered sildenafil and 
ISMN all acutely reduced systolic BP and diastolic BP compared to placebo 
(quantified as the area under the curve of the change from baseline to 4 hours after 
drug administration; all P≤0.01). The combination produced a greater reduction in 
systolic BP than did either sildenafil alone (P=0.03) or ISMN alone (P=0.01) and a 
greater reduction in diastolic BP than did sildenafil alone (P=0.02). Compared to 
placebo, from 1 to 3 hours after drug administration BP was on average 13/10 mmHg 
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lower with sildenafil alone, 18/14 mmHg lower with ISMN alone and 26/18 mmHg 
lower with the combination. 
 
The following conclusions were made. (1) Smokers exhibit impaired vascular 
responsiveness to inhaled salbutamol, indicating systemic endothelial dysfunction, 
which may be improved by sildenafil. (2) In men with stable angina there is an 
interaction on BP reduction between sildenafil 100 mg and sublingual GTN 400 µg 
for at least 8 hours after sildenafil administration, but this interaction is no more than 
additive from 6 hours after sildenafil administration. (3) Regular sildenafil 
monotherapy reduces BP in hypertension. (4) In patients with TRH maintained on 
their usual antihypertensives sildenafil alone and ISMN alone both acutely reduce 


















1.1 THE ENDOTHELIUM AND THE NITRIC OXIDE PATHWAY 
 
1.1.1 The endothelium 
The endothelium is a single layer of cells that lines the entire vascular system. 
Although once thought to be inert, it is now considered to be an ‘organ’ that has a 
range of important functions and is highly metabolically active (Aird, 2004; Galley 
et al., 2004; Pasyk et al., 2004). Its major functions include acting as a barrier 
between blood and underlying tissues, selective transport of essential molecules, 
control of vascular tone, and regulation of haemostasis and coagulation.  
 
Endothelial control of vascular tone is effected by its production and release of a 
number of vasodilators, including nitric oxide (NO), prostacyclin, and endothelium-
derived hyperpolarising factor, and vasoconstrictor substances, including 
endothelin-1 and metabolites of arachidonic acid. The discovery of NO as an 
important and potent vasodilator was a major milestone in the history of vascular 
biology. Initially, Furchgott and Zawadzki (1980) demonstrated that relaxation of 
rabbit thoracic aorta and other blood vessels by acetylcholine (ACh) required the 
presence of endothelial cells. This suggested that ACh acted on endothelial cell 
muscarinic receptors to stimulate the production of a substance or substances, 
initially termed endothelium-derived relaxing factor (EDRF), that caused vascular 
smooth muscle relaxation. EDRF was subsequently shown to be NO (Palmer et al., 
1987).  
 
1.1.2 Endothelial NO 
NO is synthesised from the substrates arginine, NADPH and oxygen by the enzyme 
nitric oxide synthase (NOS). Of the 3 known isoforms of NOS, neuronal NOS 
(nNOS, type I) and endothelial NOS (eNOS, type III) are constitutively expressed in 
the endothelium, platelets and some neurones, and are acutely activated by 
calcium/calmodulin. They are also activated or inhibited by phosphorylation via 
various protein kinases (Stuehr, 1999). Inducible NOS (iNOS, type II) is not 
constitutively expressed, but is induced by various cytokines such as interferon-γ, IL-
1β and TNF-α, endotoxin, and oxidative stress. NO increases the Vmax of soluble 
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guanylate cyclase (sGC) ~400 fold and this enzyme catalyses the cyclisation of 
guanosine 5’-triphosphate to guanosine 3’,5’-cyclic monophosphate (cGMP; Stone et 
al., 1995). In turn, cGMP regulates cellular function largely through the activation of 
cGMP-dependent protein kinases (PKGs). There are a number of substrates for PKG 
in smooth muscle, including the regulatory myosin-binding subunit of myosin 
phosphatase (Surks et al., 1999) and calcium-activated maxi K+ channels (Fukao et 
al., 1999). Phosphorylation of these targets contributes to a reduction in intracellular 
calcium concentration, which leads to vascular smooth muscle relaxation (Hofmann 
et al., 2000; Lincoln et al., 2001). 
 
A series of experiments confirmed the central role of NO in the control of vascular 
tone in humans. Infusion of NG monomethyl-L-arginine (L-NMMA), an arginine 
analogue that inhibits NOS, into the brachial artery reduced blood flow into the 
forearm (Vallance et al., 1989), indicating that NO is continuously released by 
resistance arterioles and tonically opposes vasoconstrictor mechanisms. L-NMMA 
also inhibited ACh-stimulated vasodilatation in this study. Subsequently, the role of 
NO in regulating systemic blood pressure (BP) was established when intravenous 
infusion of L-NMMA was shown to increase systemic vascular resistance and BP 
(Haynes et al., 1993a; Haynes et al., 1993b; Stamler et al., 1994). Although the 
control of vascular tone is a major function of endothelium-derived NO, it also has a 
number of other important anti-thrombotic and anti-atherosclerotic properties, 
including inhibition of platelet activation and adhesion, leukocyte adhesion and 
migration into the subendothelial space, and vascular smooth muscle proliferation 
(Naseem, 2005). 
 
1.1.3 Cyclic GMP-specific, cGMP-binding phosphodiesterase 5  
The phosphodiesterases (PDEs) are enzymes that degrade cGMP and the related 
second messenger cyclic adenosine 3’,5’-monophosphate. Of the 11 known 
mammalian PDE gene families, the cGMP-specific, cGMP-binding PDE5 is the 
major cGMP-hydrolysing PDE in arterial smooth muscle under basal (i.e. low 
calcium) conditions, although under activated, high calcium, conditions PDE1 is 
probably also important (Beavo, 1995; Matsumoto et al., 2003; Rybalkin et al., 
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2003b). PDE5 is also abundant in platelets and other tissues (Lin et al., 2003; Wallis 
et al., 1999). 
 
Intracellular cGMP concentrations are tightly controlled by PDE5 through a range of 
negative feedback mechanisms. Catalytic activity is increased by mass action with 
elevated cGMP concentration and by binding of cGMP to allosteric sites. Binding of 
cGMP to the catalytic site also increases cGMP binding to the allosteric sites. 
Furthermore, activated PKG phosphorylates PDE5 and enhances both its catalytic 
activity and binding of cGMP at allosteric sites (Corbin et al., 2003; Corbin et al., 
2000; Mullershausen et al., 2001; Rybalkin et al., 2002; Rybalkin et al., 2003a). 
 
 
1.2 INHIBITION OF PDE5 
 
1.2.1 A treatment for penile erectile dysfunction 
Inhibitors of PDE5 slow the breakdown of cGMP and thus increase its intracellular 
concentration, with the consequence that NO-mediated cellular responses, such as 
vascular smooth muscle relaxation, are promoted. Currently, the major clinical 
indication for PDE5 inhibitors is penile erectile dysfunction (PED). Normal penile 
erection is dependent upon relaxation of vascular and sinusoidal smooth muscle in 
the corpora cavernosa which leads to the penis becoming engorged with blood. The 
stimulus to this is provided by NO released from both neurones and the endothelium. 
As elsewhere in the vasculature, NO stimulates the production of cGMP, which is 
subsequently hydrolysed by PDE5. By stimulating vascular relaxation within the 
corpora cavernosa during sexual stimulation, inhibitors of PDE5 promote penile 
erection and have proved to be a highly successful treatment of PED (Carson et al., 
2005; Setter et al., 2005).  
 
1.2.2 The PDE5 inhibitors 
Sildenafil is a potent inhibitor of PDE5 (IC50 of 3.9 nM) that is >1000-fold more 
selective for PDE5 than for PDE2, PDE3 and PDE4. It is moderately selective (>80-
fold) over PDE1 but only around 10 times as potent for PDE5 as for PDE6. 
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Following oral administration, sildenafil is rapidly absorbed, reaching peak plasma 
concentrations within 1 hour (range 0.5 to 2 hours; Jackson et al., 1999; Milligan et 
al., 2002). Although 92% of sildenafil is absorbed the mean absolute bioavailability 
is around 38-41%, indicating substantial gut wall and hepatic first-pass metabolism 
(Milligan et al., 2002; Nichols et al., 2002; Walker et al., 1999). For oral doses up to 
200 mg the relationship between dose and systemic exposure is approximately linear, 
with increases in Cmax and area under the curve (AUC) of concentration over time of 
2.2 and 2.1 respectively with doubling of dose (Nichols et al., 2002). Sildenafil is 
extensively metabolised, with no unchanged drug being detected in either urine or 
faeces. Following oral administration, metabolites are mainly excreted in faeces (73-
88%) and to a lesser extent in urine (6-15%). Sildenafil is predominantly metabolised 
by the cytochrome P450 enzyme CYP3A4, although CYP2C9 also contributes. The 
main circulating metabolite, N-desmethyl sildenafil, reaches tmax 1.4 hours after oral 
administration, has 50% of the potency of sildenafil with regard to inhibition of 
PDE5 and accounts for around 20% of the pharmacological effects.  
 
As would be expected, inhibitors of CYP3A4, including erythromycin (Muirhead et 
al., 2002a) and the protease inhibitors ritonavir and saquinavir (Muirhead et al., 
2000) increase the AUC and Cmax of sildenafil. Grapefruit juice, a further inhibitor of 
CYP3A4, increases the AUC but does not affect Cmax (Jetter et al., 2002). Co-
administration of CYP2C9 inhibitors, including tolbutamide and warfarin, do not 
affect the pharmacokinetics of sildenafil (Gupta et al., 2005). Clearance of sildenafil 
is reduced in the healthy elderly (≥65 years) and in subjects with liver or severe renal 
dysfunction (Muirhead et al., 2002b).  
 
In addition to sildenafil there are now two further licensed specific PDE5 inhibitors. 
Selectivity of vardenafil for PDE5 is >1000-fold over PDE2-4 and 7-10, >300-fold 
over PDE11, >130-fold over PDE1 and >15-fold over PDE6 (Gupta et al., 2005). 
Selectivity of tadalafil for PDE5 is >9,000-fold over PDE1-4 and 7-10, >700-fold 
over PDE6 and >5-fold over PDE11 (Curran et al., 2003). A comparison of the 
pharmacological properties of sildenafil, vardenafil and tadalafil is given in Table 
1.1. With respect to the treatment of PED there are no clear differences in efficacy 
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between the 3 available PDE5 inhibitors, although the longer duration of action of 
tadalafil may facilitate greater spontaneity in sexual intercourse. 
 
The main side effects of the PDE5 inhibitors are dyspepsia, vomiting, headache, 
flushing, dizziness, raised intra-ocular pressure, and nasal congestion. Disturbance of 
colour vision can also occur. This is probably due to inhibition of PDE6 in 
photoreceptors of the retina (Boolell et al., 1996; Cheitlin et al., 1999) and appears to 
occur more commonly with sildenafil (Setter et al., 2005). Myalgia and back pain 
have also been reported as side effects of the PDE5 inhibitors, especially with 
tadalafil (Setter et al., 2005). 
 
Sildenafil, made and marketed by Pfizer Inc. as Viagra® (Figure 1.1), was the first 
widely available, convenient and effective treatment of PED. As a treatment for a 
disorder of sexual function it rapidly became known throughout the world and is 
established as an icon of the early 21st century. Following its introduction, PED was 
transformed from a condition that was barely spoken about to one that was widely 
acknowledged and treated pharmacologically. Viagra has been the subject of 
countless jokes and cartoons (Figure 1.1), and has even sparked debate on the 
potential consequences of medicalising sexual function (Potts et al., 2004), and on 
the nature of so-called “lifestyle drugs” and how healthcare systems should deal with 
them (Flower, 2004).  
 
                         
 
Figure 1.1. The highly characteristic blue, diamond-shaped Viagra tablet and a 
Viagra joke from the print media. 





 Sildenafil Vardenafil Tadalafil 
tmax, h (range) 1 (0.5-2) 0.7 (0.25-3) 2 (0.5-6) 
t1/2, h 3-5 4-5 17.5 
Renal excretion, % <1 1 <0.3 
Active metabolite N-desmethyl sildenafil 
- 50% potency 
- 20% contribution to activity 
N-desethyl vardenafil 
- 28% activity 
- 7% contribution to activity 
None 














No significant effect 
Protein binding, % 96 93-95 94 
IC50 for PDE5, nM  3.9 0.1-0.7 0.94 
 




1.3 HYPERTENSION AND THE EFFECT OF PDE5 INHIBITION ON BP 
 
1.3.1 Hypertension 
In middle and old age there is a direct relationship between increasing BP, whether 
systolic or diastolic, and the risk of death due to coronary artery disease (CAD), 
death due to stroke and overall mortality, with no evidence of a threshold down to at 
least 115/75 mmHg (Prospective Studies Collaboration, 2002). As a cause of global 
disease burden, high BP ranks 3rd, behind underweight and unsafe sex and ahead of 
tobacco, alcohol and unsafe water, sanitation and hygiene (Ezzati et al., 2002). In the 
UK (North of England Hypertension Guideline Development Group, 2004; Williams 
et al., 2004), Europe (European Society of Hypertension & European Society of 
Cardiology, 2003) and the USA (Chobanian et al., 2003a) hypertension is defined as 
a systolic BP ≥140 mmHg or a diastolic BP ≥90 mmHg. BP can vary substantially 
within individuals and there is increasing evidence that values obtained during 
ambulatory recording of BP (ABPM), for example over 24 hours, better predict the 
risk of cardiovascular disease than do values obtained in the clinic (Clement et al., 
2003; Hansen et al., 2005). ABPM values are often lower than clinic values and, as a 
result, lower BP thresholds should be used to diagnose hypertension. 
 
A number of lifestyle interventions, including weight reduction, a diet that is rich in 
fruit and vegetables and low in saturated fat and salt, physical exercise and reduction 
in alcohol consumption, can reduce BP in hypertension (Williams et al., 2004). 
Although these interventions should be widely recommended to patients with 
hypertension, antihypertensive drug therapy is often required to control BP. There 
are 5 major classes of antihypertensives: thiazide/thiazide-like diuretics, ß-
adrenoreceptor antagonists (ß-blockers), calcium channel blockers (CCBs), 
angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor (type 
AT1) antagonists (ARAs). In recent years there has been much interest in whether or 
not each of these drug classes are equivalent in their ability to reduce cardiovascular 
events when used to lower BP. A major meta-analysis from the Blood Pressure 
Lowering Trialists Collaboration (2003), which included data from 29 randomised 
trials involving 162,341 subjects, found no differences in total major cardiovascular 
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events between treatment regimes based on the major antihypertensive classes and 
also that larger reductions in BP produced larger reductions in risk. However, since 
then the waters have been somewhat muddied. First, a further meta-analysis 
suggested that ß-blockers may be less effective in preventing stroke than other agents 
(Lindholm et al., 2005). Second, the Anglo-Scandinavian Cardiac Outcomes Trial-
Blood Pressure Lowering Arm (ASCOT-BPLA) was published (Dahlöf et al., 2005). 
In this study (n = 19,257), atenolol with bendroflumethiazide added as required was 
compared to amlodipine with perindopril as required. While there was no statistical 
difference between the 2 regimens in the primary endpoint of nonfatal myocardial 
infarction and fatal CAD, in the amlodipine/perindopril arm there were lower 
incidences of stroke, total cardiovascular events and procedures, and all-cause 
mortality. Interpretation of this study is difficult because average achieved BP was 
lower in the CCB/ACE inhibitor arm. While the authors suggested that the difference 
in BP control did not fully account for the difference in event rates (Poulter et al., 
2005), this has been disputed (Staessen et al., 2005). ASCOT-BPLA also found that 
treatment with atenolol/bendroflumethiazide was associated with a much higher rate 
of new-onset diabetes and, at least for this reason, thiazide/ß-blocker combinations 
should probably be avoided wherever possible. 
 
All major hypertension treatment guidelines give targets for BP control. In the UK, 
the British Hypertension Society (BHS) target is ≤140/85 mmHg (Williams et al., 
2004) and the National Institute for Health and Clinical Excellence (NICE) target is 
≤140/90 mmHg (North of England Hypertension Guideline Development Group, 
2004). Unfortunately, control of hypertension to these targets in the population is 
poor (Table 1.2) The reasons for this are numerous, and include poor concordance 
with treatment, the use of suboptimal drug doses and combinations, and poor 
clinician persistence. It is now recognised that achieving target BP will require a 
combination of 2 or more antihypertensive drugs in most patients (Black et al., 2001; 











160/95  England 58 52 38 73 
 USA 88 78 66 84 
      
140/90 England 36 25 10 40 
 USA 69 53 29 55 
 
Table 1.2. Rates of hypertension awareness, treatment and control in the 
population and control in treated hypertensives. 
Values are shown for 2 different BP thresholds, 160/95 mmHg and 140/90 mmHg. 




1.3.2 PDE5 inhibitors and systemic BP 
1.3.2.1 Effect of sildenafil on BP in healthy subjects 
Given that NO-mediated vasodilatation contributes a tonic negative influence on 
systemic BP, enhancement of this endogenous effect of NO through PDE5 inhibition 
might be expected to reduce BP. The effect of single doses of PDE5 inhibitors, in 
particular sildenafil, on BP have been extensively investigated. Jackson et al (1999) 
investigated the haemodynamic effects of sildenafil in healthy men and found that 
sildenafil increased forearm blood flow when infused into the brachial artery, 
indicating that it is an arterial vasodilator in man. When given intravenously, 
sildenafil reduced systemic vascular resistance and BP. The mean reduction in BP 
with 80 mg sildenafil, measured at the end of the 40-minute infusion, was 9/7 mmHg 
compared to placebo. Following oral administration of single doses up to 200 mg the 
mean maximum reduction in BP was 10/7 mmHg, which was similar to the effect of 
100 mg orally in a further study in healthy subjects (Zusman et al., 1999). In the 
latter study BP had returned to normal by 8 hours after administration. In both of 
these studies there was no clear relationship between the dose of sildenafil and the 
magnitude of the reduction in BP. In addition, sildenafil did not affect heart rate 
(HR) or the BP response to standing. However, an acute reduction in BP with 
sildenafil has not been consistently demonstrated in healthy people. In a study by 
Schalcher et al (2002), which was not placebo controlled, oral sildenafil 50 mg 
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increased BP by 3/2 mmHg and HR by 4 beats per minute (bpm). Systemic 
administration of sildenafil also increased forearm blood flow and reduced forearm 
vascular resistance in this study, suggesting that sildenafil-induced peripheral 
vasodilatation was compensated for by a baroreceptor-mediated increase in HR, thus 
increasing cardiac output and maintaining BP. No effect on BP or HR of oral 
sildenafil 50 mg was observed by Dishy et al, either in healthy smokers (2004) or in 
healthy non-smokers (2001). 
 
1.3.2.2 Effect of sildenafil on BP in patients with hypertension and 
cardiovascular disease 
In a single-blind study Mahmud et al (2001) investigated the effect of a single oral 
dose of sildenafil 50 mg on BP in 8 hypertensive patients with PED and well 
controlled BP. The mean maximum reduction in BP was 24/8 mmHg with sildenafil 
and 6/3 mmHg with placebo. At 75 minutes BP was 17/11 mmHg lower with 
sildenafil than with placebo. However, interpretation of this data in terms of the 
‘pure’ effect of sildenafil on BP in hypertension is difficult. In addition to PED and 
hypertension, some subjects had other comorbid conditions including 
cerebrovascular disease, atrial fibrillation and diabetes. Furthermore, the subjects 
were taking up to 5 antihypertensives, such that interactions with other agents may 
have been important in mediating the substantial observed effect on BP.  
 
Vardi et al (2002) investigated the effect of single dose sildenafil 100 mg on 
ambulatory BP measured over 6 hours, from 21:00 to 03:00. Compared to an 
equivalent control period, mean BP was reduced by 9/6 mmHg in hypertensives and 
by 4/4 mmHg in normotensives, although this apparent difference between the 
groups was not statistically significant. As with the above study, the hypertensives 
were receiving antihypertensive drugs and drug interactions may have partly 
accounted for the slightly greater effect in this group. In addition, the study was not 
blinded, randomised or placebo-controlled. There was a suggestion that BP reduction 
may have been greater in older subjects. In patients with hypertension taking 
amlodipine 5 mg or 10 mg monotherapy the mean maximum change in supine BP 
was -17/-8 mmHg with sildenafil 100 mg compared to -9/-2 mmHg with placebo 
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(Webb et al., 1999). In this study the greatest decreases in BP with sildenafil tended 
to occur in those subjects with the highest baseline BP values, a phenomenon that is 
well characterised with other antihypertensives (Hulthen et al., 1982; Shen et al., 
1975; Shepherd, 1988; Shepherd et al., 1991).  
 
Zusman et al (2000) examined the effect of sildenafil on BP in a post-hoc 
subanalysis of 5 prospective, randomised, double-blind, placebo-controlled studies in 
men with PED. BP was measured between 1 and 6 hours after sildenafil (25 to 200 
mg) or placebo. Out of a total of 1685 men with PED, there were complete data for 
608 men who were taking one or more antihypertensives. In these subjects the mean 
reduction in BP was -3.6/-1.9 mmHg with sildenafil and -0.8/-0.1 mmHg with 
placebo. In the subjects not taking any antihypertensives the mean reduction in BP 
was -2.2/2.0 mmHg with sildenafil and -0.1/0.4 mmHg with placebo.  
 
Other studies have investigated the effects on BP of sildenafil in patients with CAD. 
In an open-label, non-placebo controlled study, in which 8 patients were withdrawn 
from antianginals, vasodilators and diuretics for 48 hours before dosing, intravenous 
sildenafil 40 mg reduced invasively measured BP by 9/8 mmHg (Jackson et al., 
1999). In 24 patients with CAD (12 also hypertensive), in whom all medicines were 
discontinued for at least 5 half-lives prior to study, oral sildenafil 100 mg reduced BP 
by 12/9 mmHg (Halcox et al., 2002a). In subjects undergoing diagnostic coronary 
angiography, a majority of whom had angiographically proven CAD, neither oral 
sildenafil 50 mg (Manfroi et al., 2003) or 100 mg (Halcox et al., 2002a) had any 
effect on invasively measured BP. In 14 men with severe CAD, who were taking 
their normal medicines except for nitrates, invasively-measured aortic BP fell by 
10/5 mmHg 1 hour after oral sildenafil 100 mg (Herrmann et al., 2000). 
 
1.3.2.3 Effects of vardenafil and tadalafil on BP 
The effects of vardenafil and tadalafil on BP have been much less extensively 
investigated than have the effects of sildenafil. Vardenafil 10 mg reduced BP by 6/5 
mmHg compared to placebo in men with stable CAD (Thadani et al., 2002) and by 
up to 8/7 mmHg in men with PED (Pomara et al., 2004). Compared to placebo, 
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single doses of tadalafil 20 mg had no effect on systolic BP but reduced diastolic BP 
by around 5 mmHg in healthy subjects (Kloner et al., 2003b). There was no effect on 
BP after 26 weeks of once daily tadalafil 20 mg in healthy men or men with mild 
PED (Kloner et al., 2003b). In patients with CAD tadalafil 10 mg reduced BP by 7/4 
mmHg (Kloner et al., 2003b). In subjects regularly taking a single antihypertensive 
drug it reduced BP by up to 8/4 mmHg compared to placebo (Kloner et al., 2003c). 
 
1.3.2.4 Summary of the data on the effects of PDE5 inhibitors on BP 
Most of the work on the effect on BP of PDE5 inhibitors, predominantly sildenafil, 
in hypertensives, has largely arisen through concerns of potentially hazardous 
reductions in BP in men taking these drugs for PED, particularly when taken with 
other drugs that reduce BP. With the exception of the interaction with NO donor 
drugs (see section 1.3.3), in this regard the data are reassuring that the effects on BP 
are no more than moderate and are unlikely to be of significance in terms of clinical 
safety. However, the effect on BP of PDE5 inhibition alone for the treatment of 
hypertension has not been investigated, either in single-dose or in chronic dosing 
studies.  
 
1.3.3 PDE5 inhibitors with organic nitrates and α-adrenoreceptor antagonists 
Organic nitrates, such as glyceryl trinitrate (GTN) and isosorbide mononitrate 
(ISMN), are commonly used to treat angina and heart failure. These drugs dilate 
arteries and veins through their action as NO donors and, given alone, reduce 
systemic BP. Although PDE5 inhibitors have no more than moderate effects on BP 
when administered alone, the simultaneous provision of exogenous NO from organic 
nitrates and inhibition of cGMP breakdown with PDE5 inhibition can result in 
substantial BP reduction. This interaction has been demonstrated for sildenafil in 
healthy subjects with GTN (Webb et al., 1999) and in men with angina with both 
GTN (Figure 1.2) and ISMN (Webb et al., 1999; Webb et al., 2000), and for tadalafil 
(Kloner et al., 2003a) and vardenafil (Summary of product characteristics for 
Levitra, 2005) in healthy subjects with GTN. The combined use of organic nitrates 
and PDE5 inhibitors is absolutely contraindicated because of the potential for harm 
from hypotension. For sildenafil, the American College of Cardiology and the 
14 14 
American Heart Association have, in a consensus document, recommended that 
sildenafil and organic nitrates are not co-administered within 24 hours of one another 
(Cheitlin et al., 1999).  
 
 













Figure 1.2. Effect of combined sildenafil and GTN on BP in men with stable 
angina. 
Subjects were given GTN 500 µg sublingually 1 hour after sildenafil 50 mg or 
matched placebo. Sitting BP was measured at regular intervals for 6 hours after GTN 
and the maximum decrease in BP during this time was recorded. Error bars are lower 




There is also evidence of an interaction on BP between PDE5 inhibitors and α-
adrenoreceptor antagonists (Kloner, 2005). However, the effects on BP are not as 
potentially dramatic as with the combination of PDE5 inhibitors and organic nitrates. 
PDE5 inhibitors and α-adrenoreceptor antagonists are not absolutely contraindicated 




1.4 ARTERIAL STIFFNESS, ARTERIAL WAVE REFLECTION AND THE 
EFFECT OF PDE5 INHIBITION 
 
1.4.1 Arterial stiffness and arterial wave reflection 
Data from the Framingham Heart Study have shown that diastolic BP increases until 
middle age and then tends to fall, whereas systolic BP and pulse pressure (PP; the 
difference between systolic BP and diastolic BP) increase continuously with age 
(Franklin et al., 1997). These changes, especially from around 50 years of age, are 
largely the result of increasing stiffness of the large arteries, such as the aorta and its 
major branches. As a result, increased large artery stiffness manifests as raised 
systolic BP.  
 
Traditionally, diastolic BP has been the major focus in the treatment of hypertension. 
However, over recent years systolic BP has become recognised as a stronger 
cardiovascular risk factor in older people, having, for example, greater predictive 
value than diastolic BP for CAD in people aged >60 years (Franklin et al., 2001b; 
Kannel et al., 1971). Isolated systolic hypertension (ISH; systolic BP ≥140 mmHg 
and DBP <90 mmHg) is the most common subtype of hypertension in middle-age 
and is overwhelmingly so in the elderly (Franklin et al., 2001a). It is a major risk 
factor for stroke (Nielsen et al., 1995), CAD (Franklin et al., 2001b; Kannel et al., 
1971), and cardiovascular and total mortality (Alli et al., 1999; Antikainen et al., 
1998). Furthermore, measurement of systolic BP alone identifies >90% of 
hypertensives, whereas diastolic BP alone identifies only ~20% (Lloyd-Jones et al., 
1999). The treatment of ISH with conventional antihypertensive drugs is of proven 
clinical benefit (SHEP Cooperative Research Group, 1991; Staessen et al., 1997). 
However, whilst it is recognised that not enough hypertensives are controlled to 
target pressures (Wolf-Maier et al., 2003), it is much more commonly systolic BP 
than diastolic BP that is not adequately controlled (Franklin et al., 2001a; Lloyd-
Jones et al., 1999).  
 
There is clearly a strong rationale for understanding the mechanisms of arterial 
stiffness to better treat ISH. In addition, other established cardiovascular risk factors 
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are also associated with increased arterial stiffness and there has been a great deal of 
interest in the extent to which more direct measures of arterial stiffness might 
improve cardiovascular risk stratification. Therapeutically targeting arterial stiffness 
might also be of benefit in the prevention and treatment of cardiovascular disease 
(Oliver et al., 2003).  
 
Windkessel theory treats the circulation as a central elastic reservoir (the large 
arteries), into which the heart pumps, and from which blood travels to the tissues 
through relatively non-elastic conduits (peripheral arteries). The elasticity of the 
proximal large arteries is the result of the high elastin to collagen ratio in their walls, 
which progressively declines towards the periphery. The increase in arterial stiffness 
that occurs with age (Hallock et al., 1937) is largely the result of progressive elastic 
fibre degeneration (Avolio et al., 1998). The elasticity of a given arterial segment is 
not constant, but depends upon its distending pressure (Greenfield et al., 1962; 
Hallock et al., 1937). As distending pressure increases there is greater recruitment of 
relatively inelastic collagen fibres (Apter, 1967; Bank et al., 1996; Roach et al., 
1957) and, consequently, a reduction in elasticity. The background level of 
distending pressure in the circulation is determined by mean arterial BP (MAP). This 
is important because MAP must be taken into account whenever measurements of 
arterial stiffness are made, so that anticipated effects of distending pressure can be 
differentiated from real differences in the elasticity of the arterial wall.  
 
Ejection of blood from the left ventricle during systole initiates an arterial pressure 
wave that travels towards the periphery. At points of impedance mismatch, chiefly at 
the high-resistance arterioles, wave reflection occurs (Nichols et al., 1998). As a 
consequence of differing elastic qualities, and wave reflection, the shape of the 
arterial waveform varies throughout the arterial tree. Whereas MAP remains virtually 
unchanged (it declines slightly), in healthy young subjects systolic BP and PP are 
amplified in the peripheral circulation (Kroeker et al., 1955). With increasing age 
this amplification is progressively reduced (Wilkinson et al., 2001a). Although 
peripheral BP is most commonly measured clinically, the information contained 
within the waveform of the proximal aorta is of particular interest because it is the 
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BP profile at this site, rather than more peripherally, that determines left ventricular 
load and coronary blood flow. The effects of increased arterial stiffness on the 
central aortic waveform and BP are illustrated in Figure 1.3. The contour and 
amplitude of the pressure waveform are influenced by large artery pulse wave 
velocity (PWV), in that faster travelling pressure waves arrive at, and are reflected 
from, the peripheral circulation earlier. When arteries are relatively compliant and 
PWV is relatively slow, reflected waves return to the central aorta in diastole, 
augmenting diastolic BP and, therefore, coronary blood flow, which occurs 
predominantly during diastole. When arteries are stiffer and PWV is higher, reflected 
waves arrive earlier and augment central systolic BP, rather than diastolic BP, 
increasing left ventricular workload and compromising coronary blood flow (Bogren 






Figure 1.3. Schematic representation of pulse pressure amplification. 
Typical pressure tracings from the brachial artery and central aorta. When the large 
arteries are compliant the arterial waveform is amplified as it travels towards the 
periphery. As the large arteries stiffen, for example with increasing age, diabetes or 
other cardiovascular risk factors, this amplification is reduced. The two subjects have 
similar BP at the brachial artery despite striking differences at the aorta, 
demonstrating the potential importance of assessing central BP. The effect of 
peripheral wave reflection on the central aortic waveform is illustrated in the lower 
tracings. When the large arteries are compliant the initial systolic pressure wave, P1, 
travelling from the heart to the periphery, is responsible for peak systolic BP. 
Reflected pressure waves, P2, arrive at the central aorta in diastole, augmenting 
diastolic BP and coronary artery filling. As large arteries stiffen, wave reflection 
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1.4.2 Measures of arterial stiffness and wave reflection 
Many methodologies, both invasive and non-invasive, have been applied to the 
assessment of arterial elasticity in vivo. Non-invasive measures fall into three broad 
groups: 1) measuring PWV, 2) relating change in diameter (or area) of an artery to 
distending pressure, and 3) assessing arterial pressure waveforms. Two of these, 
PWV and pressure waveform analysis, are used in the studies presented in this thesis. 
 
1.4.2.1 PWV 
Interest in, and measurement of, the velocity of arterial wave propagation as an index 
of vascular stiffness and vascular health, dates back to the early part of the last 
century (Bramwell et al., 1922). PWV increases with stiffness and is defined by the 








where E is Young’s modulus of the arterial wall, h is wall thickness, R is arterial 
radius at the end of diastole and ρ is blood density. There are a number of different 
ways to measure PWV and these are generally simple to perform. The arterial pulse 
wave is recorded at a proximal artery, such as the common carotid, as well as at a 
more distal artery, such as the femoral. The superficial location of the carotid and 
femoral arteries means that their pulse waveforms are readily measured non-
invasively, and between these 2 sites the pulse wave has to travel through most of the 
aorta, an artery particularly prone to the development of atherosclerosis. The time 
delay between the arrival of a predefined part of the pulse wave, such as the foot, at 
these 2 points is obtained either by simultaneous measurement, or by gating to the 
peak of the R-wave of the ECG. The distance travelled by the pulse wave is 
measured over the body surface and PWV is then calculated as distance/time (m/s). 
The measured distance is an estimate of the true distance travelled and depends to 
some extent on body habitus. Furthermore, the abdominal aorta tends to become 
more tortuous with age (Wenn et al., 1990), potentially leading to an underestimation 
of PWV. Increases in distending pressure increase PWV (Bramwell et al., 1922). 
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Therefore, account should be taken of the level of BP in studies that utilise PWV as a 
marker of cardiovascular risk or as a measure of the effects on arterial stiffness of 
interventions that reduce BP. HR has also been reported to influence PWV. In one 
study an increase in HR of 40 bpm increased PWV by >1 m/s (Lantelme et al., 
2002), a difference that may be relevant to the assessment of cardiovascular risk. 
However, it has been suggested this finding may be an artefact of the methodology 
used (Hayward et al., 2002a). 
 
Raised PWV occurs with a range of established cardiovascular risk factors (Lehmann 
et al., 1998), including age (Bramwell et al., 1923; Vaitkevicius et al., 1993), 
hypercholesterolaemia (Lehmann et al., 1992b), type II diabetes (Lehmann et al., 
1992a), and sedentary lifestyle (Vaitkevicius et al., 1993). In hypertension, carotid-
femoral PWV (CF-PWV) is an independent predictor of both cardiovascular and all-
cause mortality (Laurent et al., 2001). The odds ratio for a 5 m/s increment in PWV 
was 1.34 for all-cause mortality and 1.51 for cardiovascular mortality. It should be 
noted that 5 m/s is a relatively large change in PWV. In this study PWV ranged from 
9-13 m/s, while recently quoted values of CF-PWV in healthy individuals, with 
average ages of 24-62 years, ranged from around 6-10 m/s (O'Rourke et al., 2002). 
Differences between studies regarding the method used to calculate the distance 
travelled between the carotid and femoral sites probably explains some of the 
variation in these normal values. 
 
In hypertensives without a history of overt cardiovascular disease PWV predicts both 
coronary events (Boutouyrie et al., 2002) and stroke (Laurent et al., 2003) 
independently of classical risk factors. Blacher et al (1999a) found that an aortic 
PWV >13 m/s was a particularly strong predictor of cardiovascular mortality in 
hypertension. Effective treatment of hypertension appears to retard the rate of 
increase in PWV. Thus, CF-PWV was found to increase at a faster rate in treated 
hypertensives than in normotensive controls, but where BP was well controlled PWV 
progression was attenuated (Benetos et al., 2002). Aortic PWV, assessed using 
Doppler flow recordings, also independently predicts mortality in patients with end-
stage renal failure, a population with a particularly high rate of cardiovascular 
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disease (Blacher et al., 1999b; Pannier et al., 2005; Safar et al., 2002). The benefit 
associated with BP control in end-stage renal failure, either by adjustment of dry 
weight or the use of antihypertensives, was independently related to change in aortic 
PWV, such that a reduction in PWV of 1 m/s was associated with a relative risk of 
0.71 for all-cause mortality (Guerin et al., 2001). Aortic PWV has been shown to 
independently predict cardiovascular outcome in a number of further studies and 
these are summarised in Table 1.3. Also included in this table are 3 studies that have 
investigated the value of other measures of arterial stiffness in predicting 
cardiovascular outcome. 
 
Table 1.3. Summary of prospective studies on the value of measures of arterial 
stiffness in predicting cardiovascular events. 
 
Study Details 
  Aortic PWV  
Blacher et al (1999b) Aortic PWV independently predicted cardiovascular 
and all-cause mortality in patients with end-stage renal 
disease 
Laurent et al (2001) Aortic PWV independently predicted cardiovascular 
and all-cause mortality in patients with essential 
hypertension 
Meaume et al (2001) Aortic PWV independently predicted cardiovascular 
mortality in subjects aged 70 to 100 years 
Shoji et al (2001) Aortic PWV independently predicted cardiovascular 
and all-cause mortality in patients with end-stage renal 
disease with and without diabetes 
Boutouyrie et al (2002) Aortic PWV independently predicted coronary events 
in patients with essential hypertension 
Cruickshank et al (2002) Aortic PWV independently predicted mortality in 
diabetics and patients undergoing a glucose tolerance 
test 
Laurent et al (2003) Aortic PWV independently predicted fatal stroke in 
patients with essential hypertension 
 
Continued on next page 
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Study Details 
  Aortic PWV  
Sutton-Tyrrell et al 
(2005) 
Aortic PWV independently predicted cardiovascular 
events and mortality in generally healthy adults 
Shokawa et al (2005) Aortic PWV independently predicted cardiovascular 
mortality in a general population  
Willum Hansen et al 
(2006) 
Aortic PWV independently predicted a composite of 
cardiovascular outcomes in a general population 
Mattace-Raso et al 
(2006) 
Aortic PWV independently predicted CAD and stroke 
in a general population 
  
Ascending aorta  
Stefanadis et al (2000) Increased stiffness of the ascending aorta 
independently predicted cardiovascular events in 
patients undergoing cardiac catheterisation for CAD 
  
Carotid distensibility  
Blacher et al (1998) The carotid artery incremental modulus of elasticity 
independently predicted all-cause mortality in patients 
with end-stage renal disease 
Barenbrock et al (2002) Carotid artery distensibility independently predicted 




1.4.2.2 Arterial pressure waveform analysis 
Peripheral artery pressure waveforms can be acquired non-invasively using 
applanation tonometry, in which a highly sensitive pressure sensor, commonly 
contained within a hand-held tonometer probe, is placed on the skin overlying an 
artery (Figure 1.4). Applying sufficient pressure to slightly compress the artery 
against firm underlying structures, such as bone, produces a signal that is very 
similar to the intravascular pressure waveform inside the artery. When measured at 














A transfer function can be applied to a waveform from a peripheral artery, most 
commonly the radial, to derive a corresponding central aortic waveform, from which 
central BP values and the central aortic augmentation index (aortic AIx; Figure 1.5) 
can be calculated. This technique has been termed pulse wave analysis (PWA). 
Aortic AIx is the proportion of central PP that results from arterial wave reflection 
and is a commonly used measure of arterial stiffness. Whilst the timing of the arrival 
of the reflected wave at the proximal aorta is largely determined by large artery 
PWV, Aortic AIx is not simply a surrogate measure of PWV. It is influenced by 
vasoactive drugs independently of PWV (Kelly et al., 2001), suggesting that it is also 
determined by the intensity of wave reflection, which, in turn, is determined by the 
diameter and elasticity of small arteries and arterioles. Aortic AIx increases linearly 
with MAP, an increase of 5 mmHg being associated with an absolute increase in 
aortic AIx of around 4% (Wilkinson et al., 2001b), is inversely linearly related to 
HR, an increase of 10 bpm being associated with an absolute reduction in aortic AIx 
of around 4% (Gatzka et al., 2001; Wilkinson et al., 2000a), and is also inversely 
related to body height (Smulyan et al., 1998). PWA is simple and rapid to perform 
and has potential for use in the clinical as well as research setting. 
 
Figure 1.4. Applanation tonometry. BONE 
ARTERY 














Figure 1.5. Central aortic augmentation index (aortic AIx). 
Aortic AIx is calculated as the difference between the second (P2) and first (P1) 
systolic peaks (the augmentation pressure, AP) as a percentage of the pulse pressure 
(PP). Thus, aortic AIx is negative in healthy young people, but with aging or 
increasing cardiovascular risk arteries stiffen and aortic AIx becomes increasingly 




PWA is most commonly performed using the SphygmoCor® apparatus which is 
made by Atcor Medical (http://www.atcormedical.com). SphygmoCor uses a 
generalised transfer function (GTF) and the validity of this in determining the central 
aortic waveform has been debated in the literature. Initially, it was shown to be 
reasonably accurate in determining central aortic waveforms at rest in patients with 
CAD (Karamanoglu et al., 1993) and, in a study that measured radial waveforms 
with tonometry and aortic waveforms invasively, individualising the transfer 
function added little to the accuracy of determining central BP and aortic AIx, even 
after haemodynamic challenges such as the Valsalva manoeuvre and infusion of 
GTN (Chen et al., 1997). However, Soderstrom et al (2002) found that the GTF 
tended to underestimate aortic systolic BP by 6-8 mmHg and overestimate aortic 
diastolic BP by about 4 mmHg, and Hope et al (2002) have suggested that gender-
specific transfer functions may be more reliable than a GTF. In two studies the 
correlation coefficient of directly-measured and reconstructed aortic AIx was around 
0.66 and, in both, reconstructed aortic AIx tended to underestimate the measured 
value (Segers et al., 2000; Segers et al., 2001). Furthermore, the correlation was 






















aortic AIx obtained directly and from the reconstructed waveform was highlighted 
(Segers et al., 2001). More recently, the GTF has been shown to more accurately 
estimate central BP if the waveform is calibrated to radial artery BP rather than 
brachial artery BP, because of PP amplification between these 2 sites (Verbeke et al., 
2005). The error in constructing the central waveform from a peripheral one using a 
GTF is minimised if the peripheral waveform is calibrated to invasively, rather than 
non-invasively, measured BP (Hope et al., 2004; Wilkinson et al., 2004a). While this 
provides support for the validity of the GTF itself, it is only non-invasive BP that is 
available in clinical practice.  
 
It may not even be necessary to determine the central aortic pressure waveform at all. 
Peripheral artery waveforms, such as the radial, are also characterised by an 
inflection point that relates to pressure wave reflection (see Figure 1.3). Hope et al 
(2004) have recently demonstrated that many characteristics of the radial artery 
waveform, including AIx, are similarly or more closely correlated with the 
equivalent characteristics of the aortic waveform than are values derived using a 
GTF. Millasseau et al (2003) also found a high degree of correlation between derived 
aortic AIx and radial AIx (RAIx) and also found that GTN and norepinephrine 
produced parallel changes in each of these. Thus, RAIx might provide as much 
information on cardiovascular prognosis or the haemodynamic effects of 
interventions as does aortic AIx derived using a GTF, with the advantage that 
simpler and less expensive equipment would be required. 
 
Aortic AIx increases with age (Cameron et al., 1998; Hayward et al., 1997; Kelly et 
al., 1989; McEniery et al., 2005) and, compared to matched controls, is also higher 
in patients with type I diabetes (Wilkinson et al., 2000b) and hypercholesterolaemia 
(Wilkinson et al., 2002b), despite similar peripheral BP. Compared to PWV, there 
are relatively few data on the value of aortic AIx in predicting cardiovascular 
outcome. In a cross-sectional analysis non-invasively determined aortic AIx was an 
independent predictor of the presence of premature CAD at angiography (Weber et 
al., 2004). In a prospective study of subjects with established CAD, invasively 
measured aortic AIx independently predicted a combined endpoint of acute coronary 
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events, stroke or death (Chirinos et al., 2005). Non-invasively determined aortic AIx, 
corrected for HR, has also been demonstrated to predict cardiovascular events in 
subjects undergoing percutaneous coronary intervention (Weber et al., 2005). AIx 
can also be directly measured, using applanation tonometry, relatively close to the 
central aorta, at the carotid artery. High carotid AIx is an independent predictor both 
of cardiac ischemic threshold during exercise in patients with CAD (Kingwell et al., 
2002) and of all-cause and cardiovascular mortality in patients with ESRF (London 
et al., 2001). Of particular note from the latter study, carotid AIx predicted mortality 
even in patients considered to have a normal PWV (<11 m/s), highlighting the 
importance of assessing arterial wave reflection, rather than just arterial stiffness.  
 
 
1.4.3 The effects of cardiovascular drugs on arterial stiffness 
As arterial stiffness has become established as a cardiovascular risk factor in its own 
right it has also emerged as a potential target for intervention. Indeed, it is 
conceivable that reduction of arterial stiffness may become a major primary goal of 
treatment in particular patients at risk of cardiovascular disease. However, for this 
situation to arise increased arterial stiffness will not only have to be established as an 
important independent cardiovascular risk factor, but also reducing arterial stiffness 
will need to be shown to reduce risk, independent of other effects of treatment. 
Establishing whether currently used cardiovascular drugs exert their clinical benefit 
through improvements in arterial elasticity may lead to more appropriate targeting of 
these treatments. However, many of these agents also lower BP and this effect must 
be differentiated from any intrinsic effects, either structural or functional, on arterial 
wall stiffness.  
 
The effects of organic nitrates, especially GTN, on the central aortic waveform have 
been well characterised. GTN can reduce aortic AIx and central systolic BP and PP 
at doses that have little or no effect on peripheral arterial resistance, peripheral BP, or 
aortic PWV (Fitchett et al., 1988; Kelly et al., 1990; Yaginuma et al., 1986). This 
effect is probably the result of reduced peripheral wave reflection due to dilatation of 
muscular conduit arteries (Bank et al., 1999; Jiang et al., 2002).  
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β-blockers appear to reduce large artery stiffness, but their effects on arterial wave 
reflection and the central arterial waveform are less favourable. After six months 
treatment in hypertensives, atenolol was as effective as the ACE inhibitor cilazapril 
in increasing aortic elasticity (Savolainen et al., 1996). However, atenolol was less 
effective than either fosinopril, after eight weeks treatment (Chen et al., 1995), or 
perindopril, after one month of treatment (Pannier et al., 2001), in lowering directly-
measured carotid AIx. In a further study, treatment for 1 year with atenolol or 
perindopril/indapamide similarly reduced aortic PWV but only the ACE 
inhibitor/diuretic combination reduced carotid AIx (Asmar et al., 2001). As a 
confounding variable, HR reduction with β-blockade largely accounts for these 
differences, which may, at least in part, explain why β-blockers appear to be less 
effective than the other major antihypertensive classes in the prevention of 
cardiovascular events in the treatment of hypertension (see section 1.3.1).  
 
CCBs, ACE inhibitors and HMG-CoA reductase inhibitors (statins) also appear to 
have beneficial effects on arterial elasticity independent of effects on distending 
pressure, whereas there are conflicting data on the effects of diuretics (for full 
discussion see Oliver et al., 2003).  
 
 
1.4.4 Effect of PDE5 inhibition on arterial stiffness and wave reflection  
PDE5 inhibitors might be expected to have organic nitrate-like properties on arterial 
wave reflection and aortic AIx, given that both increase vascular smooth muscle 
cGMP concentrations. In the study by Mahmud et al (2001) in which sildenafil 50 
mg reduced BP in treated hypertensives (see section 1.3.2.2) there was also a 
reduction in aortic AIx. However, it is likely that the reduction in systemic BP that 
was observed fully accounted for the effects on aortic AIx. In hypertensive cardiac 
transplant patients in whom normal medicines were not withdrawn prior to study, 
sildenafil reduced aortic AIx by a mean maximum 7.5% (Schofield et al., 2003). 
MAP was reduced by 9 mmHg, which, once again, is probably sufficient to account 
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for the effect on aortic AIx. There was no placebo comparator in this study. In men 
with CAD (mean age 69 years) who had been withdrawn from vasoactive drugs for 
24 hours, in comparison to placebo sildenafil 50 mg acutely reduced aortic PWV by 
~0.4 m/s and aortic AIx by 2-3% (Vlachopoulos et al., 2003). The effect on PWV 
was statistically independent of the effects on systemic BP (reduction of ~10/9 
mmHg compared to placebo) leading the authors to conclude that sildenafil reduced 
stiffness through an active effect on the aortic wall. The same authors also found that 
sildenafil 50 mg acutely reduced aortic PWV in patients with heart failure, again 
statistically independently of the reduction in systemic BP that was also observed 
(Hirata et al., 2005). There was also a reduction in aortic AIx. The patients in this 
study were withdrawn from vasoactive medicines for only 12 hours. Therefore, the 
effects of sildenafil on arterial stiffness and wave reflection have only been 
investigated in single dose studies in which interactions with other drugs may have 
contributed to the observed effects. There have been no studies on the effects of 
tadalafil or vardenafil on arterial stiffness or wave reflection.  
 
 
1.5 ENDOTHELIAL DYSFUNCTION 
 
1.5.1 Measuring endothelial function 
Impairment of the physiological function of the endothelium, commonly referred to 
as endothelial dysfunction, has become recognised as a key step in the development 
of atherosclerosis, the progression of atherosclerotic plaque and also in 
atherosclerotic complications (Bonetti et al., 2003). A major characteristic of 
endothelial dysfunction is a reduction in the production and release of NO by the 
endothelium (Kuvin et al., 2003; Vogel, 2003). This can be assessed in vivo by 
methodologies that indirectly quantify the amount of NO production as the degree of 
vasodilatation that occurs when endothelial NO is stimulated.  
 
Local infusion of a substance that stimulates endothelial NO production and 
measurement of the vasodilatation that results is the gold standard in endothelium-
dependent vasomotor function assessment. Suitable substances include ACh and 
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substance P and these can be infused either into the forearm or coronary circulations 
(Ludmer et al., 1986; Newby et al., 1997; Newby et al., 2001). The degree of 
vasodilatation that occurs is quantified as the change in flow to the tissue, using 
venous occlusion plethysmography in the forearm (Wilkinson et al., 2001c) and 
either quantitative angiography or Doppler ultrasound in the coronary circulation 
(Ludmer et al., 1986; Newby et al., 2001). An impaired response to the 
“endothelium-dependent” substance could be a result of either impaired production 
and release of NO or, alternatively, impaired sensitivity of the adjacent vascular 
smooth muscle to NO. Therefore, the response to a substance that relaxes vascular 
smooth muscle directly is also measured as an “endothelium-independent” control. 
NO-donor drugs, such as GTN or sodium nitroprusside, are commonly used for this 
purpose. The major limitation of these methodologies is that they are invasive, which 
restricts their use to the research setting and, even then, to relatively small studies. 
However, non-invasive methodologies exist for the assessment of endothelium-
dependent vasomotor function and 2 of these, brachial artery flow-mediated 
dilatation (FMD) and the response of arterial wave reflection to ß2-adrenoreceptor 
stimulation, are used in the studies described in this thesis.  
 
1.5.1.1 FMD 
FMD provides a measure of conduit artery endothelium-dependent vasomotor 
function (Corretti et al., 2002; Deanfield et al., 2005). It is most commonly 
performed at the brachial artery but can also be performed at the radial, femoral and 
posterior tibial arteries. The stimulus to NO release is increased shear stress at the 
wall of the artery under study and the degree of vasodilatation is measured by 
imaging the artery directly, usually with ultrasound. For the brachial artery, the arm 
is outstretched perpendicular to the body and a longitudinal image of the artery is 
obtained just above the elbow. The ultrasound probe is then held in place with a 
clamp for the remainder of the study. After recording the artery for a period at 
baseline, a BP cuff placed around the upper forearm, i.e. distal to the site of 
measurement, is inflated to above systolic BP to occlude blood flow into the forearm. 
The cuff remains inflated for 5 minutes and during this time the forearm vascular bed 
vasodilates considerably. As a result, when the cuff pressure is released there is a 
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high rate of blood flow into the forearm (reactive hyperaemia). The increased flow 
increases shear stress at the brachial artery wall which stimulates NOS to produce 
NO that, in turn, dilates the artery. Thus, the extent of dilatation in response to 
reactive hyperaemia provides a measure of endothelium-dependent vasomotor 
function. After a short rest period to allow the artery to recover, GTN can be given 
(sublingually) as an endothelium-independent control. The flow stimulus is 
quantified as the Doppler flow signal in the artery under study. 
 
L-NMMA has no effect on the extent of reactive hyperaemia but abolishes FMD, 
indicating the NO-dependence of the response (Doshi et al., 2001; Joannides et al., 
1995). A number of studies have found that brachial artery FMD correlates with 
responses to ACh in the coronary circulation (Anderson et al., 1995; Teragawa et al., 
2005). However, in a large population study of elderly subjects there was no 
correlation between brachial artery FMD and responses to ACh in the forearm (Lind 
et al., 2005). Depressed FMD has been demonstrated both in subjects with 
atherosclerosis and in subjects with cardiovascular risk factors (Brunner et al., 2005; 
Celermajer et al., 1996; Celermajer et al., 1992; Celermajer et al., 1994). In most of 
the studies demonstrating impaired FMD in particular populations GTN responses 
have generally been reported to be preserved. However, on closer inspection of many 
of these studies there is a tendency, albeit not statistically significant, for GTN 
responses to actually be slightly reduced. Indeed, in a large study (n=800) of 
asymptomatic subjects, reduced FMD was independently associated with reduced 
response to GTN, indicating a degree of vascular smooth muscle dysfunction as well 
as reduced endothelium-dependent vasomotor function (Adams et al., 1998). 
Although non-invasive, FMD is technically challenging and operators need to be 
properly trained. For this reason, its use is likely to be confined to research. 
 
1.5.1.2 ß2-adrenoreceptor agonist-induced reduction in arterial wave reflection 
The ß2-adrenoreceptor agonist salbutamol is a vasodilator in the peripheral 
circulation and this response is dependent on endothelial NO synthesis (Dawes et al., 
1997). When given systemically via inhalation salbutamol reduces peripheral artery 
wave reflection and this response is also NO-dependent (Chowienczyk et al., 1999; 
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Hayward et al., 2002b; Wilkinson et al., 2002a). Therefore, measurement of the 
change in arterial wave reflection with inhaled ß2-adrenoreceptor agonists has 
potential as a simple, non-invasive methodology for assessing endothelium-
dependent vasomotor function that could be used in large scale population studies 
and possibly even in clinical practice. This methodology was first described by 
Chowienczyk et al (1999) in a study in which salbutamol was shown to reduce the 
height of the inflection point on the digital volume pulse obtained by 
photoplethysmography. Subsequently, salbutamol was shown to reduce aortic AIx 
(Wilkinson et al., 2002a) and RAIx (Hayward et al., 2002b). As with FMD, GTN 
can be given sublingually as an endothelium-independent control.  
 
Blunted responses to inhaled salbutamol have been demonstrated in subjects with 
type II diabetes (Chowienczyk et al., 1999), hypercholesterolaemia (Wilkinson et al., 
2002a), and CAD (Hayward et al., 2002b). GTN responses were not significantly 
impaired in these subjects, although in CAD patients there was a trend to a blunted 
response of RAIx to GTN which was almost statistically significant (P = 0.07). This 
study compared 12 CAD patients with 10 controls and it is possible that if the sample 
had been larger a statistically significant difference in GTN responses would have 
been observed.  
 
Several further studies, all of which measured the effects on aortic AIx, have been 
reported. Wykretowicz et al (2005) found that the response to salbutamol was 
blunted in CAD patients with newly diagnosed diabetes or impaired glucose 
tolerance compared to CAD patients with normal glucose tolerance. Salbutamol 
responses were also blunted in obese pre-menopausal women and improved after 
weight reduction (Park et al., 2005; Suh et al., 2005). Responses to both salbutamol 
and GTN were found to be blunted in chronic ambulatory peritoneal dialysis patients 
compared to haemodialysis patients (Covic et al., 2004), and responses to both 
agents also improved in haemodialysis patients following successful renal transplant 




1.5.2 Endothelium-dependent vasomotor function as a predictor of 
cardiovascular events 
Over the past few years a number of studies, although not all, have reported that the 
assessment of endothelium-dependent vasomotor function can predict the occurrence 
of cardiovascular events independently of established risk factors (these studies are 
summarised in Table 1.4). Not only do these data suggest that assessment of 
endothelial function may be of use in the stratification of cardiovascular risk in 
clinical practice, but they also lend support to the contention that endothelial 
dysfunction is important in the pathogenesis of atherosclerotic cardiovascular 
disease. 
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Table 1.4. Summary of prospective studies on the value of endothelium-
dependent vasomotor function in predicting cardiovascular events. 
 
Study Details 
  Coronary circulation  
Schachinger et al (2000) In patients undergoing diagnostic coronary 
angiography or coronary angioplasty impaired 
response to both ACh and GTN independently 
predicted cardiovascular events 
Suwaidi et al (2000) In patients with mild CAD cardiac events only 
occurred in those with severely impaired ACh 
responses  
Halcox et al (2002b) Impaired epicardial and microvascular responses to 
ACh independently predicted acute cardiovascular 
events in patients with and without CAD 
Targonski et al (2003) Impaired response to ACh independently predicted 
cerebrovascular events in patients with CAD 
von Mering et al (2004) In women undergoing diagnostic angiography 
impaired response to ACh independently predicted 
cardiovascular events 
Bugiardini et al (2004) In women with chest pain and initially normal 
coronary angiograms impaired response to ACh 
predicted the development of angiographically evident 
CAD 
  
Forearm circulation  
Perticone et al (2001) Impaired response to ACh independently predicted 
cardiovascular events in patients with never-treated 
hypertension 
Heitzer et al (2001) Impaired response to ACh independently predicted 
cardiovascular events in patients with CAD 
Fichtlscherer et al (2004) Impaired response to ACh independently predicted 
cardiovascular events in patients with recent acute 
coronary syndrome; improvement in ACh response 
predicted further event-free survival 
 
Continued on next page 
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Table 1.4  
Continued from previous page. 
 
Study Details 
  Brachial artery FMD  
Neunteufl et al (2000) Impaired FMD independently predicted cardiovascular 
events in patients with chest pain 
Gokce et al (2002b) Reduced FMD predicted cardiovascular events within 
30 days of vascular surgery 
Modena et al (2002) In hypertensives cardiovascular events were much 
more frequent in those in whom there was no 
improvement in FMD with treatment compared to 
those in whom there was an improvement 
Brevetti et al (2003) In patients with peripheral artery disease, reduced 
FMD was an independent predictor of cardiovascular 
events and added to the prognostic value of ankle-
brachial pressure index 
Chan et al (2003) In patients with significant carotid artery 
atherosclerotic plaque burden cardiovascular events 
were higher in those with impaired FMD 
Gokce et al (2003) Reduced FMD predicted cardiovascular events in 
patients with peripheral vascular disease 
Fathi et al (2004) In patients with or at increased risk of cardiovascular 
disease, reduced FMD correlated with but was not an 
independent predictor of cardiovascular events 
Rossi et al (2004) In apparently healthy postmenopausal women reduced 
FMD predicted future development of hypertension 
Frick et al (2005) FMD did not predict cardiovascular events in subjects 
undergoing coronary angiography 
Katz et al (2005) Reduced FMD independently predicted mortality in 
subjects with heart failure 
Meyer et al (2005) In patients with heart failure reduced FMD 
independently predicted worsening heart failure or 
death 
Patti et al (2005) Reduced FMD independently predicted in-stent 




1.5.3 A brief note on the wider assessment of endothelial function 
Although there have been countless clinical studies in which endothelium-dependent 
vasomotor function has been measured, it is important to remember that the 
endothelium has a range of functions in addition to the control of vasomotor tone and 
that measuring these may provide additional and novel insights into endothelial 
function and dysfunction. For example, one aspect of endothelial function in which 
there is growing clinical research interest is the stimulated release of tissue 
plasminogen activator (t-PA) from the endothelium (Oliver et al., 2005b). Reports of 
preserved endothelium-dependent vasodilatation in smokers (Pretorius et al., 2002) 
and in patients with hypertension (Hrafnkelsdóttir et al., 2004; Hrafnkelsdóttir et al., 
1998) despite reduced acute t-PA release suggest that, in some circumstances, 
reduced t-PA release may be a more sensitive marker of endothelial dysfunction. On 
the other hand hypercholesterolaemia is associated with impaired endothelium-
dependent vasodilatation, but no reduction in t-PA release (Newby et al., 2002) 
while vascular inflammation impairs endothelium-dependent vasodilatation but 
augments t-PA release (Chia et al., 2003). These findings highlight the complexity of 
vascular biology, and that it is perhaps naive to expect endothelial dysfunction to be 
expressed by a uniform phenotype irrespective of the insult. Indeed, the dominant 
use of term endothelial dysfunction to refer to endothelium- and NO-dependent 
vasodilatation seems unnecessarily restrictive and inaccurate.  
 
 
1.5.4 The endothelium as a regulator of arterial stiffness 
Endothelial dysfunction and increased arterial stiffness often co-exist in patients at 
increased risk of atherosclerotic disease, suggesting that the endothelium might 
regulate arterial stiffness. Indeed, studies showing that NO locally regulates the 
stiffness of the iliac arties of both sheep (Wilkinson et al., 2002c) and humans 
(Schmitt et al., 2005), strongly support this contention. The potential implication of 
this is that interventions that improve endothelial function, particularly the local 




1.5.5 Effects of PDE5 inhibition on endothelial function 
Given that the methodologies used to assess endothelium-dependent vasomotor 
function are essentially surrogate measures of endothelial NO release, PDE5 
inhibitors might be expected to improve these responses. Although this would not 
constitute an improvement in endothelial function as such, because release of NO 
and other elements of endothelial function would not be expected to change, it might 
nevertheless be of clinical benefit, given the general vasculoprotective actions of 
NO. 
 
The effects of sildenafil on endothelium-dependent vasomotor function have been 
assessed by a number of investigators. Halcox et al (2002a) found that it augmented 
the response to ACh in the coronary circulation but had no effect on the response to 
verapamil, an endothelium-independent control vasodilator. In this study the effect 
on brachial artery FMD was also investigated. Sildenafil did not affect peak FMD 
but did prolong the post-reactive hyperaemia dilatation. Other studies have found an 
improvement in peripheral endothelial vasomotor function with sildenafil in heart 
failure (Guazzi et al., 2004a; Guazzi et al., 2004b; Hryniewicz et al., 2005) and in 
hypertensive cardiac transplant patients (Schofield et al., 2003), whereas in healthy 
subjects it does not appear to affect endothelial responses (Dishy et al., 2001; Guazzi 
et al., 2004a; Guazzi et al., 2004b; Halcox et al., 2002a). In patients with CAD, 
systemic sildenafil did not affect either vasodilatation in response to ACh or t-PA 
release in response to substance P (Robinson et al., 2006). There are conflicting data 
on the effect of sildenafil on endothelial vasomotor function in smokers, with an 
improvement shown in two studies (Kimura et al., 2003; Vlachopoulos et al., 2004) 
but no effect in a further study (Dishy et al., 2004). Chronic administration of 
tadalafil, a longer-acting PDE5 inhibitor, improved endothelial vasomotor function 




1.6 OTHER EFFECTS OF PDE5 INHIBITION ON THE CARDIOVASCULAR 
SYSTEM 
In addition to the effects on BP, arterial stiffness and wave reflection and 
endothelium-dependent vasomotor function, the effects of PDE5 inhibition on other 
aspects of cardiovascular function have also been investigated in clinical studies.  
 
Sildenafil is a vasodilator in the pulmonary vascular bed as well as in the systemic 
circulation. In subjects with normal pulmonary artery BP the effects are mild 
(Herrmann et al., 2000; Jackson et al., 2005) but in patients with pulmonary arterial 
hypertension (PAH) substantial reductions in pulmonary artery BP occur (Michelakis 
et al., 2002). This physiological effect translates into improved functional capacity 
when sildenafil is taken regularly for PAH (Galiè et al., 2005; Michelakis et al., 
2003) and it has recently been licensed in both Europe and the USA for this 
indication. PDE5 inhibitors may also be an effective treatment for Raynaud’s 
phenomenon. A recent study found that regular sildenafil reduced the frequency and 
duration of acute attacks (Fries et al., 2005).  
 
Studies in animals have suggested that sildenafil can attenuate the myocardial 
damage associated with ischaemia-reperfusion, an effect that is dependent upon 
opening of mitochondrial ATP-sensitive K+ channels (Bremer et al., 2005). 
Sildenafil has also recently been shown to reduce ischaemia-reperfusion-induced 
endothelial dysfunction in man (Gori et al., 2005). Although further work is required, 
minimisation of ischaemia-reperfusion injury could be a further use for these drugs, 
for example in coronary artery bypass surgery (Fung et al., 2005). Sildenafil has also 
recently been shown to blunt the effects of ß-adrenoreceptor stimulation on the heart, 
which could translate into clinical benefit in conditions such as hypertension, left 
ventricular hypertrophy (LVH) and heart failure (Borlaug et al., 2005). Sildenafil 
also reduces ADP-stimulated platelet activation (Berkels et al., 2001; Halcox et al., 
2002a), although whether this translates into protection against arterial thrombosis 
clinically is not known.  
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Asymmetric dimethylarginine (ADMA) is a naturally occurring inhibitor of NO 
synthase. Circulating ADMA concentration is correlated with endothelial 
dysfunction and cardiovascular risk, although causal relationships have not yet been 
established (Vallance et al., 2004). There has been some recent interest in the effect 
of PDE5 inhibition on ADMA. In a rat model of hypercholesterolaemia-induced 
PED, chronic administration of a novel PDE5 inhibitor reduced plasma ADMA 
concentration (Kang et al., 2005). However, in men with PED there was no change 




1.7 SAFETY OF PDE5 INHIBITORS 
In the late 1990s case reports of myocardial infarction (MI) associated with sildenafil 
use prompted concern over its cardiovascular safety (Arora et al., 1999; Feenstra et 
al., 1998). However, it was recognised that patients with PED often have increased 
cardiovascular risk (Grover et al., 2006) and also that sexual intercourse itself is 
associated with a small increased risk of MI (Muller et al., 1996). Demonstration that 
sildenafil had minimal or no effect on various cardiac haemodynamic parameters in 
patients with severe CAD provided some reassurance on the drug’s safety (Herrmann 
et al., 2000). The concern that sildenafil might cause harm in the setting of the 
physical exertion of sexual activity was also somewhat allayed by a study in which 
sildenafil did not affect exercise duration or exercise-induced cardiac ischaemia in 
patients with stable CAD (Arruda-Olson et al., 2002). There are similar data for 
tadalafil (Patterson et al., 2005) and vardenafil (Thadani et al., 2002). Pooled data 
from clinical trials (Jackson et al., 2004; Mittleman et al., 2005) as well as 
prescription event monitoring data (Boshier et al., 2004; Shakir et al., 2001) have 
found no increased risk of acute MI with sildenafil or tadalafil use. Over recent years 
there have been a number of case reports of non-arteritic anterior ischaemic optic 
neuropathy, a cause of sudden onset, untreatable and irreversible visual loss, 
occurring after PDE5 inhibitor use (Pomeranz, 2006). It is not possible to determine 
if PDE5 inhibitors are a cause of this eye condition, but the Food and Drug 
Administration in the USA has advised patients to stop taking them immediately if 
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they experience sudden deterioration in vision and also to tell their doctors if they 





The overall aim of the work contained within this thesis was to further characterise 
the systemic vascular effects of PDE5 inhibition.  
 
Initially, to further develop the methodologies used in the non-invasive assessment of 
endothelium-dependent vasomotor function, studies were performed to characterise, 
in healthy subjects (chapter 3): 
1. The dose-response relationships of sublingual GTN to change in brachial artery 
diameter and change in arterial wave reflection, with a view to informing the most 
appropriate dose of sublingual GTN that should be used as a control in non-
invasive endothelial function studies. 
2. The effects of age and gender on the extent to which inhaled salbutamol reduces 
arterial wave reflection. 
3. The relationship between brachial artery FMD and the effect of inhaled 
salbutamol on arterial wave reflection. 
 
The following specific hypotheses were then investigated: 
1. Endothelium-dependent vasomotor function measured as the reduction in arterial 
wave reflection with inhaled salbutamol is impaired by smoking (chapter 4). 
2. In smokers sildenafil improves endothelium-dependent vasomotor function 
measured as the reduction in arterial wave reflection with inhaled salbutamol 
(chapter 4).  
3. The interaction of the hypotensive effects of sildenafil (100 mg) and sublingual 
GTN (400 µg spray) is limited to within 8 hours of giving sildenafil in a group of 
typical male patients with stable angina (chapter 5). 
4. Compared to placebo, regular administration of sildenafil reduces BP, arterial 
stiffness and arterial wave reflection, and improves endothelium-dependent 
vasomotor function in otherwise untreated hypertensive patients (chapter 6). 
5. Combined sildenafil and ISMN reduces BP in patients with treatment-resistant 














2.1 GENERAL REQUIREMENTS 
 
2.1.1 Subjects 
For all studies subjects were asked to refrain from alcohol for at least 24 hours and 
tea, coffee, other caffeinated drinks and food for at least 12 hours before each study 
visit. With the exception of the study investigating the effect of sildenafil on 
endothelial function in smokers (chapter 4), smoking was also not permitted for 12 
hours before each study visit. 
 
2.1.2 Study environment 
Studies were conducted in a quiet room kept between 22°C and 24°C. 
 
2.1.3 Research governance and ethics 
Studies were approved either by a Local Research Ethics Committee or a Multi-
centre Research Ethics Committee and were performed in accordance with the 
Declaration of Helsinki of the World Medical Association. Written informed consent 




The methodologies used in each of the studies are described here. Specific protocols 
for each of the studies are described in the relevant chapters. 
 
2.2.1 BP and HR 
Systolic BP, diastolic BP and HR were recorded using a validated oscillometric 
sphygmomanometer, the Omron HEM-705CP (Omron Healthcare (UK) Ltd, Milton 
Keynes; O'Brien et al., 1996), except in the study investigating the time course of the 
interaction on BP between sildenafil and sublingual GTN (chapter 5) in which a 
Dinamap Pro 100 BP monitor (GE Healthcare, Chalfont St Giles; Chang et al., 2003) 
was used. Where standing BP and HR were measured they were recorded after 2 
minutes standing. PP was calculated as the difference between systolic BP and 
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diastolic BP. True MAP was derived from integration of the radial artery pulse 
waveform obtained with PWA recordings (see section 2.2.3). 
 
2.2.2 Ambulatory BP 
Ambulatory BP was recorded at the brachial artery using a validated Spacelabs 
90217 ambulatory BP monitor (Spacelabs Medical Inc, Issaquah, WA, USA; 
Baumgart et al., 1998). Measurements were taken every 30 minutes for 24 hours. 
Subjects recorded the time that they went to sleep and the time that they awoke so 
that daytime average BP and night time average BP, as well as 24-hour average BP, 
could be calculated. 
 
2.2.3 PWA 
Peripheral pressure waveforms were recorded from the radial artery at the wrist by 
applanation tonometry using a high fidelity micromanometer (SPC-301; Millar 
Instruments, Texas, USA) and the SphygmoCor apparatus (AtCor Medical Pty Ltd 







Figure 2.1. PWA measurement. 
The tonometer is applied lightly over the radial artery 
at the wrist. The radial artery waveform can be seen on 
the computer's screen. 
 
 
Averaged peripheral and corresponding central (ascending aortic) pressure 
waveforms were generated from the last 10 seconds of each radial artery recording. 
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Central systolic BP, central diastolic BP, central PP, aortic AIx, and aortic AIx@75 
were calculated from the averaged central waveform. Aortic AIx was calculated as 
explained in Figure 1.5 (page 24). Aortic AIx@75 is aortic AIx adjusted to a 
standard HR of 75 bpm. To derive aortic AIx the SphygmoCor software adjusts 
aortic AIx at an inverse rate of 4.8% for each 10 bpm increment in HR.  
 
2.2.4 CF-PWV 
The SphygmoCor apparatus was also used to measure CF-PWV. During continuous 
ECG monitoring pulse wave recordings were made first at the carotid artery and then 
at the femoral artery. The software identified the foot of the pulse wave, as the 
beginning of the sharp systolic upstroke, and the wave transit time was calculated 
using the R wave of the simultaneously recorded ECG as a reference frame. Surface 









2.2.5 Flow-mediated dilatation 
The experimental set-up for FMD is shown in Figure 2.2. The right arm was 
extended approximately perpendicular to the body across a platform with the palm of 
the hand facing upwards. The brachial artery was continuously scanned 
longitudinally with B-mode ultrasound (Acuson XP 128, Siemens plc, Bracknell, 
UK) 5 cm above the elbow using a linear array transducer with an imaging frequency 
of 11 MHz. A stereotactic clamp was used to hold the probe in the same position 
throughout the study. Every 3 seconds end-diastolic (ECG R-wave triggered) frames 
were acquired on a computer equipped with a DT-3152 progressive scan frame 
grabber (Data Translation Ltd, Basingstoke, UK) and image acquisition software 
(CVI Acquisition version 1.5, Information Integrity Inc, USA). Baseline diameter 
was recorded for 1 minute, after which a paediatric-sized cuff placed just below the 
elbow was inflated to 220 mmHg (or 50 mmHg above systolic BP if systolic BP was 
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>170 mmHg) for 5 minutes. Following deflation of the cuff the artery was scanned 
for a further 5 minutes. For the assessment of the response to GTN, the brachial 
artery was scanned at baseline for 1 minute. Sublingual GTN was then administered 
and the artery was scanned for a further 5 minutes. Ultrasound recordings were 
stored on videotape. Brachial artery diameter was calculated off-line from the stored 
images using semi-automated wall-tracking software (Brachial Analyzer, Medical 
Imaging Applications, Iowa, USA).  
 
Using pulsed wave Doppler at 70° to the vessel, blood flow was recorded 
continuously with the range gate (1.5 mm) positioned midway between near and far 
artery walls. The velocity time integral (VTI), the area under the velocity/time curve, 
was measured off-line at baseline and every 3 seconds for 18 seconds after cuff 
deflation. Blood flow was calculated as 
! 
VTI "HR "# " (diameter /2)2. Reactive 
hyperaemia was quantified as the peak change in flow, expressed as percentage 











Figure 2.2. FMD set-up. 
The ultrasound probe is fixed in place by a stereotactic clamp. An image of the 
brachial artery can be seen on the ultrasound machine's screen. 
 
 
2.2.6 Assessment of LVH 
ECG criteria for LVH were gender-specific (Alfakih et al., 2004). For males the 




the S-wave in lead V3 is greater than 25 mm). For females the Sokolow-Lyon 
product was used (LVH present if the QRS duration multiplied by the sum of the S-
wave in lead V1 and the R-wave in lead V5 or V6 is greater than 2970). 
 
2.2.7 Screening blood samples 
With the exception of the study investigating the dose-response relationship between 
GTN and brachial artery diameter/arterial wave reflection (section 3.2), blood 
samples were taken from subjects for full blood count, serum urea, creatinine, 
sodium, potassium and lipid profile [total, low density lipoprotein (LDL) and high 
density lipoprotein (HDL) cholesterol, and triglyceride], and plasma glucose. These 
samples were analysed by the Western General Hospital (WGH) Haematology and 





2.3.1 Salbutamol and salbutamol placebo 
Salbutamol 400 µg or placebo training inhaler (Allen & Hanburys, Stockley Park, 
UK) were inhaled through a spacer device (Volumatic® Allen & Hanburys, Stockley 
Park, UK). Two puffs (200 µg of salbutamol) were initially placed into the spacer 
and were inhaled via a full inspiration. Subjects then held their breath for 10 seconds, 
exhaled, and once again fully inhaled through the spacer and held their breath for a 
further 10 seconds. This procedure was then repeated with a further 2 puffs. The 
casing for the salbutamol inhaler was grey and that for the training inhaler white. 
Where double blinding was required, this was achieved by salbutamol and placebo 
being administered by personnel independent of the study and subjects keeping their 
eyes closed during inhaler administration.  
 
2.3.2 GTN 
GTN was administered sublingually in a number of studies. The preparations used 
varied between these studies and, therefore, are described in the methods sections of 




Sildenafil 50 mg and 100 mg, and matched placebo tablets were obtained from Pfizer 
Ltd, Sandwich, UK. 
 
2.3.4 ISMN 
ISMN 10 mg was from APS Ltd, Eastbourne, UK. Placebo tablets for ISMN were 
manufactured by Tayside Pharmaceuticals, Dundee, UK, and were of different 
appearance to the ISMN tablets. Double blinding was achieved by ISMN and ISMN 
placebo being administered by personnel independent of the study and subjects 
keeping their eyes closed during administration. 
 
 
2.4 DATA ANALYSIS 
Methods used to analyse data differed between studies and, therefore, are described 
in the relevant chapters. Microsoft Excel 2004 for Macintosh and GraphPad Prism 4 
for Macintosh were used for statistical analyses. A P value of <0.05 was considered 
significant. Where changes in variables, for example from baseline, are presented 
these are absolute rather than relative, unless stated otherwise. 
 
2.4.1 Repeatability analysis  
Ninety-five percent limits of agreement were used to assess repeatability of 2 
measurements (Bland et al., 2003). Using this method, only 5% of pairs of 
measurements on the same subject would fall outside of the 95% limit of agreement. 
Means and SDs of the differences between 2 measurements were calculated and the 
95% limit of agreement was defined as the mean difference ±1.96 SDs. Standard 




/n  and 95% confidence intervals (CIs) 
for the limits of agreement were calculated as ±1.96 standard errors. Repeatability 
data are presented graphically as plots of the difference between 2 measurements 














3.1 CHAPTER STRUCTURE 
Two methodology development studies were performed and these are considered 
separately in the present chapter. The first investigated the relationships between 
GTN dose and change in both brachial artery diameter and arterial wave reflection. 
The second investigated the effects of age and gender on the extent to which inhaled 
salbutamol changes arterial wave reflection, and also compared these responses to 




3.2 RELATIONSHIPS OF DOSE OF SUBLINGUAL GTN TO CHANGE IN 
BRACHIAL ARTERY DIAMETER AND ARTERIAL WAVE REFLECTION  
 
3.2.1 Background 
When endothelial function is assessed in vivo the NO-dependent, endothelium-
dependent response, for example increase in brachial artery diameter secondary to 
increased shear stress in FMD or reduction in arterial wave reflection with inhaled 
salbutamol, is compared to an NO-dependent but endothelium-independent response 
to control for vascular smooth dysfunction. Most commonly, GTN is used for this 
purpose.  
 
The dose of GTN used in FMD studies varies among different investigators. 
Although a relatively high dose, such as 400 µg (Celermajer et al., 1993; Doshi et 
al., 2002; Gokce et al., 2002a; Woodman et al., 2004; Wu et al., 2004; Zilkens et al., 
2003), has most commonly been used, including in children (Celermajer et al., 1992; 
Pena et al., 2004), some studies have used 50 µg (Ghiadoni et al., 2000) or 25 µg 
(Bennett-Richards et al., 2002; Cross et al., 2003; Ghiadoni et al., 2001; Ghiadoni et 
al., 2003), stating that the degree of brachial artery vasodilatation that occurs with 
these doses more closely approximates the dilatation that occurs following reactive 
hyperaemia-induced increased shear stress. However, the dose-response relationship 
between sublingual GTN and brachial artery dilatation has not been published, nor is 
there currently any consensus on the most appropriate dose to use and why. The 
effect of salbutamol on arterial wave reflection has been compared to the effect of 
GTN given as a 500 µg tablet placed sublingually for 3 minutes (Wilkinson et al., 
2002a) and sublingual GTN 250 µg (Hayward et al., 2002b). As with the effects on 
the brachial artery, the dose-response relationship of sublingual GTN to change in 
arterial wave reflection is not known. 
 
3.2.2 Aims 
In order to inform the most appropriate dose of sublingual GTN that should be used 
as a control in endothelial function studies, the aims of the present study were to 
characterise: 
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1. The dose-response relationship of sublingual GTN to change in brachial artery 
diameter. 





Suitable subjects were identified from a database of subjects who had previously 
taken part in research at the University of Edinburgh’s Clinical Research Centre 
(CRC) and from those who responded to advertisements placed around the city of 
Edinburgh. 
 
3.2.3.1.1 Inclusion criteria 
• Healthy 
• Male or female 
• Aged 18 to 50 years 
• Weight between 60 and 95 Kg 
 
3.2.3.1.2 Exclusion criteria 
• History of major cardiac, respiratory, neurological or renal disease 
• Asthma 
• Current smoker 
• Diabetes  
• Taking any drugs that act on the cardiovascular system  
• Previous intolerance to GTN 
• Pregnant 
• Current alcohol or drug abuse 
• Previous serious drug allergy 
 
3.2.3.2 Study design 
Randomised, placebo-controlled, double blind, 9-way crossover. 
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3.2.3.3 GTN and placebo 
The doses of sublingual GTN investigated were 5, 10, 25, 50, 100, 200 and 400 µg. 
GTN 5 mg/mL for parenteral use (Faulding Pharmaceuticals plc, Leamington Spa, 
UK) was diluted to the appropriate concentration in sterile water. Administration was 
via a micropipette in a total volume of 80 µL. Placebo was 80 µL of sterile water. 
 
3.2.3.4 Protocol 
Subjects attended the CRC on 3 separate days. At each visit measurements were 
made of FMD and of the responses of the brachial artery and arterial waveforms to 3 
different doses of GTN or placebo. Because there were 7 different doses of GTN, 
placebo was administered on 2 occasions so that the format of each study day was 
identical. Two operators made recordings during each study. One, on each subject’s 
right, performed brachial artery ultrasound and the other, on each subject’s left, 
recorded HR, BP and radial artery tonometry. On each day subjects first rested semi-
recumbent for 20 minutes, after which FMD was performed. After a further 15 
minutes rest, baseline recordings were made of HR, BP and radial artery waveforms. 
Brachial artery ultrasound was then started and, after 1 minute, drug or placebo was 
administered sublingually. The brachial artery was scanned for a further 5 minutes. 
HR and BP were repeated at 4 minutes and tonometry at 5 minutes after drug 
administration. After a further 2 and 4 hours recordings were repeated in the same 
manner, but before and after different doses of GTN or placebo. Pilot studies, in 
which GTN was administered 3 times after differing time intervals, had shown that a 
period of 2 hours appeared to be sufficient for the effects of GTN on the brachial 
artery to return to baseline and also that there was no change in the sensitivity to 














































A. GTN 400µg x 3, time interval 1 hour (n = 3)
B. GTN 400µg x 3, time interval 2 hours (n = 4)
C. GTN 50 µg, 400µg and 50 µg, time interval 2 hours (n = 4)
 
Figure 3.1. Results of pilot studies on the minimum time interval for repeated 
administration of GTN. 
Baseline brachial artery diameter on the left and GTN-induced change in brachial 
artery diameter on the right (% change from baseline). With an interval of one hour 
there was an apparent progressive increase in baseline artery diameter and reduction 
in response to GTN (A). An interval of 2 hours appeared to be sufficient for the 
artery diameter to return to baseline and for the sensitivity of the artery to GTN to be 
maintained (B and C). Data are means and SEMs. 
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3.2.3.5 Randomisation process 
The randomisation process was as follows: 
1. For the first subject, a randomised sequence of the 9 different doses of GTN or 
placebo was created. 
2. This sequence was used for all subjects, but the start point in the sequence was 
varied between subjects. 
3. Subjects were randomised, in a balanced manner, to 1 of the 9 start points.  
 
3.2.3.6 Analyses 
Both FMD and the response to each dose of GTN or placebo on the brachial artery 
are expressed as percentage change from baseline. Aortic AIx is expressed as 
absolute change from baseline. RAIx is expressed primarily as percentage change 
from baseline, to facilitate comparison with the published effect of salbutamol on 
this parameter, but the absolute change from baseline is also presented. For each 
dose of GTN or placebo the baseline value of each parameter is that recorded 
immediately before drug administration. The effect of placebo was the mean of the 2 
recordings made. For each subject mean baseline values for systolic and diastolic BP, 
resting brachial artery diameter, FMD, aortic AIx and RAIx were calculated from the 
first baseline recordings taken at each of the 3 visits. 
 
3.2.4 Results 
Seventeen subjects, all men, were recruited to the study. Their baseline 
characteristics are given in Table 3.1.  
 
Age (years) 40 (9) 
Systolic BP (mmHg) 124 (14) 
Diastolic BP (mmHg) 77 (11) 
FMD (%) 3.9 (2.4) 
Aortic AIx (%) 14 (10) 
RAIx (%) 64 (14) 
 




The dose-response relationships are shown in Figure 3.2. With increasing GTN dose 
there was a progressive decrease in diastolic BP and increase in HR. In contrast, 
there was no clear dose-response relationship for GTN to systolic BP. With 
increasing dose of GTN there was also a progressive increase in brachial artery 
dilatation, and a progressively greater reduction in arterial wave reflection. The 
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Figure 3.2. Log dose-response relationships of sublingual GTN to change in HR, 
BP, brachial artery diameter, aortic AIx and RAIx. 
For brachial artery diameter the range of GTN doses that are equivalent to the normal 
FMD response (~4 to 10% dilatation) are indicated. For aortic AIx and RAIx (% 
change) the GTN doses that are equivalent to the normal responses to salbutamol are 
indicated. Values are means, error bars are SEMs. BA = brachial artery. 
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3.2.5 Discussion 
3.2.5.1 Dose of GTN as a control in FMD studies 
As has been suggested by other investigators (Bennett-Richards et al., 2002; Cross et 
al., 2003; Ghiadoni et al., 2000; Ghiadoni et al., 2001; Ghiadoni et al., 2003), the 
present study confirms that lower doses of GTN dilate the brachial artery to a degree 
that is similar to the normal FMD response. It is not possible to define a single dose 
of GTN that equates to the normal FMD response because of variability in the degree 
of brachial artery dilatation following 5 minutes of ischaemia across published 
studies. Most studies quote FMD values in the range 6 to 10% for healthy controls 
(Celermajer et al., 1996; Celermajer et al., 1993; Celermajer et al., 1994; Gokce et 
al., 2002a; Raitakari et al., 1999), although both higher (Celermajer et al., 1992) and 
lower values (Betik et al., 2004; Ghiadoni et al., 2000) have been reported. In the 
present study FMD values were relatively low (mean 3.9%). For normal FMD values 
in the range 4 to 10% the equivalent dose range of GTN is ~8 to 35 µg. Most FMD 
studies that have used lower doses of GTN have used 25 µg (Bennett-Richards et al., 
2002; Cross et al., 2003; Ghiadoni et al., 2001; Ghiadoni et al., 2003) and the data 
from this study suggest that this dose more closely approximates to the normal shear 
stress-induced response than does 50 µg (Ghiadoni et al., 2000).  
 
3.2.5.2 Dose of a GTN as a control in arterial wave reflection studies 
In previous reports salbutamol 400 µg reduced aortic AIx (absolute change) by 
~11% (Wilkinson et al., 2002a) and RAIx (percentage change) by ~12% (Hayward 
et al., 2002b) in healthy subjects. In the present study the dose of GTN that reduced 
aortic AIx by 11% was ~50 µg and the dose that reduced RAIx by 12% was ~25 µg. 
In the original study that investigated the effect of salbutamol on aortic AIx, GTN 
was given as a 500 µg tablet placed under the tongue for 3 minutes and reduced 
aortic AIx by ~12%. The present dose-response data suggest that 500 µg GTN would 
reduce aortic AIx by >18%. The disparity can largely be explained by the different 
formulations of GTN used in the 2 studies. Three minutes was not sufficient time for 
the GTN tablets to dissolve and, therefore, the dose of GTN delivered to the 
circulation could not easily be quantified, although it is likely that it was 
substantially less than 500 µg. In addition, it is probable that the variation between 
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subjects in the dose of GTN delivered to the circulation would be greater when 
delivery is via a sublingual tablet given for a period of time that does not allow for 
complete dissolution, than via a small volume of solution. For these reasons delivery 
of sublingual GTN in a small volume of solution may be preferable.  
 
Although the SphygmoCor apparatus measures aortic AIx and RAIx simultaneously 
previous studies have not reported the effects on both. The dose-response data 
suggest that the doses of GTN that are equivalent to the effects of salbutamol 400 µg 
on aortic AIx and RAIx are different, presenting a difficulty if the effects of 
salbutamol on both aortic AIx and RAIx are measured in any given study. The site of 
action of GTN within the circulation is known to vary with dose (Jiang et al., 2002), 
whereas the vascular site of action of salbutamol has not been precisely defined. 
Therefore, it is plausible that salbutamol and GTN would affect aortic AIx and RAIx 
differently. In addition, to date there are limited data on the effect of salbutamol on 
these 2 variables in healthy subjects. As has occurred with FMD, as further studies 
are published a clearer picture will emerge of the variability of these responses and 
the dose-response relationships presented here may be used as a future reference for 
any adjustment of the GTN dose that is necessary. It is critical that future studies 
should report the effects of salbutamol on both aortic AIx and RAIx. This will enable 
direct comparison of the effects on each variable and may elucidate whether one is of 
greater value than the other as a marker of endothelial function.  
 
Following administration of GTN the brachial artery was continuously scanned for 5 
minutes, which is sufficient time for peak vasodilatation to occur, at around 3 to 4 
minutes (Corretti et al., 2002). Aortic AIx and RAIx were both measured at 5 
minutes after GTN. It is possible that, at least in some of the subjects, the effect of 
GTN on these parameters was not at peak at this time. However, the effect of 
sublingual GTN on haemodynamic parameters has previously shown to peak from 2 
to 5 minutes and thereafter plateau until 6 to 9 minutes (Armstrong et al., 1979; 
Bashir et al., 1982; Nyberg et al., 1981). Therefore, it is probable that the peak effect 
was indeed captured at the 5-minute time point. 
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3.2.5.3 The rationale for using particular doses of GTN as a control 
When measuring endothelial function non-invasively one should be clear as to the 
rationale for using particular doses of GTN. Lower doses, in the range 8 to 50 µg, 
cause a change in brachial artery diameter, aortic AIx and RAIx to a degree that is 
similar to the endothelium-dependent stimulus, be it increased shear stress or 
salbutamol, in healthy subjects. It is for this reason that some researchers have 
recently used such doses of GTN in FMD studies. Thus, if a group of subjects has an 
impaired response to the endothelium-dependent stimulus but the response to low 
dose GTN is maintained one can conclude that the defect lies at the level of the 
endothelium. If the GTN response is also reduced then there is likely to be more 
generalised vascular dysfunction (for example, reduced vascular smooth muscle 
sensitivity to NO, impaired bioconversion of GTN to NO or increased inactivation of 
NO). When this is the case it is more difficult to determine the extent to which the 
endothelium itself is dysfunctional. In a recent FMD study, in which GTN 25 µg was 
given, Cross et al (2003) stated that higher doses of GTN may fail to allow 
discrimination between subtle differences of intrinsic smooth muscle reactivity. 
However, higher doses of GTN, on the plateau of the dose-response relationship, 
would provide a measure of the maximum capacity for NO-mediated dilatation, a 
different measure of vascular function and potential damage. Thus, it should be 
borne in mind that while lower doses are appropriate controls in the assessment of 
endothelial function, they may not be appropriate for assessing maximal 
responsiveness to NO. On the other hand, by 400 µg GTN there was no clear 
maximum effect plateau for any of the dose-response curves characterised in the 
present study. Whilst it is still possible that a maximal, or near-maximal, effect on 
each parameter is achieved with 400 µg GTN (i.e. this dose lies at the start of the 
plateau of the dose-response curves), it is likely that higher doses would be needed to 
assess maximum capacity for NO-mediated dilatation. However, systemic 
haemodynamic effects (increase in HR and reduction in BP) are clearly evident at 
higher doses and may act as important confounding factors. Certainly, aortic AIx 
would tend to fall with both BP reduction and increase in HR (Wilkinson et al., 
2000a). At lower doses of GTN, especially 25 µg, haemodynamic changes are 
unlikely to be of practical significance. That maximum effect plateaus were not 
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reached for brachial artery diameter, aortic AIx or RAIx until there were major 
systemic haemodynamic effects supports the argument for using lower doses of 
GTN, that produce equivalent effects to the endothelium-dependent stimuli.  
 
As an alternative to using a single dose of GTN, in one recent study GTN 50 µg was 
administered repeatedly every 5 minutes until a cumulative dose of 200 µg had been 
given (Jarvisalo et al., 2004), a principle first suggested by Corretti et al (2002) in a 
guideline paper for brachial artery FMD measurement. Brachial artery diameter was 
measured after each dose and dose-response curves constructed. In this study, 
children at increased risk for atherosclerosis, for example those with increased 
intima-media thickness, had impaired nitrate-mediated dilatation. The authors of this 
study stated that the subtle nature of the impairment in nitrate-mediated dilatation 
they reported would be unlikely to have had any significant effect on FMD. 
However, it is possible that a smaller dose of GTN would have been needed to 
directly address this. Indeed, it should be noted that the present study was performed 
in healthy adults. A further dose-response study should be performed in children. A 
further limitation to the cumulative dose approach is that the dose-response 
relationship cannot be determined accurately because GTN is rapidly metabolised, 
with a plasma half-life of 2 to 3 minutes. Nevertheless, the concept of cumulative 
doses of GTN is an interesting one that should be explored in future studies. 
 
3.2.5.4 Summary 
In summary, with increasing dose of GTN, from 5-400µg, there was a graded 
increase in brachial artery diameter, and decrease of aortic AIx and RAIx. The doses 
of GTN equivalent to endothelium-dependent stimuli were 8-35 µg for FMD, ~50 µg 
for the effect of salbutamol 400 µg on aortic AIx and ~25 µg for the effect of 
salbutamol 400 µg on RAIx.  
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3.3 CHANGE IN ARTERIAL WAVE REFLECTION AS A MEASURE OF 
ENDOTHELIAL VASOMOTOR FUNCTION: EFFECTS OF AGE AND 
GENDER, AND COMPARISON WITH FLOW-MEDIATED DILATATION 
 
3.3.1 Background 
The extent to which inhaled ß2-adrenoreceptor agonists reduce arterial wave 
reflection holds promise as a non-invasive measure of endothelial vasomotor 
function that could be widely applied in population studies and even in clinical 
practice. However, to date there is relatively limited experience with this 
methodology, especially in comparison to other methodologies used to assess 
endothelial vasomotor function. For example, there are no published data on whether 
the arterial response to ß2-adrenoreceptor agonist stimulation varies with age. At the 
outset of this study there were also no data on whether responses differ between men 
and women, or correlate with brachial artery FMD, an alternative non-invasive 
method for assessing endothelial vasomotor function. However, the population-based 
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study, 
which recruited around 1000 subjects aged 70 years, either healthy, with, or at 
increased risk of cardiovascular disease, very recently reported no difference in the 
effect on arterial wave reflection of inhaled terbutaline (like salbutamol, a ß2-
adrenoreceptor agonist) between men and women and also no correlation between 
the effect of terbutaline and brachial artery FMD (Lind et al., 2005).  
 
3.3.2 Aims 
The aims of this study were to investigate, in healthy subjects, the effects of age and 
gender on the extent to which inhaled salbutamol changes arterial wave reflection, 




3.3.3.1.1 Identification of subjects 
Suitable subjects were identified from a database of subjects who had previously 
taken part in research at the CRC and from those who responded to advertisements 
placed around the city of Edinburgh and on the internet. 
 
3.3.3.1.2 Inclusion criteria 
• Healthy 
• Male or female 
• Aged 20 to 79 years 
• Weight between 60 and 100 Kg 
 
3.3.3.2   
3.3.3.2.1 Exclusion criteria 
• History of major cardiac, respiratory, neurological or renal disease 
• Asthma 
• Current smoker 
• Taking any drugs that act on the cardiovascular system 
• Taking any drugs that might interact with salbutamol or GTN 
• Pregnant 
• Current alcohol or drug abuse 
• Previous serious drug allergy 
 
3.3.3.3 Study design 
Randomised, placebo-controlled, double blind, 2-way crossover.  
 
3.3.3.4 Protocol 
Subjects attended 2 study visits on separate days and all studies were performed first 
thing in the morning. At the first visit height and weight were measured and a fasting 
blood sample was taken for full blood count and biochemistry. Otherwise, the 
protocol, summarised in Figure 3.3, was the same at both visits. After at least 30 
minutes supine rest, brachial artery FMD was performed on the right arm. Following 
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this, baseline BP, HR and PWA were then measured 10 minutes and immediately 
before salbutamol 400 µg or placebo administration. These measures were repeated 
5, 10, 15, 20 30, 45 and 60 minutes after drug administration. Sublingual GTN 50 µg 
(prepared from a solution for intravenous injection as in section 3.2.3.3, but given in 
a total volume of 25 µL) was then administered and BP, HR and PWA repeated after 
a further 5, 10, 15 and 20 minutes. BP, HR and PWA were measured in duplicate at 

















Figure 3.3. Protocol for each study visit. 
 
 
3.3.3.5 Data analyses 
Baseline brachial artery diameter and FMD for each subject were taken as the mean 
of the values from each visit. For BP, HR, aortic AIx, aortic AIx@75 and RAIx 
baseline values were those measured at -5 minutes. Changes from baseline were 
calculated at each time point after salbutamol or placebo inhalation. The -5 minute 
BP/HR x 2, PWA x 2 -10 min 
0 
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measures, rather than those made at +60 minutes, were also used to calculate the 
changes from baseline following GTN.  
 
Responses to salbutamol and placebo were quantified as both the absolute maximum 
change from baseline to 30 minutes after drug administration and as AUC of the 
absolute change from baseline to 60 minutes after drug administration. Responses to 
GTN were quantified as the absolute maximum change from baseline to 20 minutes 
after administration and as the AUC of the absolute change from baseline to 20 
minutes after administration. Comparisons were made using Student’s t-tests and 






Forty-five subjects were initially recruited. Of these, 1 subject turned out to be 
hypertensive at his first visit and, therefore, did not complete the study. The data 
from the remaining 44 subjects were entered into the analyses. The baseline 
characteristics of the subjects are given in Table 3.2. 
 
 
 All Males Females 
Number 44 23 21 
Age (years) 42 (14) 44 (14) 41 (13) 
Weight (Kg)** 72 (12) 79 (10) 65 (9) 
BMI (Kg/m2)* 24 (3) 25 (3) 23 (3) 
Systolic BP** 110 (13) 115 (9) 104 (14) 
Diastolic BP 63 (7) 70 (8) 70 (5) 
MAP* 82 (9) 85 (8) 79 (8) 
Aortic AIx 14 (14) 12 (13) 17 (15) 
Aortic AIx@75 5 (15) 4 (13) 7 (16) 
RAIx 63 (16) 60 (14) 66 (18) 
Plasma glucose (mmol/L) 4.6 (0.4) 4.7 (0.5) 4.6 (0.4) 
Serum cholesterol:    
Total (mmol/L) 4.5 (0.8) 4.6 (0.8) 4.3 (0.8) 
LDL (mmol/L)* 2.4 (0.7) 2.7 (0.6) 2.2 (0.8) 
HDL(mmol/L)** 1.5 (0.4) 1.3 (0.4) 1.7 (0.5) 
Total:HDL ratio** 3.2 (1.0) 3.6 (1.0) 2.7 (0.9) 
Triglyceride (mmol/L) 1.2 (0.7) 1.3 (0.9) 1.0 (0.4) 
 
Table 3.2. Baseline characteristics of the subjects. 
Means (SDs) are given for continuous variables. BMI = body mass index. Values for 
haemodynamic variables are means of the baseline values from the 2 study visits. 
Comparisons between males and females by Student’s t-tests (*P<0.05, **P<0.01). 
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3.3.4.2 Flow-mediated dilatation 
Seven of the visit 1 FMD studies and 6 of the visit 2 FMD studies were not suitable 
for analysis, due to image quality that was insufficient to reliably define the margins 
of the brachial artery or because there was significant movement of the position of 
the artery relative to the ultrasound probe. From 11 subjects there was only 1 suitable 
FMD study and in 1 subject neither FMD study was suitable. 
 
Baseline brachial artery diameter increased with age (Figure 3.4) and was higher in 
males than in females [4.4 (0.5) mm vs 3.3 (0.4) mm, P < 0.001]. Both increasing 
age and increasing baseline brachial artery diameter were associated with reduced 
FMD (Figure 3.4). There was a trend to a lower FMD in males compared to females, 
but the difference did not achieve statistical significance [4.8 (2.2)% vs 6.4 (3.3)%, P 
= 0.07].  
 

































Figure 3.4. Relationships between age and baseline brachial artery diameter (A) 
and FMD (B), and between baseline brachial artery diameter and FMD (C). 
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3.3.4.3 Measures of arterial wave reflection at baseline 
Mean baseline aortic AIx, aortic AIx@75 and RAIx were strongly related to age 
(Figure 3.5). Mean baseline MAP was not significantly related to age (Figure 3.5), 
aortic AIx (r = 0.2, P = 0.2) or RAIx (r = 0.14, P = 0.4) but was weakly correlated 
with aortic AIx@75 (r = 0.34, P = 0.02). There were no significant differences 
between males and females in aortic AIx [males 12 (12)% vs females 17 (15)%, P = 
0.3], aortic AIx@75 [males 4 (13)% vs females 7 (16)%, P = 0.5], or RAIx [males 
62 (15)% vs females 69 (18)%, P = 0.2]. 
 
























































3.3.4.4 Responses to salbutamol and glyceryl trinitrate 
The effects of salbutamol and GTN, in all subjects, on aortic AIx, aortic AIx@75 and 
RAIx are shown in Figure 3.6 and on HR and MAP in Figure 3.7. Aortic AIx and 
RAIx were significantly lower 60 minutes after salbutamol than after placebo (aortic 
AIx: 13% vs 17%, P = 0.01; RAIx: 63% vs 68%, P = 0.003). Aortic AIx@75 also 
tended to be lower after salbutamol at this time (5% vs 8%, P = 0.051) and HR was 
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higher (59 bpm vs 56 bpm, P = 0.008), although there was little difference in MAP 
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Figure 3.6. Effects on aortic AIx (top), aortic AIx@75 (middle) and RAIx 
(bottom) of placebo () and salbutamol (), and of GTN after placebo () and 
salbutamol (). 
The tables give the mean maximum changes from baseline to 30 minutes (Max ∆) 
and the mean AUCs from baseline to 60 minutes. Comparisons are between 
salbutamol and placebo phases. GTN (plac) = GTN following placebo; GTN (salb) = 
GTN following salbutamol. 
 
 Max ∆ AUC 
   Placebo 2(10) 130(287) 
Salbutamol -6(10) -189(338) 
P value <0.001 <0.001 
      GTN (plac) -7(11) -74(123) 
GTN (salb) -14(8) -171(127) 
P value <0.001 <0.001 
    
 Max ∆ AUC 
   Placebo 6(19) 165(333) 
Salbutamol -8(11) -283(413) 
P value <0.001 <0.001 
      GTN (plac) -11(13) -113(131) 
GTN (salb) -18(11) -223(159) 
P value 0.001 <0.001 
    
 Max ∆ AUC 
   Placebo 2(11) 117(294) 
Salbutamol -4(10) -100(313) 
P value 0.01 0.001 
      GTN (plac) -5(12) -67(127) 
GTN (salb) -11(10) -145(125) 
P value 0.004 0.003 
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Figure 3.7. Effects on HR (top) and MAP (bottom) of placebo () and 
salbutamol (), and of GTN after placebo () and salbutamol (). 
The tables give the mean maximum changes from baseline to 30 minutes (Max ∆) 
and the mean AUCs from baseline to 60 minutes. Comparisons are between 
salbutamol and placebo phases. GTN (plac) = GTN following placebo; GTN (salb) = 




Increasing age was associated with a greater maximum change in RAIx with 
salbutamol (r = -0.31, P = 0.04) but did not correlate with the change in RAIx 
quantified as the AUC of the change from baseline (r = -0.15, P = 0.3). Age was not 
significantly correlated with the effect of salbutamol on aortic AIx (r = -0.1, P = 0.5 
for maximum change from baseline and r = -0.04, P = 0.8 for AUC of the change 
from baseline) or aortic AIx@75 (r = -0.2, P = 0.3 and r = -0.04, P = 0.8 
respectively). There were no differences between males and females in the responses 
to salbutamol of aortic AIx, aortic AIx@75 or RAIx, HR or MAP (Table 3.3). 
 Max ∆ AUC 
   Placebo -1(5) -21(129) 
Salbutamol 7(6) 191(230) 
P value <0.001 <0.001 
      GTN (plac) 2(5) 13(57) 
GTN (salb) 6(7) 58(79) 
P value 0.001 <0.001 
    
 Max ∆ AUC 
   Placebo 3(6) 130(185) 
Salbutamol -2(7) -14(178) 
P value <0.003 <0.001 
      GTN (plac) 1(8) 1(78) 
GTN (salb) -4(6) -42(66) 
P value <0.001 <0.001 




  Males Females P value 
Aortic AIx Max ∆ to 30 minutes (%) -6 (10) -6 (9) 1 
 AUC to 60 minutes (AU) -193 (340) -185 (344) 0.9 
     
Max ∆ to 30 minutes (%) -5 (10) -3 (10) 0.6 Aortic 
AIx@75 
AUC to 60 minutes (AU) -127 (301) -70 (332) 0.6 
     
RAIx Max ∆ to 30 minutes (%) -8 (11) -9 (11) 0.8 
 AUC to 60 minutes (AU) -270 (402) -298 (436) 0.8 
     
HR Max ∆ to 30 minutes (bpm) 5 (5) 8 (7) 0.2 
 AUC to 60 minutes (AU) 136 (188) 252 (259) 0.09 
     
MAP Max ∆ to 30 minutes (mmHg) -2 (7) -1 (7) 0.4 
 AUC to 60 minutes (AU) -28 (175) 2 (185) 0.6 
 
Table 3.3. Effects of salbutamol in males and females. 
 
 
3.3.4.5 Relationships between FMD and responses to salbutamol 
FMD was not significantly correlated with the responses of aortic AIx, aortic 
AIx@75 or RAIx to salbutamol (Table 3.4).  
 
  Correlation with FMD 
  r value P value 
Aortic AIx Max ∆ to 30 minutes -0.004 0.98 
 AUC to 60 minutes 0.1 0.5 
    
Aortic AIx@75 Max ∆ to 30 minutes 0.15 0.3 
 AUC to 60 minutes 0.14 0.4 
    
RAIx Max ∆ to 30 minutes 0.13 0.4 
 AUC to 60 minutes 0.16 0.3 
    
 
Table 3.4. Relationships between FMD and responses to salbutamol. 
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3.3.5 Discussion 
3.3.5.1 Main findings 
The main findings from the present study are that in healthy subjects: 
1. Age and gender do not influence the effect of inhaled salbutamol on arterial wave 
reflection. 
2. There is no correlation between the effect of inhaled salbutamol on arterial wave 
reflection and brachial artery FMD. 
 
3.3.5.2 Response to salbutamol as a measure of endothelial function 
Consistent with previously published work, in this study FMD was inversely related 
to both baseline brachial artery diameter (Silber et al., 2005) and age (Allen et al., 
2000; Celermajer et al., 1994; Ryliskyte et al., 2004) in healthy subjects. Baseline 
brachial artery diameter itself increased with age, but the age-related decline in FMD 
is known to occur independently of this (Celermajer et al., 1994). So as not to 
influence the response to salbutamol, GTN was not given as a control to FMD in the 
present study (see section 3.3.5.4.1). However, it has previously been shown that 
dilatation of the brachial artery in response to GTN is not affected by age 
(Celermajer et al., 1994), indicating that reduced FMD is the result of impaired 
endothelium-dependent vasomotion.  
 
In contrast to the clear inverse relationship between age and FMD, there was no 
impairment of the systemic arterial response to salbutamol, whether measured as 
aortic AIx, aortic AIx@75 or RAIx, with increasing age. Indeed, there was a greater 
reduction in RAIx in older subjects. However, this was evident only when measured 
as the maximum change from baseline and not when measured as the AUC of the 
change from baseline. This was also only marginally statistically significant in the 
setting of multiple statistical testing and should, therefore, be interpreted with 
caution.  
 
In addition to the established effect of aging on FMD, there is also a well 
documented progressive decline in muscarinic agonist, mainly ACh, stimulated 
vasodilatation in both the forearm (DeSouza et al., 2000; Gerhard et al., 1996; 
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Taddei et al., 2001; Taddei et al., 1997; Taddei et al., 1995) and coronary (Egashira 
et al., 1993; Yasue et al., 1990) circulations that is evident from the 3rd or 4th decade 
of life. In these studies endothelium-independent vasodilatation, with either sodium 
nitroprusside, GTN or papaverine, was either unaffected or minimally affected, 
suggesting that ageing is associated with reduced endothelial NO release. Ageing is 
also associated with reduced vasoconstriction to the NO synthase inhibitor L-NMMA 
and to the cyclo-oxygenase inhibitor aspirin but not to the direct smooth muscle 
vasoconstrictor noradrenaline, suggesting impairment of basal endothelial NO and 
prostanoid pathways (Singh et al., 2002).  
 
Thus, there is a well characterised decline in both conduit vessel and resistance 
vessel endothelial vasomotor function with ageing, but systemic arterial responses to 
salbutamol are unaffected by age, even in a group of subjects in which there is a 
demonstrable age-related decline in FMD. Does this finding call into question the 
use of this novel methodology as a measure of endothelial vasomotor function, 
especially given the proven value of FMD in independently predicting cardiovascular 
events (Brevetti et al., 2003; Fichtlscherer et al., 2004; Patti et al., 2005)? For 
example, it may be less sensitive than FMD in the detection endothelial dysfunction. 
However, there a number of alternative explanations for the lack of effect of ageing 
on salbutamol responses observed in the present study. For example, in contrast to 
muscarinic agonists, the degree of vasodilatation in the forearm with other 
endothelium-dependent agents, including bradykinin and substance P, is not affected 
by ageing (DeSouza et al., 2002). This suggests that the age-related decline in 
endothelium-dependent vasodilatation may be agonist specific. It follows that 
salbutamol responses in the forearm might also be relatively preserved in older 
subjects, although this hypothesis has not been investigated directly. Even if vascular 
responsiveness to salbutamol is unaffected by ageing, it does not necessarily follow 
that there would also be no reduction in the response to salbutamol with other causes 
of endothelial dysfunction. For example, both smoking and hypercholesterolaemia 
are associated with impaired vasodilatation to substance P in the forearm (Newby et 
al., 2002; Newby et al., 1999). Indeed, hypercholesterolaemia is associated with 
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reduced systemic arterial effect of salbutamol, with individual salbutamol responses 
correlating with responses to ACh in the forearm (Wilkinson et al., 2002a).  
 
Regular aerobic exercise prevents, and even reverses, the age-related decline in 
vasodilatation of the forearm vasculature to ACh (DeSouza et al., 2000; Taddei et 
al., 2000). Thus, if a number of the subjects recruited to the study participated in 
regular exercise, a tendency to reduced responsiveness to salbutamol with age might 
have been concealed. A study specifically recruiting sedentary and exercise-trained 
subjects would address this issue. Just 4 subjects over 60 years of age were recruited 
to the study. Therefore, the possibility that the arterial response to salbutamol is 
relatively preserved until around 60 years and declines thereafter cannot be excluded.  
 
In the present study there was a trend to a reduced FMD in males compared to 
females, which is consistent with the observation that the age-related decline in FMD 
is relatively delayed in females compared to males, with the deterioration in males 
evident from the early 40s and the deterioration in females evident from the early 50s 
(Celermajer et al., 1994). However, there were no differences, or even trends to 
differences, between males and females in the effects of salbutamol on arterial wave 
reflection. The recently reported PIVUS study found no differences between men 
and women in either FMD or in the effect of terbutaline on arterial wave reflection. 
The explanation for the lack of difference in FMD between the genders in PIVUS 
may be that all subjects were 70 years of age, which is old enough for the age-related 
decline in FMD to have affected both genders equally. One might speculate that the 
lack of even a trend to any difference between men and women in the response to 
salbutamol in the present study, which recruited a much younger population than did 
PIVUS, indicates that this methodology may be less sensitive than FMD in the 
detection of endothelial vasomotor dysfunction. 
 
Vasodilatation in response to both increased shear stress and salbutamol are 
endothelium-dependent, largely through the acute release of endogenous endothelial 
NO (Dawes et al., 1997; Doshi et al., 2001). Despite this, there was no correlation 
between FMD and salbutamol responses. However, this finding is consistent with 
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data from PIVUS in which different methodologies for the assessment of endothelial 
vasomotor function were compared (Lind et al., 2005). There was no correlation 
between FMD and the effect of terbutaline on arterial wave reflection. There was 
also no correlation between FMD and the degree of vasodilatation to ACh in the 
forearm. In contrast, responses to terbutaline were correlated, albeit rather weakly (r 
= 0.12, P = 0.001), with responses to ACh, which is consistent with the correlation 
shown between the responses to forearm ACh and systemic salbutamol in 
hypercholesterolaemia (Wilkinson et al., 2002a). Endothelial vasomotor dysfunction 
as defined as impaired vasodilatation to ACh in the forearm is independently 
predictive of cardiovascular events, and so the correlation between local responses to 
ACh and systemic responses to ß2-adrenoreceptor agonists provides some support for 
the hypothesis that the latter will also be of value in predicting cardiovascular 
outcome. Local responses to ACh and systemic responses to ß2-adrenoreceptor 
agonists may be correlated because both stimulate NO release in resistance vessels. 
The lack of correlation of either of these techniques with FMD of the brachial artery 
may suggest that assessment of conduit artery endothelial vasomotor function 
provides different, perhaps even complementary, information on vascular health/risk. 
Interestingly, in the PIVUS study all 3 methodologies correlated with the 
Framingham risk score. Ultimately though, the relative value of each of these 
methodologies in cardiovascular risk assessment can only be assessed in longitudinal 
studies and, in this regard, the follow-up data on the PIVUS participants will be of 
particular interest. 
 
3.3.5.3 Baseline arterial wave reflection 
Although responses to salbutamol were not influenced by age, baseline measures of 
arterial wave reflection were strongly correlated with age. The observed relationship 
between age and aortic AIx is consistent with recently reported data from the Anglo-
Cardiff Collaborative Trial (ACCT) a large population study of 4001 subjects, in 
which aortic AIx progressively increased with age, virtually linearly until around 60 
years (McEniery et al., 2005). It is not possible to comment on the relationship 
between age and aortic AIx in subjects older than 60 years from the present study 
because only 4 subjects of this age were recruited. However, in the ACCT there was 
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a progressive decline in the rate of rise of aortic AIx in older subjects. Aortic 
AIx@75 and RAIx were not reported by the ACCT, but the present study 
demonstrates that these are also strongly related to age. 
 
3.3.5.4 Methodological considerations 
3.3.5.4.1 GTN as a control  
There is no consensus on whether GTN should be given before or after salbutamol in 
non-invasive endothelial function studies. Wilkinson et al (2002a) administered GTN 
(500 µg tablet kept sublingually for 5 minutes and then removed) 25 minutes before 
administering salbutamol, on the basis of pilot studies that had shown, in contrast to 
the pilot studies detailed in Figure 3.1 (page 53), that 20 minutes was sufficient for 
the haemodynamic effect of GTN to return to baseline, but that longer was required 
for salbutamol. In contrast, Hayward et al (2002b) administered sublingual GTN 
(250 µg, formulation not stated) 20 minutes after salbutamol. A recent placebo-
controlled study in the CRC (not yet published) found that following sublingual GTN 
50 µg aortic AIx fell acutely, remained lower than baseline for around 40 minutes 
and, from 60 minutes, tended to increase above baseline, suggesting compensatory 
neurohormonal activation, such as stimulation of the renin-angiotensin system. As a 
measure of endothelial vasomotor function, it is the change in arterial wave 
reflection in response to salbutamol that is the primary outcome of interest, with 
GTN being used as a control for vascular smooth muscle NO responsiveness. 
Therefore, given the possibility that the haemodynamic changes resulting from GTN 
might affect the response to ß2-adrenoreceptor stimulation, salbutamol was 
administered first and GTN second.  
 
The inclusion of a placebo arm in the present study facilitates analysis of the effect 
of prior salbutamol on GTN responses. Measures of arterial wave reflection were 
significantly lower and HR significantly higher 60 minutes after salbutamol 
compared to 60 minutes after placebo. Although this is consistent with the plasma 
half life of salbutamol of 4 to 6 hours, it means that GTN was administered at a time 
that salbutamol was still exerting an effect on the vasculature. The consequence of 
this was that the effect of GTN, when expressed as change from baseline, was greater 
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when administered after salbutamol (Figure 3.6 and Figure 3.7). Thus, a potential 
limitation of the methodology is that the response to GTN is affected by prior 
salbutamol and the response to salbutamol may be affected by prior GTN. Currently, 
the evidence that prior GTN affects the salbutamol response is indirect 
(haemodynamic changes suggesting neurohormonal activation) and a study 
comparing salbutamol responses after GTN to after GTN placebo would establish 
definitively whether or not this is an issue. If it is, then administering the drugs on 
separate days could be considered for future studies. Clearly, this would reduce the 
convenience of the methodology (one of its major strengths), although administering 
GTN could be restricted to a representative subset of subjects.  
 
Based on the results of the previous study (section 3.2), the dose of GTN used, 50 
µg, was chosen as that which would reduce aortic AIx to a similar degree as inhaled 
salbutamol 400 µg in healthy subjects. However, the effect of salbutamol on arterial 
wave reflection in healthy subjects was lower in the present study than in previous 
work, for example a mean maximum change in aortic AIx of 6% compared to around 
10-11% in the study by Wilkinson et al (2002a). The consequence of this was that 
GTN had a greater effect on arterial wave reflection than did salbutamol. A lower 
dose, 25 µg, would most likely have more closely approximated the effect of the ß2-
adreoreceptor agonist (Oliver et al., 2005a). Another potential advantage of a lower 
dose is that it might result in less neurohormonal activation and influence any 
subsequent response to salbutamol to lesser degree.  
 
3.3.5.5 Which measure of arterial wave reflection? 
Previous studies have quantified the effect of salbutamol on arterial wave reflection 
either as the change in aortic AIx (Wilkinson et al., 2002a) or as the change in RAIx 
(Hayward et al., 2002b). The advantage of using RAIx is that it is directly measured. 
aortic AIx, on the other hand, is calculated from the aortic pressure waveform which, 
in turn, is derived from the peripheral pressure waveform using a GTF. This requires 
additional investment in equipment and one might also speculate that the potential 
for error in the calculation of aortic AIx may have the consequence that its response 
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to salbutamol will be less powerful than the response of RAIx in predicting future 
cardiovascular events.  
 
Salbutamol increased HR by up to 7 bpm and this, in itself, would be expected to 
reduce aortic AIx (Wilkinson et al., 2000a). Given that salbutamol has very little 
effect on BP, it is likely that the increase in HR is largely the result of a direct 
positive chronotropic effect through stimulation of cardiac ß-adrenoreceptors. The 
consequence of this is that some of the salbutamol-induced reduction in aortic AIx 
may occur independently of effects on the vascular endothelium. In this regard, the 
effect of salbutamol on aortic AIx@75, which is aortic AIx normalised to a HR of 75 
bpm, might be a more appropriate measure of endothelial vasomotor function. As 
would be expected given its effect on HR, salbutamol significantly reduced aortic 
AIx@75 but not as much as it reduced aortic AIx. Currently, there is no consensus 
on whether the response to salbutamol is best quantified as the change in RAIx, in 
aortic AIx or in aortic AIx@75. The value of each in predicting cardiovascular 
events in prospective longitudinal studies will determine if one is superior to the 
others. In addition, in published studies, the responses of aortic AIx and RAIx to 
salbutamol and GTN have been expressed as maximum changes from baseline. An 
alternative method for quantifying the effects on arterial wave reflection of these 
drugs is as the AUC of the change from baseline. The relative value of these 2 
approaches should also be evaluated in prospective studies.  
 
3.3.5.6 Summary 
In summary, the effect of inhaled salbutamol on arterial wave reflection is not 

















Smoking impairs endothelium-dependent vasodilatation and this has been 
demonstrated as reduced responses to endothelium-dependent agonists in both the 
coronary (Kugiyama et al., 1996; Zeiher et al., 1995) and forearm circulations 
(Heitzer et al., 1996; Kimura et al., 2003) and as reduced FMD of the brachial artery 
(Celermajer et al., 1993). The effect of smoking on the systemic vascular 
responsiveness to salbutamol has not been investigated.  
 
There are conflicting data on the effect of PDE5 inhibition on endothelial vasomotor 
function in smokers. Kimura et al (2003) found that oral sildenafil 100 mg 
augmented ACh-induced vasodilatation in the forearm and Vlachopoulos et al (2004) 
found that sildenafil 50 mg improved brachial artery FMD. In contrast, Dishy et al 
(2004) found that sildenafil 50 mg had no effect on brachial artery FMD. In all of 
these studies, other than being smokers, the subjects were healthy. The effect of 
PDE5 inhibition on the systemic vascular responsiveness to salbutamol in smokers 
has not been investigated. 
 
4.1.1 Aims 
The aims of this study were to investigate in healthy men: 
1. The effect of smoking on endothelium-dependent vasomotor function measured as 
the change in peripheral arterial wave reflection with inhaled salbutamol. 
2. The acute effect of sildenafil on endothelium-dependent vasomotor function in 






4.2.1.1 Identification of subjects 
Suitable subjects were identified from a database of subjects who had previously 
taken part in research at the CRC and from those who responded to advertisements 
placed around the city of Edinburgh. 
 
4.2.1.2 Inclusion criteria 
• Healthy male 
• Aged 18 to 50 years 
• Smokers: at least a 2 pack-year history of smoking 
• Non-smokers: never smoked 
 
4.2.1.3   
4.2.1.4 Exclusion criteria 
• History of major cardiac, respiratory, neurological or renal disease 
• Known risk factors for cardiovascular disease 
• Family history of premature cardiovascular disease 
• Asthma 
• Taking any regular medicine 
• Current alcohol or drug abuse 
• Previous serious drug allergy 
 
4.2.2 Study design 
Randomised, placebo-controlled, single-blind, 2-way crossover.  
 
4.2.3 Protocol 
Subjects attended on 2 occasions, each separated by at least 5 days. Smokers smoked 
a single cigarette 1 hour before resting supine. At the first visit height and weight 
were measured and a fasting blood sample was taken for full blood count and 
biochemistry. Otherwise, the protocol was the same at both visits. After at least 30 
minutes rest, BP, HR and PWA were measured at -20, -10 and -5 minutes. Sildenafil 
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100 mg or matched placebo were administered at 0 minutes and the measurements 
were repeated after 30 and 55 minutes. Salbutamol 400 µg was administered at 60 
minutes and measurements were again repeated every 5 minutes for a further 30 
minutes. All measures were made in duplicate and the mean values were entered into 
the analyses.  
 
4.2.4 Data analyses 
Data are presented as means (SDs). Baseline was taken as the mean of the measures 
at -10 and -5 minutes. The effects of sildenafil at +55 minutes are presented as 
absolute changes from baseline. Response to salbutamol was defined, for each 
subject, as both the maximum absolute change from the +55 minute time point and 
as the AUC of the absolute change from the +55 minute time point until 30 minutes 
after salbutamol. Paired Students’ t-tests were used for sildenafil vs placebo 








Twelve smokers and 11 non-smokers were recruited. There were no differences in 
the baseline characteristics between the smokers and non-smokers (Table 4.1). The 
mean number of pack years for the smoking group was 6.1 (7.8). 
 
  Non-smokers Smokers 
Age (years) 25 (9) 24 (8) 
Systolic BP (mmHg) 120 (11) 119 (7) 
Diastolic BP (mmHg) 67 (9) 69 (6) 
HR (bpm) 63 (11) 68 (7) 
RAIx (%) 41 (11) 50 (12) 
Aortic AIx (%) 0 (8) 4 (10) 
Aortic AIx@75 (%) -6 (10) 1 (11) 
BMI (Kg/m2) 25 (2) 24 (3) 
Plasma glucose (mmol/L) 4.8 (0.3) 4.8 (0.4) 
Serum cholesterol:    
Total (mmol/L) 4.5 (1.1) 4.5 (0.7) 
LDL (mmol/L) 2.4 (0.9) 2.5 (0.8) 
HDL (mmol/L) 1.3 (0.2) 1.4 (0.3) 
Total:HDL ratio 3.4 (1.2) 3.4 (1.1) 
Triglycerides (mmol/L) 1.4 (0.7) 1.3 (0.6) 
 
Table 4.1. Baseline characteristics of the subjects.  
For BP, HR, RAIx, aortic AIx and aortic AIx@75 values are the means of the 
baselines from each visit. 
 
 
4.3.2 Baseline responses to salbutamol 
Responses to salbutamol when administered 1 hour after placebo provided a measure 
of baseline endothelium-dependent vasomotion. When analysed as the AUC of the 
change in aortic AIx, smokers had a significantly reduced response to salbutamol 
compared to non-smokers. However, there were no significant differences between 
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smokers and non-smokers either in the response of aortic AIx when analysed as the 
maximum change, or in the response of any other parameter, however analysed.  
 
 Maximum change*  AUC (AU) 
 Non-smokers Smokers P  Non-smokers Smokers P 
SBP 3 (9) -1 (10) 0.4  34 (158) -34 (155) 0.3 
DBP -5 (6) -1 (9) 0.2  -56 (84) -23 (128) 0.5 
HR 1 (13) 5 (11) 0.5  56 (212) 35 (183) 0.8 
AAIx -8 (8) -4 (10) 0.3  -159 (124) -29 (143) 0.03 
AAIx@75 -5 (9) -1 (12) 0.4  -104 (130) 5 (161) 0.09 
RAIx  -5 (7) -3 (11) 0.7  -79 (77) -42 (174) 0.5 
 
Table 4.2. Responses to salbutamol when administered after placebo. 
SBP = systolic BP, DBP = diastolic BP. *For maximum changes units are mmHg for 
SBP and DBP, bpm for HR and % for aortic AIx (AAIx), aortic AIx@75 
(AAIx@75) and RAIx. 
 
 
4.3.3 Effect of sildenafil 
The effects of sildenafil and placebo on each haemodynamic parameter is shown in 
Table 4.3. Compared to placebo, sildenafil reduced systolic BP in smokers but not in 
non-smokers. There were no significant effects of sildenafil or placebo on diastolic 
BP, HR or any measure of arterial wave reflection in either smokers or non-smokers, 
except for a significant reduction in aortic AIx@75 with placebo in smokers.  
 
 Non-smokers  Smokers 
 Placebo Sildenafil P  Placebo Sildenafil P 
Systolic BP (mmHg) 0 (4) -1 (3) 0.9  -1 (7) -9 (7) 0.02 
Diastolic BP (mmHg) 0 (4) -3 (6) 0.3  -3 (4) -6 (5) 0.3 
HR (bpm) -2 (5) -1 (9) 0.7  -5 (6) -1 (7) 0.1 
Aortic AIx 0 (9) 0 (6) 0.9  -1 (7) 2 (8) 0.1 
Aortic AIx@75 0 (8) 0 (6) 0.7  -3 (8) 1 (8) 0.02 
RAIx  2 (8) 1 (8) 0.9  0 (7) -4 (15) 0.4 
 
Table 4.3. Effects of sildenafil and placebo on haemodynamic parameters. 
Data are changes from baseline to +55 minutes. Comparisons are between sildenafil 
and placebo. 
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There were no statistically significant effects of sildenafil on the responses to 
salbutamol, although there were trends to an improvement in smokers when analysed 
as AUCs of the changes from +55 minutes (Table 4.4).  
 
 Non-smokers  Smokers 
 Placebo Sildenafil P  Placebo Sildenafil P 
       Max. change*       
SBP 3 (9) -2 (10) 0.3  -1 (10) 2 (11) 0.4 
DBP -5 (6) -2 (7) 0.3  -1 (9) -3 (10) 0.5 
HR 1 (13) 4 (11) 0.6  5 (11) 9 (7) 0.2 
AAIx -8 (8) -10 (7) 0.7  -4 (10) -3 (19) 0.8 
AAIx@75 -5 (9) -5 (10) 0.9  -1 (12) 1 (19) 0.8 
RAIx  -5 (7) -6 (9) 0.7  -3 (11) -10 (11) 0.4 
        
AUC (AU)        
SBP 34 (158) -48 (151) 0.2  -34 (155) 68 (175) 0.08 
DBP -56 (84) -49 (79) 0.8  -23 (128) -47 (119) 0.5 
HR 56 (212) 68 (211) 0.9  35 (183) 123 (133) 0.1 
AAIx -159 (124) -140 (95) 0.8  -29 (143) -96 (266) 0.2 
AAIx@75 -104 (130) -95 (113) 1  5 (161) -31 (222) 0.5 
RAIx  -79 (77) -100 (108) 0.7  -42 (174) -134 (110) 0.5 
 
Table 4.4. Effects of salbutamol after sildenafil and after placebo. 
Comparisons are between sildenafil and placebo. *For maximum changes units are 
mmHg for SBP and DBP, bpm for HR and % for aortic AIx (AAIx), aortic AIx@75 




4.4.1 Main findings 
The main findings of the present study were: 
1. The AUC of the change in aortic AIx with salbutamol was reduced in smokers 
compared to non-smokers. 
2 Sildenafil reduced systolic BP in smokers but not in non-smokers.  
3. There was a trend to an improvement in the response to salbutamol with sildenafil 
in smokers. 
 
4.4.2 Baseline endothelium-dependent vasomotion 
In the present study there was a reduced vascular response to salbutamol in smokers, 
indicating systemic endothelial vasomotor dysfunction. Although smoking is known 
to impair endothelial vasomotor function this has not previously been demonstrated 
using the salbutamol-based methodology. The data provide further evidence in 
support of the validity of the methodology in assessing endothelial vasomotor 
function, especially given its ability to detect endothelial vasomotor dysfunction in 
such a small, young population with a relatively short exposure to smoking. 
 
This difference between smokers and non-smokers only achieved statistical 
significance with aortic AIx and, even then, only when analysed as the AUC of the 
change in this parameter following salbutamol. Nevertheless, consistent with this 
effect, there were trends to reduced responsiveness to the mean maximum change in 
aortic AIx, and also to the AUC of the changes and the mean maximum changes in 
aortic AIx@75 and RAIx. These data suggest that systemic endothelial vasomotor 
dysfunction might be most sensitively detected when the AUC of the change in 
aortic AIx is used and this should be specifically investigated in future studies that 
utilise the methodology. A potential explanation for the superiority of the AUC over 
the maximum change is that the noise related to the inherent variability in the 
measurement of aortic AIx (and the other wave reflection parameters) may be 
minimised when the AUC, rather than the maximum change, is calculated.  
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4.4.3 The effect of sildenafil on endothelium-dependent vasomotion 
Although not statistically significant there was a trend to an improvement in 
salbutamol responsiveness in smokers with sildenafil, at least when analysed as 
AUCs of changes in measures of arterial wave reflection. Thus, sildenafil may 
improve systemic endothelial vasomotor function, but the study was probably 
underpowered to detect this effect of treatment. Indeed, sixty-two smokers would be 
required to detect a difference of 67 AUC units between sildenafil and placebo (the 
mean difference in the current study) in the effect of salbutamol on aortic AIx with 
80% power at 5% significance.  
 
The present study is the 4th to investigate the effect of sildenafil on endothelium-
dependent vasomotor function in smokers. Of the 3 previous studies, 2 showed an 
improvement with sildenafil (Kimura et al., 2003; Vlachopoulos et al., 2004) and 1 
showed no effect (Dishy et al., 2004). In terms of size and subject demographics 
these studies were similar. All were relatively small, (n = 9, 10 and 14) and all 
recruited relatively young, otherwise healthy men (mean ages 39, 33 and 28 years). 
In the study by Kimura et al the conditions may have been maximised to detect an 
effect of sildenafil. They used the highly sensitive gold standard methodology for the 
assessment of endothelium-dependent vasomotor function, forearm venous 
plethysmography, recruited subjects with a relatively extensive smoking history (≥20 
cigarettes per day for ≥10 years) and gave sildenafil in a dose of 100 mg. If, as is 
thought, systemic salbutamol reduces arterial wave reflection by causing resistance 
artery vasodilatation (see sections 1.5.1.2 and 3.3.5.2), these data are consistent with 
the, admittedly statistically non-significant, data from the present study in suggesting 
that sildenafil improves endogenous NO-mediated responses at the resistance vessel 
level. The 2 other studies investigated the effect of sildenafil 50 mg on brachial 
artery FMD. As in the present study, but in contrast to that by Kimura et al, in both 
of these measurements were made following acute smoking. In addition, in both 
studies subjects with a relatively extensive history of smoking were recruited. 
Therefore, the discrepancy in the observed effects of sildenafil is difficult to explain. 
Overall, there remains some uncertainty on the effects of sildenafil on endothelium-
86 86 
dependent vasomotor function in smokers, including whether effects differ between 
vascular sites.  
 
4.4.4 Baseline arterial wave reflection 
There was no statistically significant difference in baseline measures of arterial wave 
reflection between smokers and non-smokers, although there was a trend to an 
increase in smokers. In a much larger study in young subjects, aortic AIx was shown 
to be increased in smokers (Mahmud et al., 2003) indicating that the present study 
was probably underpowered to detect a significant difference. The demonstration of 
impaired endothelial vasomotor function but less clear effect on arterial wave 
reflection may indicate that smoking affects endothelial function before it affects 
arterial wave reflection or arterial stiffness in smokers, in keeping with the 
hypothesis that endothelial dysfunction contributes causally to arterial stiffening 
(Oliver et al., 2003; Wilkinson et al., 2004b). However, appropriately designed 
longitudinal studies are required to properly address this question.  
 
4.4.5 Effect of sildenafil on BP 
Sildenafil reduced systolic BP only in smokers, even though baseline BP was no 
different to non-smokers. Although this contrasts with a previous study in which 
there was no effect of sildenafil 50 mg on BP in smokers (Dishy et al., 2004), the 
possibility that smokers are more sensitive to the BP-lowering effect of PDE5 
inhibition is worthy of further investigation.  
 
4.4.6 Limitations 
The effect on arterial wave reflection of an NO-dependent, endothelium-independent 
control such as sublingual GTN was not assessed. This is because of the potential 
interaction on BP between sildenafil and organic nitrates (see section 1.3.3). As a 
result, it is not possible to be absolutely confident that the impaired response of 
aortic AIx to salbutamol in smokers relates to dysfunction at the level of the 
endothelium. However, given that the salbutamol-induced changes in aortic AIx are 
endothelium-dependent (Wilkinson et al., 2002a) and that smokers are known to 
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exhibit endothelial dysfunction, it is most likely that the mechanism is through 
reduced endothelial NO release.  
 
Peak plasma concentrations of sildenafil occur between 0.5 and 2 hours after oral 
administration. The effect of sildenafil on endothelial function was assessed 1 hour 
after oral administration. Although this is the average time to peak plasma 
concentration, in some subjects the peak effect on endothelial function may not have 
been captured, limiting the ability to demonstrate a statistically significant effect. 
Unfortunately, a limitation of using systemic salbutamol is that it is not possible to 
make short-term serial measurements of endothelial function. The minimal interval 
between salbutamol challenges has not been determined, but given that the plasma 
half life of salbutamol is 4 to 6 hours further acute assessments of the effect of 
sildenafil are unlikely to be feasible.  
 
4.4.7 Summary 
Smokers exhibit impaired vascular responsiveness to inhaled salbutamol, indicating 
systemic endothelial dysfunction. Sildenafil may improve the vascular response to 












THE TIME COURSE OF THE INTERACTION BETWEEN ORAL 







The simultaneous provision of exogenous NO from organic nitrates and inhibition of 
cGMP breakdown with PDE5 inhibition can result in substantial BP reduction and, 
as a result, the combined use of organic nitrates and PDE5 inhibitors is absolutely 
contraindicated. A recommendation has been made that organic nitrates should not 
be administered to patients who have taken sildenafil within 24 hours (Cheitlin et al., 
1999). Organic nitrates, especially GTN, are highly effective and commonly used in 
the treatment of acute angina. Therefore, if a patient presents with acute angina 
treatment is more difficult if they have taken sildenafil in the previous 24 hours 
because GTN is not a therapeutic option. 
 
Most studies on the interaction between sildenafil and organic nitrates have 
concentrated on the maximum interaction (Webb et al., 1999; Webb et al., 2000). 
However, in keeping with its plasma half-life of 3-5 hours, blood concentrations of 
sildenafil are very low 24 hours after a single dose. Therefore, it is possible that 
organic nitrates could safely be administered at a shorter interval after sildenafil than 
the 24 hours that is currently recommended. A previous study performed in the CRC 
found that the interaction of GTN 400 µg spray and oral sildenafil 100 mg lasted less 
than 4 hours after sildenafil administration (Figure 5.1). The main limitation of this 
study, which is not yet published, was that it was performed in healthy subjects and it 
may not be appropriate to extrapolate the findings to patients with angina, the 
clinically relevant population. 
 
5.1.2 Aim 
To characterise the time course of the interaction on BP of sildenafil 100 mg with 
sublingual GTN 400 µg in men with stable angina. 
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Figure 5.1. Effect of GTN on BP after sildenafil and placebo in healthy men. 
Sublingual GTN 400 µg spray was administered at different times (as indicated on 
the x-axis) after sildenafil (blue) and matched placebo (red). Sitting BP was 
measured at baseline (before sildenafil or placebo) and at regular intervals after each 
GTN challenge (every 3 minutes for the first 30 minutes and then every 15 minutes 
for a further 90 minutes). The maximum reduction in BP from baseline during each 
2-hour monitoring period was recorded for each subject. The mean maximum 
changes, presented in the charts, were compared at each time point between 
sildenafil and placebo phases. Only at the 1-hour time point was the GTN-induced 







5.2.1.1 Identification of subjects 
Suitable subjects were identified from those attending the WGH for diagnostic 
coronary angiography and by searching the patient databases of 4 local General 
Practices.  
 
5.2.1.2 Inclusion criteria 
• Male  
• Aged 30 to 80 years 
• Weight between 60 and 100 Kg 
• Stable angina with one of: 
- Classical history of exertional angina pectoris 
- Previous diagnostic exercise test 
- Angiographic evidence of CAD 
 
5.2.1.3 Exclusion criteria 
• Regular treatment with long-acting nitrates or nicorandil where these cannot be 
withdrawn 72 hours before the study 
• MI, unstable angina, stroke or transient cerebral ischaemia within 3 months 
• Systolic BP > 170 mmHg or diastolic BP > 100 mmHg 
• Systolic BP < 100 mmHg or diastolic BP < 60 mmHg 
• Orthostatic hypotension (> 20 mmHg fall in systolic BP on standing) 
• Diabetes treated with oral hypoglycaemic agents or insulin 
• Any clinically significant disease other than stable angina, excepting other 
cardiovascular disease risk factors, e.g. smoking, hypercholesterolaemia and 
diet-controlled diabetes  
• Taking any drug that significantly interacts with sildenafil 
• Evidence of drug abuse 
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5.2.2 Screening visit 
Potentially suitable subjects who agreed to be considered for the study attended a 
screening visit at the CRC. At this visit the study was explained fully and written 
consent was obtained. A medical history was taken and a physical examination, 
including measurement of standing BP, and 12-lead ECG were performed. A non-
fasting screening blood sample was also taken. 
 
5.2.3 Study design 
Randomised, placebo-controlled, double blind, 4-way crossover. 
 
5.2.4 Drugs 
GTN 400 µg (Nitrolingual Pumpspray®, Merck Pharmaceuticals, West Drayton, 
UK) was administered as a single spray sublingually. Sildenafil 100 mg and matched 
placebo were administered orally as single tablets. 
 
5.2.5 Protocol 
Subjects attended the research unit on 4 occasions, each separated by at least 5 days. 
On each study day, they took their regular morning medicines immediately after 
waking and had a light breakfast before attending the research unit at 07:00 hours. At 
visit 1 GTN was administered 4 and 8 hours after oral sildenafil or matched placebo 
and at visit 2 GTN was administered 4 and 8 hours after the alternative treatment 
(sildenafil or placebo). Similarly, at visits 3 and 4, GTN was administered 1 and 6 
hours after sildenafil or placebo, with alternate treatments given at each visit. The 
order in which sildenafil and placebo were given was randomised between visits 1 
and 2 and visits 3 and 4. Following at least 20 minutes rest, baseline sitting and 
standing BP and HR were recorded, in duplicate, 20 minutes and 5 minutes before 
sildenafil or placebo administration. Five minutes before and every 3 minutes for 33 
minutes after each GTN dose further measurements of sitting BP and HR were made, 
duplicate measures before GTN and single measures after GTN. Standing BP and 










Baseline BP and HR were calculated as the mean of measurements taken 20 and 5 
minutes before oral sildenafil or matched placebo administration. The pre-specified 
primary analysis was a comparison of the effects of the combination of sildenafil and 
GTN and the combination of placebo and GTN on the maximum reduction from 
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baseline in sitting BP and the maximum increase from baseline in HR that occurred 
in the 33 min following each GTN challenge.  
 
Effects from pre-GTN values were also assessed for each time point. Pre-GTN BPs 
and HRs were calculated as the mean of the 2 measurements made before each GTN 
challenge. Maximum reductions in BP, maximum increases in HR and AUCs for 
changes in these parameters from pre-GTN values, during the 33 min following each 
GTN challenge, were compared between sildenafil and placebo phases. The effects 
of sildenafil and placebo on standing BP and HR 36 min after each GTN challenge 
were also compared.  
 
Unless stated, data are presented as means (SEMs). All comparisons between 
sildenafil and placebo were made using 2-way ANOVA allowing for variation due to 
subject, treatment and treatment order. Differences in proportions between groups 
were analysed using the binomial test for comparison of proportions. Correlation 








Twenty-three subjects were formally assessed for suitability for the study and, of 
these, 2 were not suitable. Of the 21 recruited, 1 was withdrawn because his baseline 
BP was too low (90/58 mmHg) at his first visit. Analyses were performed using the 
data from the remaining 20 subjects. In 1 further subject, 4 hours after sildenafil 
administration on visit 2, BP had decreased from 120/70 mmHg to 86/46 mmHg and, 
as a result, GTN was not administered. These data were included in the comparison 
of the effects of sildenafil and placebo on pre-GTN BP and HR, but the comparison 
of sildenafil with GTN and placebo with GTN at 4 hours was analysed using the data 
from the remaining 19 subjects. GTN was administered to this subject at the 8 hour 
time point on the same day and at all time points at the other 3 visits. One subject 
was taking regular ISMN and this was withdrawn 72 hours prior each visit. None of 
the subjects had used sublingual GTN in the 24 hours preceding any of the visits. 
The baseline subject characteristics are given in Table 5.1. 
 
 Number (%)   Mean (SD) 
Current smokers 7 (35)  Age (years) 66 (8) 
Ex-smokers 3 (15)  Plasma glucose (mmol/L) 5.5 (0.6) 
Previous PCI 12 (60)  Serum cholesterol:  
Previous CABG 2 (10)  Total (mmol/L) 4.2 (0.5) 
Hypertension 7 (35)  LDL (mmol/L)* 2.1 (0.5) 
Current drugs:   HDL (mmol/L) 1.1 (0.2) 
Aspirin 19 (95)  Total:HDL ratio 3.9 (0.9) 
Clopidogrel 4 (20)  Triglyceride (mmol/L) 2.4 (1.6) 
ß-blocker 19 (95)    
CCB 7(35)    
ISMN 1 (5)    
ACE inhibitor 9 (45)    
ARA 2 (10)    
Statin 19 (95)    
Thiazide diuretic 5 (25)    
 
Table 5.1. Subject baseline characteristics. 
*Values from 18 subjects (in 2 subjects serum LDL concentration could not be 
calculated because serum triglyceride concentration was too high). PCI = 
percutaneous coronary intervention. CABG = coronary artery bypass graft. 
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5.3.2 Sitting BP and HR 
5.3.2.1 Effect of sildenafil alone 
Compared to placebo, sildenafil alone reduced sitting systolic BP and diastolic BP. 
This effect was evident from 1 hour, peaked at 4 hours [when placebo-corrected 
changes in systolic BP and diastolic BP were: -12 (6) mmHg (P = 0.01) and -8 (3) 
mmHg (P = 0.0008) respectively], and was maintained until at least 8 hours after 
administration (Figure 5.3). There was no effect of sildenafil alone on HR. 
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Figure 5.3. Effect of sildenafil alone on sitting BP and HR. 
Sildenafil in blue and placebo in red. Measures are those taken before each GTN 
challenge. *P<0.05, **P<0.01. 
 
97 97 
5.3.2.2 Effect of the combination of sildenafil and GTN 
The absolute effects on sitting BP and HR of GTN with sildenafil and GTN with 
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Figure 5.4. Mean effects on sitting BP and HR of GTN with sildenafil and with 
placebo.  
Sildenafil in blue and placebo in red. Baseline values are those taken before 
sildenafil or placebo administration. For each time point, baseline values are 




Compared to the combination of GTN and placebo, the combination of GTN and 
sildenafil resulted in greater mean maximum reductions in systolic BP at 1, 4 and 8 
hours, and in diastolic BP at all time points (Figure 5.5). At 6 hours there was a trend 
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to a greater mean maximum reduction in systolic BP with sildenafil, but this did not 
achieve statistical significance. There was a greater effect on the maximum increase 
in HR with the combination of GTN and sildenafil than with the combination of 
GTN and placebo at 1 hour, but not at 4, 6 or 8 hours.  
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Figure 5.5. Mean maximum changes in sitting BP and HR with GTN given after 
sildenafil and after placebo. 
Sildenafil in blue and placebo in red. Changes are from baseline recordings taken 




Table 5.2 shows how often systolic BP was reduced to less 100 mmHg, 90 mmHg 
and 80 mmHg and how often diastolic BP was reduced to less than 60 mmHg, 50 
mmHg and 40 mmHg at some point during the monitoring period after each GTN 
challenge. Table 5.3 shows how often systolic BP was reduced by more than 20 
mmHg, 30 mmHg and 40 mmHg and how often diastolic BP was reduced by more 





 Systolic BP <100 mmHg  Systolic BP <90 mmHg  Systolic BP < 80 mmHg 
 1 hr** 4 hr* 6 hr 8 hr  1 hr** 4 hr** 6 hr** 8 hr  1 hr** 4 hr 6 hr 8 hr 
               Sildenafil 19 (95) 15 (79) 15 (75) 12 (60)  12 (60) 8 (42) 10 (50) 8 (40)  7 (35) 4 (21) 2 (10) 2 (10) 
Placebo 11 (55) 9 (45) 12(60) 7 (35)  2 (10) 2 (10) 1 (5) 3 (15)  0 (0) 1 (5) 1 (5) 0 (0) 
               
               
 Diastolic BP <60 mmHg  Diastolic BP <50 mmHg  Diastolic BP < 40 mmHg 
 1 hr** 4 hr** 6 hr* 8 hr*  1 hr** 4 hr** 6 hr 8 hr  1 hr 4 hr 6 hr 8 hr 
               Sildenafil 19 (95) 18 (95) 17 (85) 17 (85)  11 (55) 9 (47) 6 (30) 6 (30)  0 (0) 0 (0) 0 (0) 0 (0) 
Placebo 9 (45) 11 (55) 13 (65) 11 (55)  1 (5) 1 (5) 1 (5) 1 (5)  0 (0) 0 (0) 0 (0) 0 (0) 
 
 
Table 5.2. Frequency with which BP was reduced below different thresholds at each GTN challenge.  
Numbers (percentages) of subjects whose sitting BP fell to below different thresholds at some point in the 33-minute monitoring period 
after each GTN challenge. Comparisons between sildenafil and placebo were made of the proportions of subjects in whom BP fell below 






 Systolic BP fall >20 mmHg  Systolic BP fall >30 mmHg  Systolic BP fall >40 mmHg 
 1 hr** 4 hr* 6 hr* 8 hr  1 hr** 4 hr* 6 hr 8 hr  1 hr* 4 hr* 6 hr 8 hr 
               Sildenafil 19 (95) 16 (84) 15 (75) 13 (65)  12 (60) 7 (37) 7 (35) 8 (40)  4 (20) 6 (32) 3 (15) 4 (20) 
Placebo 6 (30) 9 (45) 8 (40) 8 (40)  1 (5) 2 (10) 4 (20) 4 (20)  0 (0) 1 (5) 2 (10) 1 (5) 
               
               
 Diastolic BP fall >15 mmHg  Diastolic BP fall >20 mmHg  Diastolic BP fall >25 mmHg 
 1 hr** 4 hr* 6 hr 8 hr*  1 hr** 4 hr* 6 hr 8 hr  1 hr 4 hr 6 hr 8 hr 
               Sildenafil 12 (60) 7 (37) 9 (45) 8 (40)  8 (40) 4 (21) 4 (20) 3 (15)  1 (5) 3 (16) 2 (10) 0 (0) 
Placebo 3 (15) 2 (10) 5 (25) 2 (10)  1 (5) 0 (0) 2 (10) 0 (0)  0 (0) 0 (0) 0 (0) 0 (0) 
 
 
Table 5.3. Frequency with which BP was reduced by different thresholds with each GTN challenge. 
Numbers (percentages) of subjects whose sitting BP fell by more than various thresholds at some point in the 33-minute monitoring period 
after each GTN challenge. Comparisons between sildenafil and placebo were made of the proportions of subjects in whom BP fell by more 
than each of the thresholds (if significant indicated as *P<0.05 or **P<0.01). 
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When the data from each of the GTN challenges following sildenafil administration 
were combined there was a significant correlation between baseline BP and the 
minimum BP recorded following GTN challenge (Figure 5.6). Correlations between 
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Figure 5.6. Relationships between baseline BP and minimum BP after GTN 
challenge following sildenafil administration.  
Data from all 4 GTN challenges are included. 
 
 
  Pearson r P value 
Systolic BP 1 hour 0.51 0.02 
 4 hour 0.51 0.03 
 6 hour 0.49 0.02 
 8 hour 0.37 0.11 
Diastolic BP 1 hour 0.33 0.16 
 4 hour 0.62 0.005 
 6 hour 0.41 0.07 
 8 hour 0.6 0.005 
 
Table 5.4. Correlations between baseline BP and minimum BP recorded after 




The magnitude of the maximum reduction in BP with the combination of sildenafil 
and GTN was significantly correlated with baseline BP when all time points were 
combined (Figure 5.7), with baseline systolic BP at each time point and with baseline 
diastolic BP at 1 hour (Table 5.5).  
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Figure 5.7. Relationships between baseline BP and maximum change in BP after 
GTN challenge following sildenafil administration. 




  Pearson r P value 
Systolic BP 1 hour -0.62 0.003 
 4 hour -0.49 0.03 
 6 hour -0.48 0.03 
 8 hour -0.65 0.003 
Diastolic BP 1 hour -0.6 0.006 
 4 hour -0.06 0.8 
 6 hour -0.44 0.053 
 8 hour -0.28 0.23 
 
Table 5.5. Correlations between baseline BP and maximum change in BP after 
each GTN challenge following sildenafil administration.  
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The absolute changes in sitting BP and HR from pre-GTN values are shown in 



















1 hour 4 hours 6 hours 8 hours





Figure 5.8. Mean changes in sitting BP and HR with GTN following sildenafil 
and placebo.  
Sildenafil in blue and placebo in red. Changes are calculated from pre-GTN 
recordings. AUCs were compared statistically between sildenafil and placebo.  
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Figure 5.9. Mean maximum changes in sitting BP and HR with GTN given after 
sildenafil and after placebo. 
Sildenafil in blue and placebo in red. Changes are from pre-GTN recordings. 
 
 
At 1 hour, sildenafil appeared to prolong the duration of GTN-induced reduction in 
systolic BP. However, there were no statistically significant differences between 
sildenafil and placebo in the change in systolic BP from pre-GTN values at any time 
point, whether analysed as maximum reduction or as AUC. At 1 hour, the change in 
diastolic BP from the pre-GTN value was greater with sildenafil than with placebo, 
whether measured as the maximum reduction or as the AUC and, as with systolic 
BP, sildenafil appeared to prolong the duration of GTN action. At other time points 
there were no statistically significant differences between sildenafil and placebo in 
the change in diastolic BP from pre-GTN values. There were also no statistically 
significant differences between sildenafil and placebo in the change in HR from pre-
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GTN values at any time point. Table 5.6 shows how often systolic BP was reduced 
by more than 20 mmHg, 30 mmHg and 40 mmHg and how often diastolic BP was 
reduced by more than 10 mmHg, 15 mmHg and 20 mmHg from pre-GTN values at 







 Systolic BP fall >20 mmHg  Systolic BP fall >30 mmHg  Systolic BP fall >40 mmHg 
 1 hr* 4 hr 6 hr 8 hr  1 hr 4 hr 6 hr 8 hr  1 hr 4 hr 6 hr 8 hr* 
               Sildenafil 15 (75) 8 (42) 8 (40) 9 (45)  3 (15) 5 (26) 1 (5) 3 (15)  1 (5) 3 (16) 1 (5) 0 (0) 
Placebo 9 (45) 8 (40) 11 (55) 6 (30)  3 (15) 4 (20) 3 (15) 5 (25)  0 (0) 0 (0) 0 (0) 5 (25) 
               
               
 Diastolic BP fall >10 mmHg  Diastolic BP fall >15 mmHg  Diastolic BP fall >20 mmHg 
 1 hr* 4 hr 6 hr 8 hr*  1 hr 4 hr* 6 hr 8 hr  1 hr 4 hr 6 hr 8 hr 
               Sildenafil 13 (65) 9 (47) 4 (20) 8 (40)  3 (15) 4 (21) 2 (10) 2 (10)  1 (5) 1 (5) 0 (0) 1 (5) 
Placebo 7 (35) 5 (25) 2 (10) 7 (35)  3 (15) 2 (10) 0 (0) 2 (10)  1 (5) 1 (5) 0 (0) 1 (5) 
 
 
Table 5.6. Frequency with which BP was reduced by different thresholds with each GTN challenge. 
Numbers (percentages) of subjects whose sitting BP fell, from pre-GTN values, by more than various thresholds at some point in the 33-
minute monitoring period after each GTN challenge. Comparisons between sildenafil and placebo were made of the proportions of subjects 
in whom BP fell by more than each of the thresholds (if significant indicated as *P<0.05 or **P<0.01). 
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When the data from each of the GTN challenges following sildenafil administration 
were combined the maximum reductions in both systolic BP and diastolic BP from 
pre-GTN values were significantly correlated with pre-GTN values (Figure 5.10). 
The correlations at each time point are shown in Table 5.7.  
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Figure 5.10. Relationships between pre-GTN BP and maximum change in BP 
from pre-GTN values after GTN challenge following sildenafil administration. 




  Pearson r P value 
Systolic BP 1 hr -0.4 0.08 
 4 hr -0.57 0.01 
 6 hr -0.25 0.29 
 8 hr -0.42 0.06 
Diastolic BP 1 hr -0.46 0.04 
 4 hr -0.26 0.3 
 6 hr -0.32 0.16 
 8 hr -0.6 0.006 
 
Table 5.7. Correlations between pre-GTN BP and maximum change in BP from 
pre-GTN values after each GTN challenge following sildenafil administration.  
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5.3.3 Standing BP and HR 
Symptomatic hypotension prevented standing measurements being made in 2 
subjects 1 hour after sildenafil, but the data set was complete at all other time points. 
The effects on standing BP and HR of GTN with sildenafil and GTN with placebo 
are shown in Figure 5.11. Compared to the combination of GTN and placebo, the 
combination of GTN and sildenafil resulted in greater mean reductions in standing 
systolic BP and standing diastolic BP at all time points except systolic BP at 4 hours. 
There was also a greater increase in standing HR with the combination of GTN and 
sildenafil, although this achieved statistical significance only at 1 hour. 
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Figure 5.11. Mean changes in standing BP and HR with sildenafil and placebo.  
Sildenafil in blue and placebo in red. *P<0.05, **P<0.01. 
 
There was no interaction, by ANOVA, between treatment and treatment order for 
any of the parameters, either sitting or standing, at any of the time points. 
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5.3.4 Side effects 
Symptoms of hypotension (described as feeling dizzy or light headed, or having a 
“fuzzy” head) following GTN occurred in 8 subjects during the sildenafil phase but 
none of the subjects during the placebo phase. Of the 8 subjects who experienced 
hypotensive symptoms with sildenafil, 6 experienced them at the 1 hour GTN 
challenge (3 of whom needed to be lain supine with the foot of the bed elevated) and 
3 experienced them at the 4 hour GTN challenge (2 of whom needed to be lain 
supine with the foot of the bed elevated). None of the subjects experienced 
hypotensive symptoms at the 6 and 8 hour GTN challenges. Hypotensive symptoms 
were not reported by any subject outwith the monitoring periods following each 
GTN administration. It can be seen from Figure 5.12 that those who had to be lain 
supine because of hypotensive symptoms tended to be those whose BPs fell to the 





































Figure 5.12. Minimum BP and hypotensive symptoms. 
Scatter plot of minimum systolic (left) and diastolic (right) BPs after GTN challenges 
at 1 (top) and 4 hours (bottom) after sildenafil, stratified according to whether there 
were hypotensive symptoms but the subject remained sitting (Sympts RS), there 
were hypotensive symptoms requiring the subject to be lain supine (Sympts LS) or 
there were no hypotensive symptoms (No sympts). Horizontal lines are mean values. 
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A headache or “thick” head was experienced by 7 subjects after sildenafil (in 4 
instances temporally related to GTN administration) and 3 subjects after placebo (in 
1 instance temporally related to GTN administration and in a further instance a pre-
existing headache was worsened with GTN). Indigestion/heartburn, stuffy nose and 
facial flushing were each experienced by 2 subjects following sildenafil but no 
subjects after placebo. One subject experienced a subconjunctival haemorrhage 
following sildenafil. This did not affect vision and resolved over several weeks, as 
would be expected. One subject experienced an episode of sickness, facial pain and 







5.4.1 Main findings 
In the present study there was a greater mean maximum reduction in BP with oral 
sildenafil 100 mg and GTN 400 µg than with matched placebo and GTN 400 µg for 
at least 8 hours after sildenafil administration, although the magnitude of this 
difference was greater at 1 and 4 hours than at 6 and 8 hours. In addition, sildenafil 
alone significantly reduced BP compared to placebo at all time points. 
 
5.4.2 An additive or synergistic interaction? 
That sildenafil alone significantly reduced BP, raises the question as to the degree to 
which the interaction on BP that was observed with the combination of sildenafil and 
GTN could be accounted for by additive effects of the two drugs. In this respect, 
analysis of the effects of GTN on BP from pre-GTN values provides some insight 
into nature of the interaction at each time point. At 6 and 8 hours the acute change in 
systolic and diastolic BPs from pre-GTN values was no different between sildenafil 
and placebo phases, suggesting that the overall greater reduction in BP observed with 
sildenafil and GTN compared to placebo and GTN was, at least on average, no more 
than additive. At 4 hours there was a trend, albeit statistically non-significant, to a 
greater reduction in diastolic BP with GTN following sildenafil than following 
placebo, perhaps suggesting that the interaction was more than simply additive (i.e. a 
possible degree of synergism). At 1 hour the reduction in BP, especially diastolic BP, 
with GTN was clearly greater following sildenafil than following placebo, 
suggesting a synergistic interaction between the two drugs. However, it should be 
noted that the study design does not allow for precise determination of the nature of 
the interaction in terms of additive or synergistic effects. Thus, the effects of 
sildenafil on BP were only measured at 1, 4, 6 and 8 hours (pre-GTN values). 
Although the peak plasma concentrations of sildenafil generally occur 1 hour after 
oral administration it is possible that its effect on BP continued to increase after 1 
hour, potentially accounting for at least some of the difference observed between 
sildenafil and placebo phases in the change in diastolic BP following GTN at this 
time. In order to determine if this was the case, the effects of sildenafil with placebo 
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GTN and placebo sildenafil with placebo GTN would also have needed to be studied. 
This would have doubled the size of the study and meant that subjects would have 
had to attend eight long days, making it practically much more difficult to achieve. 
Moreover, these additional arms would not have altered the conclusion that the 
interaction between sildenafil and GTN on BP is, on average, no more than additive 
from 6 hours after sildenafil.  
 
The discussion on whether the interaction is additive or synergistic at different time 
points has important clinical relevance. When treating a patient with acute angina 
who has recently taken sildenafil, the likely effect of GTN on BP will be the major 
factor in determining whether it might be safe to administer GTN. Although the BP 
at presentation will probably be lower than the patient’s usual BP, due to the effect of 
sildenafil alone, if the expected further reduction in BP with GTN is likely to be no 
greater than would be expected if sildenafil had not been taken, then cautious use of 
GTN could be carefully considered. In contrast, if the interaction between sildenafil 
and GTN is synergistic then the potential for severe hypotension would mean that 
GTN should not be administered.  
 
5.4.3 Symptoms of hypotension 
Consistent with the effects on BP, symptoms suggestive of hypotension occurred at 1 
hour and 4 hours, although more commonly at 1 hour, but not at 6 and 8 hours after 
sildenafil. It is notable that of the 3 subjects who experienced hypotensive symptoms 
at 4 hours, only 1 had also experienced them at 1 hour, suggesting variability 
between individuals in the time to peak interaction rather than some individuals 
being susceptible to the interaction for prolonged periods.  
 
5.4.4 Comparison to effects in healthy men 
In contrast to the current study, in the previous similar study in healthy men the 
interaction on maximum reduction in sitting BP between sildenafil and GTN only 
occurred at 1 hour after sildenafil (Figure 5.1). At subsequent time points (including 
4, 6, and 8 hours) no interaction was observed. In this study sildenafil alone reduced 
diastolic BP at 1 hour but did not affect BP at other times (Figure 5.13).  
 
 113 







Time after sildenafil/placebo (hours)








Time after sildenafil/placebo (hours)
Systolic BP Diastolic BP
 
Figure 5.13. Effect of sildenafil and placebo alone on sitting BP and HR in 
healthy men. 




Given that the interaction between sildenafil and GTN in angina patients was 
generally no more than additive at 6 and 8 hours, it is likely that the difference 
between the groups in the effect on BP of sildenafil alone largely explains the 
different effects on mean maximum reductions in BP between the studies. There are 
a number of differences between the angina patient group and the healthy volunteer 
group that may have contributed to their different haemodynamic responses to 
sildenafil. For example, in addition to the presence of CAD, in the present study the 
subjects were older (mean age 66 years vs 49 years) and were taking a variety of 
vasoactive and other medicines.  
 
5.4.5 Standing BP 
There was a significant interaction on standing BP, both systolic and diastolic, for up 
to 8 hours, although this was most marked at 1 hour. When given after placebo GTN 
had little, if any, effect on standing BP and it is likely that this is because standing 
BP was not assessed until 36 min after GTN administration. Standing BP was not 
assessed before each GTN challenge (so as not to disturb pre-GTN sitting measures) 
and it is, therefore, not possible to formally to assess whether the interaction between 
the 2 drugs was additive or synergistic. However, the greater magnitude of the 
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interaction at 1 hour might suggest a degree of synergism at this time point. It should 
be noted that although effects on standing BP may be of academic interest, they are 
not relevant to the clinical situation because patients with acute angina will be kept 
supine or semi-recumbent.  
 
5.4.6 HR 
Sildenafil alone did not significantly affect HR at any time point. The increase in HR 
with GTN was greater with sildenafil than with placebo, both sitting and standing, 
only at 1 hour. Although the magnitude of the difference was small and unlikely to 
be of clinical significance in itself, it is consistent with a compensatory response to 
the potentially synergistic hypotensive interaction between sildenafil and GTN that 
occurred at this time point. The mean maximum increase in HR with the combination 
of sildenafil and GTN was around 5 to 10 bpm. In the previous healthy volunteer 
study the mean maximum increase in HR was greater, around 16 to 25 bpm. All but 
one of the angina patients in the current study were taking a ß-blocker and this may 
explain the difference in HR responses between the studies.  
 
5.4.7 Is it safe to administer sublingual GTN from 6 hours after sildenafil in 
clinical practice? 
Although the data from the present study indicate that the interaction between 
sublingual GTN and sildenafil is on average no more than additive from 6 hours after 
sildenafil, it is important to note that the possibility of clinically significant 
hypotension occurring in some patients when GTN is administered from 6 hours 
after sildenafil cannot be excluded. At 6 hours systolic BP fell to less than 90 mmHg 
in 10 (50%) subjects after sildenafil but only 1 (5%) subject after placebo. At 6 and 8 
hours systolic BP fell to less than 80 mmHg in 2 (10%) subjects after sildenafil 
whereas after placebo a systolic BP of less than 80 mmHg occurred in 1 (5%) subject 
at 6 hours and no subjects at 8 hours. At 6 and 8 hours diastolic BP fell to less than 
50 mmHg in 6 (30%) subjects after sildenafil and 1 (5%) subject after placebo. 
Similarly, at 6 and 8 hours systolic BP fell by more than 30 mmHg or 40 mmHg and 
diastolic BP by more than 20 mmHg or 25 mmHg in more subjects after sildenafil 
than after placebo. The lack of statistical significance in the difference in the 
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frequencies with which systolic BP fell to less than 80 mmHg or by more than 30 or 
40 mmHg and diastolic BP fell to less than 50 mmHg or by more than 20 or 25 
mmHg at 6 and 8 hours should not be interpreted as there being no clinically 
significant difference in hypotensive effect at these times. The study was relatively 
small and was not powered to detect an increased frequency of relatively uncommon, 
let alone rare, severe hypotension. On the other hand, there was no consistent 
tendency at 6 and 8 hours for systolic BP to fall more than 20, 30 or 40 mmHg or for 
diastolic BP to fall more than 10, 15 or 20 mmHg from pre-GTN values with any 
greater frequency with sildenafil than with placebo, although, once again, a larger 
sample size would allow for greater confidence in this.  
 
Overall, the hypotensive interaction between sildenafil and GTN is, on average, 
relatively diminished and not synergistic from 6 hours after sildenafil, but there is 
still a possibility of clinically significant hypotension in some patients given GTN up 
to 8 hours. Therefore, the study does not provide evidence that the recommended 
time interval between sildenafil and GTN should be reduced to less than 24 hours. 
However, these data are relatively reassuring and, when otherwise strongly indicated, 
cautious use of GTN could be considered in subjects with acute angina who have 
taken sildenafil at least 6 hours previously and who are haemodynamically stable. 
Bearing in mind that the subjects with lowest BPs at baseline were generally those in 
whom the lowest BPs occurred when sildenafil and GTN were co-administered, BP 
at presentation will be an important factor in the risk-benefit assessment under these 
clinical circumstances.  
 
A number of other factors should be taken into consideration before administering 
GTN to a patient who has taken sildenafil. In this study, sublingual GTN was 
administered in a standard clinical dose of 400 µg. However, it is not uncommon for 
a dose of 800 µg to be used for acute angina and it should not be assumed that the 
time course of the interaction between sildenafil and GTN that we have characterised 
in this study would be similar for higher doses of GTN. It is possible that lower 
doses of either drug would be safer at earlier time points after sildenafil, although 
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this would need to be investigated specifically. Similarly, the data should not be 
extrapolated to the buccal or intravenous use of GTN. 
 
Hepatic metabolism of sildenafil is reduced, and its plasma concentration increased, 
by a number of drugs, including cimetidine (Wilner et al., 2002), macrolide 
antibiotics (Muirhead et al., 2002a) and antifungal agents (Warrington et al., 2002). 
Therefore, concomitant administration of these drugs could prolong the time after 
taking sildenafil that individuals would be susceptible to a significant interaction on 
BP with GTN.  
 
The main outcome measure of the study was BP taken in the sitting position. When a 
patient presents to hospital with angina they are likely to be kept supine. Therefore, 
in this respect, our data may not be directly applicable to the clinical situation. 
However, we elected to measure sitting BP to maximise the observed effect on BP of 
sildenafil with GTN. If anything, lesser reductions in BP would have been expected 
in the supine position, so the conclusion that the interaction between sildenafil and 
GTN is, on average, no more than additive from 6 hours after sildenafil remains valid 
to the clinical situation.  
 
Potential limitations 
Subjects received two doses of GTN at each visit, either at 4 and 8 hours or at 1 and 
6 hours after sildenafil or placebo. During the placebo phase of the study the effects 
of GTN on BP were no less at 8 and 6 hours than at 4 hours and 1 hour (Figure 5.5, 
page 98), indicating that no significant nitrate tolerance occurred following the first 
dose of GTN on each day. 
 
When subjects experienced symptoms of hypotension it was often necessary to lie 
them supine and elevate the foot of the bed. Although this is clearly clinically 
appropriate, it has the potential to minimise the observed effect on BP – if subjects 
had remained sitting it is likely that their BP would have remained lower than in the 
supine position and may even have fallen further than the minimum BP that was 
actually recorded. However, this would not materially affect the main conclusion of 
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the study, as the differences between sildenafil and placebo would only be greater at 
1 and 4 hours, whereas there would have been no effect on the data at 6 and 8 hours 
because it was not necessary to lie any subjects supine at these time points.  
 
Subjects took their usual medicines, many of which were vasoactive, as normal 
during the study. These other medicines may have influenced the changes in BP that 
we observed with sildenafil and GTN, both alone and in combination. Indeed, as 
discussed above, concomitant use of other drugs may explain the difference in the 
effect on BP of sildenafil alone in the angina patients from the present study and the 
healthy volunteers from the previous study. However, withdrawing regular 
vasoactive medicines might have placed the participants at increased risk of 
symptomatic angina and, moreover, the study design was intended to be as 
applicable to the clinical situation as possible.  
 
The 4 visits of the study were not completely randomised. Rather, GTN was 
administered at 4 and 8 hours after sildenafil or placebo during the first 2 visits and 
at 1 and 6 hours after sildenafil or placebo during visits 3 and 4 (the order in which 
sildenafil and placebo were given being randomised between visits 1 and 2 and visits 
3 and 4). This design meant that there would have been an opportunity to prevent any 
subject who experienced severe hypotension at 4 hours from proceeding to visits 3 
and 4 when they would have received GTN at 1 hour, in light of the data from the 
previous study the likely time of maximum interaction. 
 
5.4.8 Summary 
In men with stable angina there is an interaction on BP reduction between sildenafil 
100 mg and sublingual GTN 400 µg for at least 8 hours after sildenafil 
administration, but this interaction is, on average, no more than additive from 6 hours 













THE EFFECTS OF REGULAR SILDENAFIL ON BLOOD PRESSURE, 
ARTERIAL STIFFNESS, ARTERIAL WAVE REFLECTION AND 








The major treatments for hypertension are diuretics, inhibitors of the renin-
angiotensin system and non-NO-mediated vasodilators. The NO-cGMP pathway is 
not commonly targeted, even though NO is a potent vasodilator that tonically 
reduces systemic BP. The organic nitrates are NO-donor drugs but their use in 
hypertension is limited by the development of tolerance to their haemodynamic 
effects when given continuously (Munzel et al., 2005). Enhancement of the effects of 
endogenous NO by inhibiting PDE5 is a potential alternative approach to reducing 
BP in hypertension. Most studies have shown that PDE5 inhibitors reduce BP, both 
in healthy subjects and patients with vascular disease (see section 1.3.2). However, 
these have generally been single dose studies and in many, in particular those that 
recruited patients with or at risk of cardiovascular disease, sildenafil was 
administered in addition to other cardiovascular drugs. The effects on BP of PDE5 
inhibition when given regularly as monotherapy for hypertension have not been 
investigated previously. Similarly, the effects of PDE5 inhibition on endothelium-
dependent vasomotor function, arterial stiffness and arterial wave reflection have not 
been investigated under these conditions.  
 
6.1.2 Aims 
To investigate the effects of 16 days of treatment with sildenafil given 3 times daily 
on BP, endothelium-dependent vasomotor function, arterial stiffness and arterial 







6.2.1.1 Identification of subjects 
Potentially suitable subjects were identified from patients attending nurse-led 
General Practice hypertension clinics, a database of subjects previously involved in 
research at the CRC, and from the WGH Cardiovascular Risk Clinic.  
 
6.2.1.2 Inclusion criteria  
• Male or female. 
• At least 3 separate office measurements of systolic BP ≥160 mmHg or diastolic 
BP ≥100 mmHg, not taking antihypertensive drugs. 
• Hypertension confirmed on ambulatory monitoring (average daytime systolic BP 
≥145 mmHg or diastolic BP ≥95 mmHg), within 3 months of the screening visit. 
• Subjects with ‘borderline’ hypertension were eligible if their calculated 10-year 
risk of cardiovascular disease was >20% or they had evidence of target organ 
damage. Borderline hypertension was defined according to ambulatory BP criteria 
alone as an average awake systolic BP ≥135 and <145 mmHg or diastolic BP ≥85 
and <95 mmHg. 
• Established hypertensives were eligible if their BP was controlled (systolic BP 
<160 mmHg and diastolic BP <100 mmHg) on a single antihypertensive agent 
(see section 6.2.1.4). 
 
    
6.2.1.3 Exclusion criteria 
• History of other major cardiac, respiratory, neurological or renal disease. 
• Systolic BP consistently >210 mmHg or diastolic BP consistently >120 mmHg. 
• Systolic BP consistently >180 mmHg or diastolic BP consistently >110 mmHg in 
those withdrawn from existing therapy . 
• Current alcohol abuse. 
• Diabetes. 
• Taking vasoactive drugs. 




• Participation, within 6 months, in other research studies. 
 
6.2.1.4 Procedure for recruiting patients taking treatment for hypertension 
For any subjects who were identified as potentially suitable for the study who were 
already taking a regular antihypertensive, ABPM would have been performed 4 
weeks after stopping treatment. They would have been eligible if, on ABPM, their 
average daytime BP was ≥145/95 mmHg. Office BP would have been recorded 2 and 
4 weeks after stopping treatment, as well as during the study, and if systolic BP was 
consistently >180 mmHg or diastolic BP was consistently >110 mmHg subjects 
would have either not progressed or would have been withdrawn from the study and 
restarted on their usual therapy with immediate effect. After the study, subjects 
would have continued with their usual medicine as before (unless a clinical reason to 
change this was identified). 
 
6.2.2 Screening visit 
Potentially suitable subjects who agreed to be considered for the study attended a 
screening visit at the CRC. At this visit the study was explained fully and written 
consent was obtained. A medical history was taken and a physical examination and 
12-lead ECG were performed. A non-fasting blood sample was also taken. A 24-hour 
ambulatory BP monitor was fitted to those subjects who had not had ambulatory BP 
monitoring performed in the previous 3 months. 
 
6.2.3 Study design 
Randomised, placebo-controlled, double blind, 2-way crossover. 
 
6.2.4 Protocol 
Subjects underwent the protocol outlined in Figure 6.1. Duplicate measures of BP, 
HR, PWA, and CF-PWV were made at each time point. The screening ambulatory 


































Figure 6.1. Study protocol. 
BP, HR, PWA, CF-PWV and FMD were measured in the order shown. 
 
Continue sildenafil 50 mg or placebo 3 times daily 
Washout, at least 6 days 
Period 1, day 1 Arrive CRC 08:00, rest supine 30 minutes 
BP, HR, PWA, CF-PWV, FMD 
Sildenafil 50 mg or placebo 
 
BP, HR, PWA, CF-PWV, FMD 
Discharge 
60 minutes 
Arrive CRC 08:00, attach ambulatory BP monitor Period 1, day 15 
Period 1, day 16 Arrive CRC 08:00, remove ambulatory BP monitor 
Rest supine 30 minutes 
BP, HR, PWA, CF-PWV, FMD 
Sildenafil 50 mg or placebo 
 




Period 2, day 1 
 
Arrive CRC 08:00, rest supine 30 minutes 
BP, HR, PWA, CF-PWV, FMD 
Sildenafil 50 mg or placebo  




Arrive 08:00, attach ambulatory BP monitor Period 2, day 15 
 Period 2, day 16 
 
Arrive CRC 08:00, remove ambulatory BP monitor 
Rest supine 30 minutes 
BP, HR, PWA, CF-PWV, FMD 
Sildenafil 50 mg or placebo 








Tablets were packed by the WGH pharmacy. Subjects were instructed to take 1 tablet 
3 times each day, at around 08:00, 14:00 and 22:00 hrs. They were given a diary card 
to record the time at which they took each tablet. During each phase of the study 
subjects were provided with a total of 46 tablets, 2 more than were actually required, 
and were asked to return all unused tablets.  
 
6.2.6 Adverse effects 
Subjects were issued with cards on which they were asked to write down any 
symptoms that they experienced during each period of the study and rate them as 
mild, moderate or severe. Details of symptoms experienced were clarified when 
subjects attended the CRC.  
 
6.2.7 Analyses 
Data are given as means and SDs. Means were compared by paired Student’s t-tests. 
Correlation coefficients were calculated using the Pearson method. 
 
The number of tablets returned was used to determine the ‘maximum adherence’, 
calculated as 
! 
100 " (number returned # 2)
44
 and expressed as a percentage. Thus, a 
subject who returned 2 tablets may have taken all 44 tablets and would have a 
maximum adherence of 100%. A subject who returned 6 tablets can only have taken 








Thirty-six subjects, none of whom were taking regular antihypertensive treatment, 
underwent screening to assess eligibility for the study. Thirty subjects were identified 
from General Practice hypertension clinics, 4 from the CRC database and 2 from the 
WGH Cardiovascular Risk Clinic. Of the 36 screened, 10 did not meet the inclusion 
and exclusion criteria and 1 subject withdrew before starting the study. Of the 25 
subjects who started the study, 3 were withdrawn due to side effects. Analyses were 
performed on the data from the remaining 22 subjects. The baseline characteristics of 
the subjects are given in Table 6.1. 
 
 
Table 6.1. Baseline characteristics of the subjects. 
Means (SDs) are given for continuous variables. Central BP, CF-PWV and wave 
reflection variables are a mean of the values obtained at baseline at each of the 2 
study visits. Other values are those obtained at the screening visit.  
 
 Subjects who completed (n=22) 
Subjects withdrawn 
(n=3) 
Male/female 18/4 1/2 
Age (years) 60 (12) 60 (17) 
24-hour BP (mmHg) 144 (7) / 84 (7) 149 (4) / 87 (8) 
Daytime BP (mmHg) 153 (8) / 92 (6) 157 (8) / 94 (11) 
Night time BP (mmHg) 124 (9) / 71 (7) 137 (8) / 75 (6) 
Office BP (mmHg) 165 (16) / 96 (9) 179 (25) / 102 (15) 
Central BP (mmHg) 144 (16) / 89 (7) 154 (20) / (98 (5) 
Aortic AIx (%) 32 (9) 33 (11) 
Aortic AIx@75 (%) 25 (8) 29 (8) 
Radial AIx (%) 89 (13) 89 (16) 
CF-PWV (m/s) 10.3 (2.6) 9.0 (0.4) 
Weight (Kg) 89 (12) 87 (13) 
BMI (Kg/m2) 29 (3) 30 (5) 
 




Continued from the previous page. 
 
 Subjects who completed (n=22) 
Subjects withdrawn 
(n=3) 
LVH 1 0 
Plasma glucose (mmol/L) 5.3 (0.6) 5.9 (1.2) 
Serum cholesterol:   
Total (mmol/L) 5.4 (0.7) 5.9 (0.2) 
LDL (mmol/L) 3.2 (0.7) 3.9 (0.3) 
HDL (mmol/L) 1.3 (0.3) 1.3 (0.4) 
Total:HDL ratio 4.5 (1.3) 5.0 (1.4) 





There was good repeatability between the 2 baseline measures (placebo phase and 
sildenafil phase) for the various clinical parameters recorded during the study. Figure 
6.2 shows Bland-Altman plots for peripheral clinic BP and central BP and Figure 6.3 
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Figure 6.2. Bland-Altman plots of baseline measures of peripheral clinic BP and 
central BP. 
Solid lines are mean differences and dotted lines are upper and lower 95% limits of 
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Figure 6.3. Bland-Altman plots of baseline measures of aortic AIx, aortic 
AIx@75, RAIx, CF-PWV and FMD. 
Solid lines are mean differences and dotted lines are upper and lower 95% limits of 




6.3.3 Office BP and HR 
Baseline office systolic BP, diastolic BP, MAP, PP and HR were not significantly 
different between placebo and sildenafil phases of the study.  
 
The effects of sildenafil and placebo on office BP and HR are summarised in Table 
1.1 (absolute values) and Table 1.2 (changes). Sildenafil reduced office systolic BP, 
diastolic BP and MAP acutely (1 hour after administration), but by day 16 of regular 
treatment the magnitude of this reduction in BP was reduced compared to the acute 
effect. Office diastolic BP and MAP were significantly lower than at baseline when 
measured prior to sildenafil administration on day 16 (trough), but systolic BP was 
not. Office systolic BP, diastolic BP and MAP were all significantly lower than 
baseline when measured 1 hour after sildenafil administration on day 16 (peak). 






   Placebo  Sildenafil 
   P value, vs:  P value, vs: 
   
Mean 
(SD) baseline trough, d 16  
Mean 
(SD) baseline trough, d 16 
          Systolic BP (mmHg) Baseline  154 (15)    150 (12)   
 1 hour  155 (15) 0.5   141 (13) <0.001  
 Trough, d 16  152 (15) 0.3   146 (13) 0.1  
 Peak, d 16  158 (18) 0.07 0.004  145 (13) 0.04 0.7 
                    Diastolic BP (mmHg) Baseline  89 (7)    88 (7)   
 1 hour  90 (8) 0.2   82 (9) <0.001  
 Trough, d 16  88 (8) 0.8   85 (7) 0.003  
 Peak, d 16  90 (9) 0.3 0.06  83 (8) <0.001 0.1 
                    MAP (mmHg) Baseline  113 (10)    111 (8)   
 1 hour  113 (10) 0.7   102 (11) <0.001  
 Trough, d 16  112 (10) 0.4   107 (9) 0.006  
 Peak, d 16  115 (12) 0.3 0.03  105 (9) 0.001 0.4 
          Continued on next page 
 
Table 6.2. Effects of sildenafil and placebo on office BP and HR, absolute values. 





   Placebo  Sildenafil 
   P value, vs:  P value, vs: 
   
Mean 
(SD) baseline trough, d 16  
Mean 
(SD) baseline trough, d 16 
          PP (mmHg) Baseline  65 (13)    62 (12)   
 1 hour  66 (15) 0.7   59 (10) 0.07  
 Trough, d 16  63 (13) 0.2   62 (12) 0.7  
 Peak, d 16  68 (15) 0.2 0.005  62 (11) 0.98 0.6 
                    HR (bpm) Baseline  61 (8)    62 (9)   
 1 hour  58 (7) 0.001   63 (8) 0.5  
 Trough, d 16  61 (7) 0.8   62 (7) 0.8  
 Peak, d 16  60 (7) 0.3 0.2  61 (7) 0.3 0.1 
           
Table 6.2 







   Placebo Sildenafil P value 
      Systolic BP (mmHg) Baseline to 1 hour  1 (9) -10 (10) <0.001 
 Baseline to trough, d 16  -2 (8) -4 (11) 0.4 
 Baseline to peak, d 16  4 (10) -5 (11) 0.003 
 Trough, d 16 to peak, d 16  6 (9) -1 (10) 0.01 
            Diastolic BP (mmHg) Baseline to 1 hour  2 (6) -6 (6) <0.001 
 Baseline to trough, d 16  0 (5) -3 (5) 0.06 
 Baseline to peak, d 16  2 (7) -5 (5) 0.002 
 Trough, d 16 to peak, d 16  2 (4) -2 (6) 0.04 
            MAP (mmHg) Baseline to 1 hour  1 (7) -8 (7) <0.001 
 Baseline to trough, d 16  -1 (6) -4 (6) 0.1 
 Baseline to peak, d 16  2 (8) -5 (7) 0.003 
 Trough, d 16 to peak, d 16  3 (6) -1 (7) 0.03 
      Continued on next page 
 
Table 6.3. Changes in office BP and HR with sildenafil and placebo. 







   Placebo Sildenafil P value 
      PP (mmHg) Baseline to 1 hour  1 (9) -3 (8) 0.1 
 Baseline to trough, d 16  -2 (7) -1 (10) 0.7 
 Baseline to peak, d 16  2 (8) 0 (8) 0.3 
 Trough, d 16 to peak, d 16  4 (6) 1 (7) 0.1 
            HR (bpm) Baseline to 1 hour  -4 (5) 0 (3) <0.001 
 Baseline to trough, d 16  0 (5) 0 (5) 0.7 
 Baseline to peak, d 16  -1 (6) -1 (6) 0.9 
 Trough, d 16 to peak, d 16  -1 (4) -1 (5) 0.7 
       
Table 6.3. 




6.3.4 Ambulatory BP 
The effects of 16 days of treatment with sildenafil and placebo on 24-hour, daytime 
and night time ambulatory BPs are shown in Table 6.4 (absolute values) and Table 
6.5 (changes). Sildenafil significantly reduced both systolic and diastolic ambulatory 
24-hour, daytime and night time BPs compared both to baseline and to placebo. 
 
Baseline ambulatory systolic BP, whether 24-hour, daytime or night time, was 
significantly correlated with the change in ambulatory systolic BP that occurred after 
16 days of sildenafil, with increasing baseline BP being associated with a greater 
reduction with treatment. In contrast, baseline ambulatory diastolic BP was not 
correlated with the change in ambulatory diastolic BP that occurred with sildenafil. 








  Baseline (B) Placebo (P) Sildenafil (S) P value, B vs P P value, B vs S 
       24-hour Systolic BP 144 (7) 147 (7) 138 (8) 0.2 0.003 
 Diastolic BP 85 (7) 87 (10) 80 (9) 0.3 <0.001 
       
Daytime Systolic BP 153 (8) 155 (7) 145 (8) 0.4 0.001 
 Diastolic BP 92 (6) 92 (10) 86 (8) 0.9 <0.001 
       
Night time Systolic BP 124 (9) 129 (10) 119 (9) 0.05 0.02 
 Diastolic BP 71 (7) 74 (11) 68 (9) 0.08 0.01 
        




 Systolic BP  Diastolic BP 
 Placebo Sildenafil P value  Placebo Sildenafil P value 
24-hour 3 (10) -7 (9) <0.001  1 (6) -5 (5) <0.001 
Daytime 2 (9) -8 (9) <0.001  0 (6) -6 (5) <0.001 
Night time 5 (12) -5 (9) 0.02  3 (8) -4 (6) 0.01 
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Figure 6.4. Correlations between baseline ambulatory BP and change with 
sildenafil. 




6.3.5 Pulse wave analysis 
Baseline aortic AIx, aortic AIx@75, RAIx, central systolic BP, central diastolic BP 
and central PP were not significantly different between placebo and sildenafil phases 
of the study. The effects of placebo and sildenafil on each of these are summarised in 
Table 6.6 (absolute values) and Table 6.7 (changes). Sildenafil reduced aortic AIx, 
aortic AIx@75 and RAIx acutely (1 hour after administration), but as with the effects 
on office BP, by day 16 the magnitude of these effects was reduced compared to the 
acute effects. These parameters were not significantly different to baseline when 
measured prior to sildenafil administration on day 16 (trough) but were significantly 
lower than baseline when measured 1 hour after sildenafil administration on day 16 
(peak). The changes from baseline in aortic AIx, aortic AIx@75 and RAIx with 
sildenafil were significantly different to placebo acutely but were not significantly 
different to placebo either before or after sildenafil administration on day 16.  
 
Sildenafil reduced central systolic BP and central diastolic BP from baseline values 
acutely and both before and after sildenafil administration on day 16, although the 
changes in each of these parameters were not significantly different to the changes 
observed with placebo when measured before drug administration on day 16. 







   Placebo  Sildenafil 
   P value, vs:  P value, vs: 
   
Mean 
(SD) baseline trough, d 16  
Mean 
(SD) baseline trough, d 16 
          Aortic AIx (%) Baseline  32 (10)    32 (9)   
 1 hour  33 (9) 0.4   28 (10) <0.001  
 Trough, d 16  31 (11) 0.4   30 (9) 0.1  
 Peak, d 16  31 (11) 0.5 0.6  30 (10) 0.03 0.7 
                    Aortic AIx@75 (%) Baseline  25 (9)    25 (8)   
 1 hour  24 (9) 0.3   22 (9) <0.001  
 Trough, d 16  24 (11) 0.5   23 (9) 0.1  
 Peak, d 16  23 (9) 0.03 0.04  23 (8) 0.004 0.3 
                    RAIx (%) Baseline  89 (14)    88 (13)   
 1 hour  90 (13) 0.3   82 (14) <0.001  
 Trough, d 16  87 (15) 0.4   85 (13) 0.1  
 Peak, d 16  88 (14) 0.6 0.6  84 (13) 0.002 0.2 
          Continued on next page 
 
Table 6.6. Effects of sildenafil and placebo on PWA-derived parameters, absolute values. 





   Placebo  Sildenafil 
   P value, vs:  P value, vs: 
   
Mean 
(SD) baseline trough, d 16  
Mean 
(SD) baseline trough, d 16 
          Central systolic BP Baseline  145 (17)    142 (15)   
(mmHg) 1 hour  148 (17) 0.2   130 (15) <0.001  
 Trough, d 16  144 (17) 0.4   137 (15) 0.03  
 Peak, d 16  149 (20) 0.09 0.005  136 (16) 0.01 0.8 
                    Central diastolic BP Baseline  90 (8)    89 (7)   
(mmHg) 1 hour  90 (10) 0.9   82 (9) <0.001  
 Trough, d 16  89 (8) 0.8   86 (7) 0.002  
 Peak, d 16  91 (9) 0.3 0.07  84 (8) <0.001 0.2 
                    Central PP Baseline  55 (14)    53 (13)   
(mmHg) 1 hour  57 (16) 0.3   48 (11) 0.005  
 Trough, d 16  54 (14) 0.3   51 (12) 0.3  
 Peak, d 16  58 (16) 0.1 0.004  53 (13) 0.7 0.4 
           
Table 6.6. 






   Placebo Sildenafil P value 
      Aortic AIx Baseline to 1 hour  1 (4) -4 (4) 0.003 
 Baseline to trough, d 16  -1 (5) -2 (5) 0.7 
 Baseline to peak, d 16  -1 (5) -2 (4) 0.3 
 Trough, d 16 to peak, d 16  0 (3) 0 (3) 0.4 
            Aortic AIX@75 Baseline to 1 hour  -1 (3) -3 (4) 0.02 
 Baseline to trough, d 16  -1 (4) -2 (4) 0.5 
 Baseline to peak, d 16  -2 (4) -1 (3) 0.7 
 Trough, d 16 to peak, d 16  -1 (3) -1 (3) 0.6 
            RAIx Baseline to 1 hour  1 (7) -6 (6) <0.001 
 Baseline to trough, d 16  -2 (8) -3 (8) 0.6 
 Baseline to peak, d 16  -1 (9) -4 (6) 0.1 
 Trough, d 16 to peak, d 16  1 (4) -2 (6) 0.1 
      Continued on next page 
Table 6.7. Changes in PWA-derived parameters with sildenafil and placebo. 






   Placebo Sildenafil P value 
      Central systolic BP Baseline to 1 hour  2 (9) -12 (10) <0.001 
(mmHg) Baseline to trough, d 16  -2 (9) -5 (10) 0.1 
 Baseline to peak, d 16  4 (11) -6 (10) 0.001 
 Trough, d 16 to peak, d 16  6 (9) -1 (10) .02 
            Central diastolic BP Baseline to 1 hour  0 (8) -6 (6) <0.001 
(mmHg) Baseline to trough, d 16  0 (5) -3 (4) 0.06 
 Baseline to peak, d 16  1 (7) -5 (5) 0.002 
 Trough, d 16 to peak, d 16  2 (4) -2 (6) 0.04 
            Central PP Baseline to 1 hour  2 (8) -5 (8) 0.003 
(mmHg) Baseline to trough, d 16  -1 (6) -2 (8) 0.8 
 Baseline to peak, d 16  3 (8) -1 (7) 0.1 
 Trough, d 16 to peak, d 16  4 (6) 1 (6) 0.1 
       
Table 6.7. 




Baseline CF-PWV was not significantly different between placebo and sildenafil 
phases of the study. The effects of placebo and sildenafil on CF-PWV are 
summarised in Table 6.8 (absolute values) and Table 6.9 (changes). CF-PWV was 
not significantly different to baseline following sildenafil, either acutely or after 16 




  Placebo  Sildenafil 
  Mean (SD) P   Mean (SD) P  
       Baseline  10.2 (3.0)   10.4 (2.3)  
1 hour  10.4 (2.6) 0.3  10.2 (2.3) 0.3 
Trough, day 16  10.7 (2.9) 0.03  9.9 (2.6) 0.1 
Peak, day 16  10.3 (2.5) 0.4  9.6 (2.6) 0.053 
        
Table 6.8. Effects of sildenafil and placebo on CF-PWV, absolute values. 
Units are m/s. P values are vs baseline. Statistically significant comparisons are 




  Placebo Sildenafil P 
     Baseline to 1 hour  0.2 (0.8) -0.2 (0.9) 0.1 
Baseline to trough, day 16  0.5 (0.9) -0.5 (1.3) 0.02 
Baseline to peak, day 16  0.1 (0.9) -0.8 (1.8) 0.06 
      
Table 6.9. Changes in CF-PWV with sildenafil and placebo. 





6.3.7 Baseline BP and baseline arterial stiffness and arterial wave reflection 
For each subject, means of the 2 baseline measures of MAP, aortic AIx, RAIx and 
CF-PWV were calculated. The relationships between baseline values of MAP and 
each of aortic AIx, RAIx and CF-PWV are shown in Figure 6.5. 
 
 






































6.3.8 Flow-mediated dilatation 
Baseline FMD was not significantly different between placebo and sildenafil phases 
of the study. Sildenafil did not affect FMD either acutely or after 16 days of regular 
treatment. FMD responses during the sildenafil phase of the study are illustrated in 
Figure 6.6 and these responses, as well as those with placebo, are quantified as peak 
percentage dilatation and AUC of the change in brachial artery diameter over time in 
Table 6.10 (absolute values) and Table 6.11 (changes). Sildenafil also did not affect 



























Figure 6.6. FMD responses during the sildenafil phase of the study. 
Values are mean changes from baseline. Response at baseline (pre-sildenafil) is 
shown in blue. In red is the response at 1 hour (top), in green the response at trough 




  Placebo  Sildenafil 
  Mean (SD) P   Mean (SD) P  
       Peak dilatation (%)     
Baseline  2.1 (1.8)   2.6 (1.7)  
1 hour  2.8 (2.1) 0.07  2.1 (1.9) 0.2 
Trough, day 16  2.2 (1.6) 0.7  2.7 (1.7) 0.8 
Peak, day 16  3.2 (2.1) 0.02  2.6 (2.9) 1 
       
AUC of change from baseline (AU)    
Baseline  5.6 (8.7)   7.1 (8.8)  
1 hour  4 (14) 0.9  7.4 (10.5) 0.9 
Trough, day 16  6.9 (8.1) 0.9  7.3 (9.9) 0.9 
Peak, day 16  6.4 (10.2) 0.9  7.9 (11.6) 0.8 
        
Table 6.10. Effects of placebo and sildenafil on FMD, absolute values. 




  Placebo Sildenafil P 
     Peak dilatation (absolute %)     
Baseline to 1 hour  0.7 (1.7) -0.4 (1.3) 0.05 
Baseline to trough, day 16  0.1 (1.8) 0.1 (1.5) 0.8 
Baseline to peak, day 16  1.1 (2.1) 0.0 (2.8) 0.1 
     
AUC of change from baseline (AU)   
Baseline to 1 hour  -0.3 (12.9) 0.3 (13.0) 0.9 
Baseline to trough, day 16  0.5 (11.9) 0.3 (12.8) 0.7 
Baseline to peak, day 16  -0.3 (11.2) 0.8 (15.6) 0.9 
      





6.3.9 Subject withdrawals and adverse effects 
Two of the 3 subjects who were withdrawn from the study were withdrawn while 
taking sildenafil. One of these subjects was withdrawn because of severe headache 
and the other because of back pain and feeling generally unwell. The subject 
withdrawn while taking placebo was withdrawn because of joint pains, nausea and 
headache. 
 
A summary of the symptoms experienced during each phase of the study is given in 
Table 6.12. The most common adverse effect was indigestion/heartburn, which 
lasted up to 5 days. One subject was prescribed omeprazole and 7 other subjects took 
over-the-counter acid suppression treatments, all with good effect. Headache was the 
next most common adverse effect experienced. Headaches were generally mild and 
transient, even though severe headache was the reason that 1 subject was withdrawn. 
Sildenafil was also associated with low back/buttock/leg pain, which was generally 
described as a muscular aching sensation. This was usually responsive to 
paracetamol, although a few subjects also took ibuprofen, and tended to settle within 
a few days, with no further analgesic requirement. Plasma creatine kinase 
concentrations were measured in 4 of the subjects who experienced these symptoms 








 Sildenafil  Placebo 
 Total Mild Mod Severe  Total Mild Mod Severe 
          Indigestion/heartburn 10 (40) 5 (20) 4 (16) 1 (4)  1 (4) 1 (4)   
Headache 8 (32) 6 (24) 1 (4) 1 (4)  1 (4)   1 (4) 
Back/buttock/leg ache 7 (28) 1 (4) 5 (20) 1 (4)  1 (4) 1 (4)   
Abdominal discomfort 2 (8)  2 (8)   0    
Fatigue 2 (8)  1 (4) 1 (4)  0    
Facial flushing 2 (8) 2 (8)    0    
Cramp 1 (4) 1 (4)    1 (4)  1 (4)  
Dizziness 1 (4) 1 (4)    1 (4)  1 (4)  
Insomnia 1 (4)  1 (4)   0    
Joint pain 1 (4)   1 (4)  1 (4)   1 (4) 
Loin pain 1 (4)  1 (4)   0    
Nausea 1 (4)  1 (4)   2 (8)   2 (8) 
Neck pain 1 (4) 1 (4)    1 (4)  1 (4)  
Urinary frequency 1 (4) 1 (4)    0    
Diarrhoea 0     1 (4)   1 (4) 
Stress 0     1 (4)  1 (4)  
Vomiting 0     1 (4)  1 (4)  
 
Table 6.12. Symptoms experienced with placebo and sildenafil in all subjects 
recruited (n=25). 





6.3.10 Drug adherence 
Mean maximum adherence was 96% (range 80 to 100%) during the placebo phase 
and 96% (range 87 to 100%) during the sildenafil phase. There was no indication 
that the level of maximum adherence had any influence on the measured effect of 
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6.4.1 Main findings 
The major findings from this study are that in untreated hypertensives regular oral 
sildenafil reduced BP and arterial wave reflection but had no effect on CF-PWV or 
brachial artery FMD.  
 
6.4.2 Measurement repeatability 
As can be seen from the Bland-Altman-plots, there was generally good repeatability 
of baseline measurements, with no tendency for repeatability to vary with mean 
values of each of the parameters. The repeatability of baseline aortic AIx and of 
baseline CF-PWV compare well with previously published data (Wilkinson et al., 
1998), particularly given that the 2 baseline recordings were made on different days, 
which is in contrast to the published data.  
 
6.4.3 Effects on peripheral BP 
Sildenafil reduced BP both acutely and after 16 days of regular administration. The 
reduction in average daytime BP was 8/6 mmHg compared to baseline and around 
10/6 mmHg compared to placebo. A number of studies have compared the effects on 
BP of the major antihypertensive drugs when given as monotherapy for 
hypertension. In a large multi-centre, double-blind study that recruited 1292 
hypertensive men (mean age 59 years and mean sitting BP 152/99 mmHg), subjects 
were randomised to placebo or 1 of 6 antihypertensives (Materson et al., 1993). 
Subjects initially entered a dose titration phase lasting 4 to 8 weeks during which the 
assigned drug was started at the lowest dose and titrated until either a diastolic BP of 
less than 90 mmHg was achieved or the maximum dose was reached. At the end of 
the dose titration phase placebo-corrected reductions in BP were 11/5 mmHg with 
hydrochlorothiazide, 8/7 mmHg with atenolol, 6/5 mmHg with captopril and 10/9 
mmHg with diltiazem.  
 
In an open label, 4-way crossover study, 36 untreated hypertensives (age 22 to 51 
years, mean supine BP 161/98 mmHg) were rotated through treatment with lisinopril 
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20 mg, bisoprolol 5 mg, hydrochlorothiazide/triamterene 25/50 mg and nifedipine 
(slow-release) 30 mg (Dickerson et al., 1999). Each treatment was given for 1 month 
and there was a washout period of 1 month between treatments. At the end of each 
month of treatment the reductions in BP were ~10/12 mmHg with lisinopril, ~11/13 
mmHg with bisoprolol, ~6/6 mmHg with hydrochlorothiazide/triamterene and ~7/7 
mmHg with nifedipine. The same research group subsequently performed a similar 
crossover study in which 34 untreated hypertensives (age 28 to 55 years, mean 
supine BP 160/101 mmHg) each received double-blind treatment with 5 
antihypertensives and placebo (Deary et al., 2002). The placebo-corrected reductions 
in BP after 6 weeks of each treatment were ~13/9 mmHg with amlodipine 5 mg, 
~10/8 mmHg with doxazosin 4 mg, ~17/11 mmHg with lisinopril 10 mg, ~10/12 
mmHg with bisoprolol 5 mg and ~4/2 mmHg with bendroflumethiazide 2.5 mg.  
 
It can be seen from these previous studies that the degree of BP reduction observed 
with sildenafil is similar to the degree of BP reduction that occurs with other, 
commonly used, antihypertensive drugs when they are given as monotherapy. The 
subjects recruited to the current study had relatively mild hypertension (average 
daytime BP 153/92 mmHg) and, given that higher baseline BP was associated with 
greater BP reduction, at least for systolic BP, it is likely that the absolute effect of 
sildenafil on BP would have been greater if the population had been more 
hypertensive.  
 
Examination of the office BP data shows that there was some attenuation of the acute 
effect of sildenafil with chronic treatment. Sildenafil reduces BP directly through 
peripheral arterial vasodilatation secondary to preservation of vascular smooth 
muscle cGMP (Jackson et al., 1999). Following the relatively rapid onset of this 
pharmacodynamic effect it is likely that neurohormonal counter regulatory 
mechanisms would be stimulated, including release of catecholamines and 
stimulation of the renin-angiotensin system. These responses would tend to 
counteract the sildenafil-induced BP reduction by promoting vasoconstriction and 




An alternative mechanism that might explain the observed attenuation of the acute 
effect of sildenafil is that tolerance develops to its action as a vasodilator. Tolerance 
is a well described phenomenon with organic nitrates and is associated, within a few 
days of continuous administration, with loss of hypotensive as well as anti-anginal 
efficacy (Elkayam, 1991). In vivo, some of the attenuation of the acute effects of 
organic nitrates with continuous treatment can be explain by neurohormonal counter 
regulatory mechanisms with consequent volume expansion and vasoconstriction 
(Munzel et al., 1996; Stewart et al., 1986), so-called ‘pseudo tolerance’. However, 
vascular nitrate tolerance also occurs, in which there is a loss of nitrovasodilator-
responsiveness. Vascular nitrate tolerance appears to be the result of increased 
vascular superoxide production and, at least for GTN, impaired bioactivation of the 
organic nitrate to produce NO (Munzel et al., 2005). Whether or not chronic 
sildenafil administration is associated with a reduction in the responsiveness of the 
vasculature to PDE5 inhibition cannot be addressed directly from the in vivo data 
presented here. However, the persistent hypotensive effect of sildenafil with chronic 
treatment, even if slightly diminished compared to the acute effect, contrasts with the 
complete loss of hypotensive effect that is associated with chronic organic nitrate 
therapy, suggesting that little or no vascular tolerance occurs. Furthermore, in rats 
chronic sildenafil dosing, for up to 8 weeks, is associated with up-regulation of 
PDE5 expression but no attenuation of the ability of sildenafil to induce penile 
erection (Behr-Roussel et al., 2005; Musicki et al., 2005), providing further evidence 
that the effects of sildenafil on the vasculature do not undergo tolerance. 
 
On day 16 of sildenafil treatment office BP was higher before the administration of 
sildenafil than at 1 hour afterwards. Indeed, the changes from baseline in both 
systolic BP and diastolic BP were not significantly different to placebo when 
measured before sildenafil administration, but were significantly lower than placebo 
when measured 1 hour after sildenafil administration. Although sildenafil effectively 
reduced average night time BP, these data suggest that the overnight dose interval of 
between 10 and 11 hours was sufficient for the antihypertensive effect of sildenafil to 
begin to wane. This may have important clinical implications. There is a recognised 
diurnal variation in BP with night time BP generally being 10-20% lower than day 
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time BP. Coincident with arousal and arising from overnight sleep there is an abrupt 
increase in BP. The incidence of cardiovascular events, both coronary (Muller et al., 
1985) and cerebrovascular (Wroe et al., 1992), also follows a diurnal pattern, with 
the hour of awakening rather than the hour in the day being most predictive (Willich 
et al., 1992). The early morning BP surge has been suggested as a trigger for 
cardiovascular events (Giles, 2005; Kario et al., 2003b) and recent evidence has 
confirmed that patients with a higher morning BP surge are at greater risk of stroke 
(Kario et al., 2003a). Therefore, despite reducing BP overall, the 3 times daily dosing 
regime used in the current study may provide suboptimal early morning protection, 
whereas alternative dosing strategies, for example using a modified-release 
formulation, or a longer acting PDE5 inhibitor, such as tadalafil, might afford better 
protection. 
 
Sildenafil reduced both systolic BP and diastolic BP. As a result, it also reduced 
MAP but did not reduce PP. This suggests that the primary mode of action is through 
peripheral vasodilatation rather than through reduction in large artery stiffness. The 
lack of effect on PP might also reflect the population of hypertensives studied. Thus, 
subjects with raised systolic BP, diastolic BP or both were recruited. If the study had 
been confined to subjects with isolated systolic hypertension there might have been a 
preferential effect on systolic BP with a consequent reduction in PP. 
 
6.4.4 Effects on arterial wave reflection, arterial stiffness and central BP 
In keeping with the established relationships between BP and measures of arterial 
stiffness (Oliver et al., 2003), baseline MAP was significantly correlated with aortic 
AIx and RAIx. Baseline CF-PWV also tended to increase with MAP, although these 
measures were less closely correlated. Sildenafil reduced aortic AIx, and did so in a 
manner that was similar to the effect on office BP, with a greater reduction acutely 
than was evident after 16 days. The effect on RAIx was similar, as was the effect on 
aortic AIx@75, which would be expected given the lack of effect of sildenafil on 
HR. The reduction in aortic AIx indicates that sildenafil reduced peripheral artery 
wave reflection. However, the relatively small magnitude of this effect is no more 
than would be expected simply as a result of the reduction in systemic BP 
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(Wilkinson et al., 2001b), suggesting that sildenafil did not act specifically to reduce 
large artery stiffness. This conclusion may also be supported by the lack of effect of 
sildenafil on CF-PWV, a more direct measure of large artery stiffness. On the other 
hand, although the effects were not statistically significant there was a trend to a 
progressive reduction in CF-PWV (-0.2 m/s at 1 hour, -0.5 m/s on day 16 before 
sildenafil and -0.8 m/s on day 16 after sildenafil). The P value for the comparison 
between baseline and day 16 after sildenafil was 0.053, very nearly statistically 
significant. Thus, the possibility of a real effect on CF-PWV should not be 
dismissed; a larger sample size or a longer treatment period may have demonstrated 
a significant effect. Given that distending pressure is conventionally considered to an 
important influence on arterial stiffness, the acute reduction in MAP that occurred 
with sildenafil might, in itself, have been expected to significantly reduce CF-PWV. 
However, CF-PWV was not acutely affected by sildenafil. Although this observation 
may seem surprising, it is consistent with data recently reported by Stewart et al 
(2006). They investigated the effect of acute changes in BP on CF-PWV in 
normotensive and hypertensive subjects. As expected, in the normotensive subjects 
increasing BP with angiotensin II increased CF-PWV and decreasing BP with GTN 
decreased CF-PWV. However, in the hypertensive subjects, despite reducing MAP 
by 22 mmHg to the same level as in the normotensive subjects, GTN had no effect 
on CF-PWV. These data suggest that the increased aortic stiffness characteristic of 
hypertension is the result of structural changes in the arterial wall rather than 
elevated BP per se. It is intriguing to speculate that the seemingly progressive 
reduction in CF-PWV observed with regular sildenafil in the present study was the 
result of progressive improvement of the intrinsic stiffness of the aortic wall.  
 
With chronic treatment, sildenafil reduced central BP with a similar magnitude to the 
effect on peripheral BP. Measurement of central BP did not, therefore, provide any 
additional information on the hypotensive action of sildenafil over and above the 
measurement of peripheral BP. Acutely, there was a slightly greater effect on central 
systolic BP than on central diastolic BP, which manifested as reduced central PP, but 




6.4.5 Effects on endothelium-dependent vasomotor function 
Mean FMD at baseline of the subjects in the present study was 2.1 to 2.6% (placebo 
and sildenafil phases respectively). Even though there was no healthy control group, 
these values are low compared to published values in healthy subjects and, consistent 
with most previous studies in hypertensives (Ghiadoni et al., 2003; Gokce et al., 
2001; Panza et al., 1990; Taddei et al., 1998), likely indicate impaired endothelium-
dependent vasomotion.  
 
Sildenafil had no effect on FMD, indicating that it did not modulate endothelium-
dependent vasomotion, either acutely or after chronic treatment. As outlined in the 
introduction (section 1.5.5), there are conflicting data on the acute effects of 
sildenafil on endothelium-dependent vasomotor responses, with some reports of an 
improvement and other reports showing no effect. While these previous studies have 
recruited different patients and used different methodologies there are no apparent 
consistent differences to explain the different effects observed. For example, there 
are positive and negative studies that used forearm plethysmography (Kimura et al., 
2003; Robinson et al., 2006) or FMD (Dishy et al., 2004; Vlachopoulos et al., 2004), 
and positive and negative studies that recruited smokers (Dishy et al., 2004; 
Vlachopoulos et al., 2004) or patients with CAD (Halcox et al., 2002a; Robinson et 
al., 2006). One of these studies found that sildenafil did not affect FMD when 
measured as peak dilatation of the brachial artery but did prolong the period of 
vasodilatation after reactive hyperaemia (Halcox et al., 2002a). However, in the 
present study sildenafil had no effect on either peak dilatation or the period of 
dilatation. Given that FMD is largely NO-mediated it would seem logical that 
sildenafil, by preserving NO-stimulated cGMP, would improve FMD. Possible 
explanations for the lack of any effect on FMD include insufficient sensitivity of the 
methodology, insufficient dose of sildenafil or predominant action of sildenafil in the 
resistance circulation rather than in conduit arteries (see section 6.4.7), although the 
previous positive studies using FMD argue against each of these. An alternative 
explanation is that, compared to healthy subjects (Doshi et al., 2001; Joannides et al., 
1995), NO contributes relatively little to shear-stress induced vasodilatation at the 
brachial artery in hypertensives. In support of this possibility it has previously been 
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shown that although vasodilatation to bradykinin in the forearm is NO-mediated in 
healthy subjects, in hypertensives it is not only reduced but is also mediated by a 
different pathway, possibly involving endothelium-dependent hyperpolarisation 
(Taddei et al., 1999). Although not previously investigated, if similar changes occur 
in the brachial artery sildenafil might be expected to have little or no effect on FMD 
in hypertension.  
 
The lack of any effect of sildenafil on FMD despite reduction in BP suggests that BP 
reduction per se is not sufficient to improve endothelium-dependent vasomotor 
function, at least within 16 days. The effect of antihypertensive treatment on FMD 
has been investigated previously. In one study, FMD improved after 6 and 12 months 
of treatment with various antihypertensives and also after 2 months of monotherapy 
with nifedipine but not hydrochlorothiazide (Muiesan et al., 1999). In a further study, 
6 months of treatment with perindopril improved FMD but there was no effect on 
FMD after 6 months of treatment with telmisartan, nifedipine (directly contradicting 
the previous study), amlodipine, atenolol or nebivolol, despite these drugs similarly 
reducing BP (Ghiadoni et al., 2003). Thus, it appears that BP reduction, in itself, may 
not be sufficient to improve endothelium-dependent vasomotion and, in this respect, 
the data from the present study are consistent with the previous studies.  
 
What are the implications of the finding that sildenafil does not affect FMD in terms 
of its potential use as an antihypertensive in clinical practice? There is evidence that 
cardiovascular prognosis is better in hypertensive patients in whom there is an 
improvement in FMD with treatment (Modena et al., 2002). In this study both BP 
reduction and the antihypertensives used to reduce BP were similar in the group in 
which there was an improvement in FMD to the group in which there was no 
improvement in FMD. This may suggest that drugs that consistently improve FMD 
might be more effective in reducing cardiovascular events in patients with 
hypertension. On the other hand, with the possible exception of ß-blockers 
(Lindholm et al., 2005), there is good evidence that the major antihypertensive drug 
classes are substantially equivalent in reducing cardiovascular events (Blood 
Pressure Lowering Trialists Collaboration, 2003). This calls into question the clinical 
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relevance of the studies that have demonstrated differences between these agents in 
their effects on FMD. Therefore, the lack of effect of sildenafil on FMD, especially 
after just 16 days, should not, in itself, detract from its potential as an 
antihypertensive in clinical practice.  
 
6.4.6 Tolerability 
Side effects from regular sildenafil treatment were experienced relatively commonly, 
especially indigestion/heart burn, headache and low back/buttock/leg muscle ache. 
Dyspepsia and headache are common side effects of sildenafil. In the seminal 
clinical trial in which sildenafil was established as an effective treatment for PED 
(Goldstein et al., 1998), headache was reported by 21% of subjects taking sildenafil 
50 mg and 30% of subjects taking sildenafil 100 mg, similar to the frequency in the 
current study (32%). In a study recently reported by Galiè et al (2005), in which 
sildenafil was given regularly for 12 weeks to patients with pulmonary hypertension, 
headache occurred in 42% of those taking 40 mg three times daily and in 49% of 
those taking 80 mg three times daily. Dyspepsia was experienced by 40% of subjects 
in the current study. This is more frequent than when used intermittently for PED 
(16% with 100 mg sildenafil; Goldstein et al., 1998), and is also more frequent than 
was reported in the pulmonary hypertension study (13% of subjects taking 80 mg 3 
times daily; Galiè et al., 2005).  
 
Low back/buttock/leg muscle ache was reported by 28% of subjects in the current 
study. These sorts of symptoms were not reported as side effects of sildenafil in the 
clinical trial by Goldstein et al, although this may be because only those symptoms 
that occurred in 5% or more subjects were reported at all. Indeed, in a further study 
in which sildenafil was given for PED, back pain was reported by 2.5% of 367 men 
(Eardley et al., 2005). Other studies have reported myalgia as a side effect of 
sildenafil (Olsson et al., 2000; Osegbe et al., 2003), for example occurring in 3% of 
58 men in a study from Nigeria (Osegbe et al., 2003). In the pulmonary hypertension 
study, myalgia occurred in 14% of subjects taking 80 mg 3 times daily (Galiè et al., 
2005). Thus, myalgia appears to occur more frequently with chronic regular use 
compared to with intermittent use. The lack of any rise in plasma creatine kinase 
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suggests that the muscle aches experienced by some subjects are not due to an 
underlying myositis.  
 
6.4.7 Nitrate-like action of sildenafil? 
Although sildenafil acts on the NO-cGMP pathway, the data from the present study 
suggest that it is not particularly “nitrate-like” in its haemodynamic action. For 
example, even in very small doses nitrates dilate conduit arteries. This can be 
observed directly at the brachial artery and indirectly as a reduction in peripheral 
artery wave reflection, even at doses that do not affect systemic BP (see section 0). 
In contrast, sildenafil did not affect brachial artery diameter (or FMD at this site) and 
had no greater effect on peripheral artery wave reflection than would be expected 
from its effect on systemic BP, suggesting that it acts predominantly in the resistance 
circulation rather than at conduit arteries.  
 
6.4.8 PDE5 inhibition – monotherapy for hypertension in clinical practice?  
Given that sildenafil has a persistent effect on BP after 2 weeks of regular treatment, 
it seems likely that its antihypertensive action will also be sustained over longer 
treatment periods. Indeed, it is possible that the maximum effect on BP had not 
occurred by 2 weeks and that additional antihypertensive effect would be observed 
over longer periods of time. A longer term study is needed to address these 
questions.  
 
The dose of sildenafil in the current study was 50 mg 3 times daily. In single dose 
studies, the effect of sildenafil on BP does not appear to be strongly dose-related 
(Jackson et al., 1999; Zusman et al., 1999). However, exploration of the hypotensive 
effects of other doses in chronic therapy should be investigated. While there may be 
no additional antihypertensive effect in some subjects with doses of more than 150 
mg/day, higher doses may be more effective in other subjects. Alternatively, lower 
doses, such as 25 mg 3 times daily, may effectively lower BP but with fewer side 
effects. A study in which hypertensives are initially started at a low dose that is then 
titrated upwards according to BP response would be particularly informative in 
elucidating a clinical dosing strategy. Once the most appropriate doses of PDE5 
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inhibitors have been established for the treatment of hypertension, head-to-head 
comparison with established treatments of antihypertensive efficacy and tolerability 
would be of value in determining their potential place in clinical practice.  
 
Hypertension guidelines recommend particular drugs for the first-line treatment of 
hypertension. For example, both NICE (North of England Hypertension Guideline 
Development Group, 2004) and JNC 7 (Chobanian et al., 2003b) guidelines 
recommend low dose thiazide diuretics. However, it is also recognised that there are 
often compelling reasons to use alternative agents. For example, ß-blockers in 
patients with CAD, inhibitors of the renin-angiotensin system in heart failure or 
alpha-adrenoreceptor antagonists in men with symptomatic benign prostatic 
hypertrophy (Williams et al., 2004). A potential valuable indication for the use of 
PDE5 inhibitors as antihypertensives is in men with PED. However, it would first be 
necessary to demonstrate that the effect of PDE5 inhibition on PED is maintained in 
the long term with the frequent, regular dosing pattern that would be required for the 
treatment of hypertension. As discussed above, there are encouraging animal data 
suggesting that no tolerance develops to the effects on erectile function with 
continuous use of sildenafil for up to 8 weeks (Behr-Roussel et al., 2005; Musicki et 
al., 2005), but human data are currently lacking. 
 
Antihypertensives are frequently prescribed to patients who do not feel unwell and, 
as a consequence, gain no symptomatic benefit from treatment (in contrast to the 
treatment of angina or heart failure, for example). Furthermore, most hypertensives 
are not generally at immediate risk of a cardiovascular event and treatment is aimed 
at reducing risk in the long term. Thus, the benefits of antihypertensive treatment 
may not be all that tangible to an individual patient. It is clearly desirable for any 
chronic drug treatment to be as free as possible from side effects but, for these 
reasons, concordance with treatment, and consequently BP control, are likely to be 
maximised when antihypertensives with a low incidence of side effects are used. 
Side effects from regular sildenafil were relatively frequent in the current study and 
may limit the potential for widespread use as an antihypertensive. However, the 
major side effects, dyspepsia, headache and myalgia, generally lasted a few days. 
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Thus, if patients were warned that these might occur at the outset of treatment but 
that they are then likely to subside, the long-term acceptability might be good.  
 
A number of questions arise from the pattern of side effects experienced with regular 
sildenafil. A possible mechanism for the dyspeptic symptoms is that sildenafil 
relaxes the smooth muscle of the lower oesophageal sphincter (Eherer et al., 2002) 
so that gastric contents reflux into the oesophagus. This might increase the risk of 
chronic reflux oesophagitis and even Barrett's oesophagus and oesophageal 
adenocarcinoma. Given this possibility, investigation of the effects of chronic PDE5 
inhibition on the lower oesophagus would be warranted. Plasma creatine kinase was 
not elevated in 4 of the subjects who experienced muscle ache in the current study. 
While this suggests that there was no underlying myositis in these subjects, the 
possibility that myositis might occur in some subjects with regular treatment, even if 
only rarely, should continue to be borne in mind. Routine monitoring of plasma 
creatine kinase concentrations should be considered as part of future studies of 
chronic sildenafil, or other PDE5 inhibitor, treatment.  
 
6.4.9 Summary 
In untreated hypertensives oral sildenafil 50 mg given 3 times daily reduces BP. It 
also reduces arterial wave reflection but to no greater an extent than would be 













POTENTIAL OF COMBINED ORGANIC NITRATE AND 







7.1.1 Treatment-resistant hypertension 
The current US national guideline on hypertension (JNC 7; Chobanian et al., 2003b) 
defines treatment-resistant hypertension (TRH) as the failure to achieve goal BP in 
patients who are adhering to full doses of an appropriate 3-drug regimen that 
includes a diuretic. The current BHS guideline (BHS IV; Williams et al., 2004) does 
not give a specific definition, but states that one of the indications for specialist 
referral is “resistance to multi-drug regimen, that is, ≥3 drugs”. It is probably 
reasonable to not include the need for a diuretic as one of the 3 drugs in the 
definition, especially given the recent ASCOT data showing that BP control was 
better with a CCB/ACE inhibitor combination than a diuretic/ß-blocker combination 
(Dahlöf et al., 2005). In terms of published studies on TRH there is considerable 
variation in the definition. This, along with the problems of identifying truly 
treatment-resistant patients, means that there are no accurate estimates of the 
prevalence of TRH in the hypertensive population. However, apparent TRH is a 
common reason for referral to specialist hypertension clinics and it is likely that TRH 
will become increasingly common as a result of factors such as an ageing population 
and increasing obesity and diabetes.  
 
TRH must be confirmed with out-of-office measurement of BP. In a study, of 286 
patients referred for TRH on the basis of an office BP of ≥140/90 mmHg, 56% were 
found to have true TRH, as defined as an average 24-hour ABPM of ≥135/85 mmHg 
(Muxfeldt et al., 2003). In this study, patients with true TRH had higher rates of 
target organ damage (nephropathy and LVH) than patients with ‘white coat’ TRH 
(i.e. uncontrolled office BP but normal 24-hour ABPM). Relatively high rates of 
target organ damage in TRH, also documented in other studies (Cuspidi et al., 2001; 
Muxfeldt et al., 2005), suggest that TRH is associated with increased cardiovascular 
risk, which would be expected on the basis of the known association between BP and 
cardiovascular events (Prospective Studies Collaboration, 2002). While there are few 
specific data on the prognosis of TRH, a recent prospective study reported that true 
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TRH independently predicted cardiovascular events over a 5-year follow-up period 
(Pierdomenico et al., 2005).  
 
Once true TRH has been established, potential contributing factors should be 
evaluated and managed (Taler, 2005). Such factors include obesity, excess sodium or 
alcohol intake, and the use of oral contraceptives or non-steroidal anti-inflammatory 
drugs. It may also be appropriate to investigate for identifiable causes of 
hypertension, including renal, renovascular or endocrine abnormalities, or 
obstructive sleep apnoea. There has been a lot of interest recently in the potential 
contribution of aldosterone excess to TRH. Calhoun et al (2002) found that primary 
hyperaldosteronism, diagnosed as a low plasma renin activity and high urinary 
aldosterone concentration in the setting of high sodium intake, was present in 20% of 
patients with TRH and Eide et al (2004) found that a low plasma renin activity was 
present in 67% of TRH patients. 
 
The recognition that aldosterone excess is relatively common in patients with TRH 
has led to increased use of aldosterone antagonists to reduce BP in this condition. For 
example, in the study by Calhoun et al BP fell significantly in all patients with 
hyperaldosteronism who were given sprionolactone, while in the study by Eide et al 
89% of low renin subjects given amiloride with hydrochlorothiazide, had 
substantially reduced BP compared to with placebo. These effects on BP were 
additional to existing therapy, often including ACE inhibitors or ARAs. Other 
common pharmacological approaches to TRH are the intensification of diuretic 
treatment, to counteract intravascular volume expansion, or the addition of α-
adrenoreceptor antagonists such as doxazosin. Drugs such as the centrally acting 
moxonidine (Martin et al., 2005) or the vasodilator minoxidil (Sica, 2004), which 
can cause hypertrichosis and must be given concomitantly with a ß-blocker to 
prevent reflex tachycardia and a loop diuretic to prevent fluid retention, may also be 




7.1.2 Combined organic nitrate and PDE5 inhibition as a possible treatment 
for TRH 
The haemodynamic interaction between organic nitrates and PDE5 inhibitors has 
been discussed extensively in section 1.3.3 and in chapter 5, with an emphasis on the 
potentially harmful systemic hypotension that can result when these drugs are 
administered in combination. Although, for this reason, co-administration of these 
drugs is currently contraindicated, the unique antihypertensive potency of the 
combination may actually be therapeutically useful in controlling BP in patients with 
TRH, at least in the setting of a specialist hypertension clinic. However, the extent to 
which these drugs in combination reduce BP in TRH is not known. The effect may 
be similar to that in healthy men or men with angina (Webb et al., 1999; Webb et al., 
2000). Alternatively, there may either be a greater reduction in BP, because of higher 
baseline BP, or a lesser reduction in BP, because patients are generally resistant to 
antihypertensive treatment.  
 
7.1.3 Aim 
As the initial investigation of the potential of combined organic nitrate and PDE5 
inhibitor in the management TRH, the aim of the present study was to characterise 
the effect on BP of a combination of single doses of sildenafil and ISMN in patients 








7.2.1.1 Identification of subjects 
Potentially suitable subjects were identified from patients attending the WGH 
Cardiovascular Risk Clinic.  
 
7.2.1.2 Inclusion criteria 
• Male or female. 
• Essential hypertension. 
• Office BP >140/85 mmHg despite treatment with 3 or more antihypertensive 
drugs. 
• Daytime average ambulatory BP >130/801 mmHg on the current antihypertensive 
drug regime, within 6 months of the start of the study. 
• Resistance to treatment proven by directly observed therapy (to exclude poor 
compliance as a cause of uncontrolled BP, see below). 
 
7.2.1.3 Exclusion criteria 
• Identifiable underlying cause for hypertension (e.g. Conn’s or Cushing’s 
syndromes, renal artery stenosis, phaeochromocytoma or coarctation of the aorta). 
• Clinically evident coronary artery or cerebrovascular disease. 
• Taking regular organic nitrates or nicorandil. 
• Significant renal or liver impairment. 
• Pregnant. 
• Current alcohol or drug abuse. 
• Previous serious drug allergy. 
 
7.2.2 Screening visit 
Potentially suitable subjects who agreed to be considered for the study attended a 
morning screening visit at the CRC. At this visit the study was explained fully and 
                                                
1An daytime average ambulatory BP of 130/80 is considered equivalent to an office BP of 140/85 
mmHg (Williams et al., 2004) 
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written consent was obtained. A medical history was taken, a physical examination 
and 12-lead ECG were performed, and a non-fasting screening blood sample was 
taken. A 24-hour ambulatory BP monitor was fitted if necessary. 
 
During the screening visit the BP response to directly observed therapy was 
recorded. This was performed to ensure that the patients recruited had true TRH, 
rather than uncontrolled BP due to poor adherence to treatment. In addition, it was 
important to exclude patients whose uncontrolled BP was related to poor adherence 
for safety reasons. If such patients had been administered sildenafil and ISMN 
concurrently with their usual antihypertensives there would have been a significant 
risk of severe hypotension. Subjects were asked not to take their normal morning 
medicines but to bring them to the CRC. Following 30 minutes rest, baseline semi-
erect BP was recorded in duplicate. Subjects then took all of their usual medicines 
under direct observation and single measures of BP were repeated every 15 minutes 
for 4 hours. The average systolic and diastolic BPs over the last 2 hours of the 
observation period were calculated and if either was >40 mmHg lower than the 
average at baseline the subject was not eligible for the study. 
 
7.2.3 Study design 
Randomised, placebo-controlled, double blind, 4-way crossover. 
 
7.2.4 Protocol 
All studies were performed first thing in the morning. On each study day patients 
took their usual medicines at home before coming to the CRC. They were asked to 
ensure that they took them at the same time for each visit. On separate visits, at least 
5 days apart, subjects received the following orally: 
 
• Placebo sildenafil and placebo ISMN 
• Sildenafil 50 mg and ISMN placebo 
• Placebo sildenafil and ISMN 10 mg 




The 2 drugs were administered simultaneously. The protocol is outlined in Figure 
7.1. Subjects were studied supine. All measures were made in duplicate and mean 



















Figure 7.1. Study protocol. 




For each parameter, the AUC of the change from baseline to 4 hours after drug 
administration was calculated. The mean AUCs were compared between study 
phases by paired Student’s t-tests. 
 
-40 min Rest supine  
BP, HR, PWA, CF-PWV 
-10 min 
-5 min 
















Thirteen subjects attended for screening to assess eligibility for the study and, of 
these, 7 were recruited. Of the 5 patients not recruited, 3 had well controlled BP at 
ABPM, 1 did not take part for personal reasons, and it emerged that another had 
recently had a minor stroke. On initial review of the data 1 subject had consistently 
well-controlled BP at baseline (117/72 mmHg, 121/72 mmHg, 117/63 mmHg 106/62 
mmHg at visits 1, 2, 3 and 4 respectively) and, as a result, this subject’s data were 
excluded from analysis. Therefore, the data presented are from the remaining 6 
subjects. The baseline characteristics of the subjects are given in Table 7.1. 
 
Table 7.1. Baseline characteristics of the subjects. 
Means (SDs) are given for continuous variables. Values for RAIx, aortic AIx, aortic 
AIx@75, CF-PWV and central BP are means of the baselines of all 4 visits. 
 
 All subjects (n = 7) 
Subjects analysed 
(n = 6) 
Males/females 3/4 3/3 
Age (years) 61 (10) 61 (11) 
Screening office BP (mmHg):   
Systolic 167 (13) 169 (12) 
Diastolic 91 (14) 93 (14) 
Ambulatory BP (mmHg):   
24 hour systolic  139 (13) 141 (13) 
24 hour diastolic 77 (9) 77 (9) 
Daytime systolic 145 (11) 146 (11) 
Daytime diastolic 81 (10) 81 (11) 
Night time systolic 124 (18) 125 (19) 
Night time diastolic 64 (7) 63 (7) 
Central BP (mmHg):   
Systolic 131 (11) 135 (4) 
Diastolic 80 (13) 82 (13) 




 All subjects (n = 7) 
Subjects analysed 
(n = 6) 
RAIx (%) 86 (5) 86 (5) 
Aortic AIx (%) 32 (2) 32 (3) 
Aortic AIx@75 (%) 24 (4) 24 (4) 
CF-PWV (m/s) 11.0 (3.1) 11.8 (2.5) 
BMI (Kg/m2) 31 (5) 30 (4) 
LVH 0 0 
Plasma glucose (mmol/L) 5.7 (1.3) 6.0 (1.2) 
Serum cholesterol:    
Total (mmol/L) 5.2 (0.8) 5.1 (0.9) 
LDL (mmol/L) 3.1 (0.7) 3.2 (0.8) 
HDL (mmol/L) 1.4 (0.3) 1.3 (0.2) 
Total:HDL ratio 3.8 (0.7) 4.0 (0.6) 
Triglyceride (mmol/L) 1.4 (0.8) 1.5 (0.8) 
Number of antihypertensives:   
3 5 4 
4 2 2 
Antihypertensive drugs:   
Thiazide diuretic 4 3 
Loop diuretic 2 2 
CCB 4 3 
ACE inhibitor 4 3 
ß-blocker 4 4 
ARA 2 2 
Doxazosin 1 1 
Minoxidil 2 2 
Aspirin 2 2 




Continued from previous page. 
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7.3.2 Effects on BP, HR, arterial wave reflection and CF-PWV 
The data for peripheral BP and MAP are shown in Figure 7.2. Sildenafil alone, 
ISMN alone and the combination all reduced systolic BP, diastolic BP and MAP 
compared to placebo. The effects of sildenafil alone and ISMN alone were not 
significantly different for systolic or diastolic BP, but ISMN caused a greater fall in 
MAP. The combination of sildenafil and ISMN produced a greater fall in systolic BP 
than either drug given alone but the effect on diastolic BP and MAP was not 
significantly different. Compared to placebo, from 1 to 3 hours after drug 
administration BP was on average 13/10 mmHg lower with sildenafil alone, 18/14 
mmHg lower with ISMN alone and 26/18 mmHg lower with combined sildenafil and 
ISMN.  
 
The data for measures of arterial wave reflection are shown in Figure 7.3. The 
relative effects of sildenafil alone, ISMN alone and the combination of sildenafil and 
ISMN on each of aortic AIx, aortic AIx@75 and RAIx were the same. There 
appeared to be a small but statistically non-significant reduction in arterial wave 
reflection with sildenafil. In contrast, ISMN alone and in combination with sildenafil 
reduced arterial wave reflection, compared both to placebo and to sildenafil alone. 
There was a slight trend to a greater reduction in arterial wave reflection with the 
combination of ISMN and sildenafil compared to ISMN alone, but this was not 
statistically significant. Compared to placebo, from 1 to 3 hours after drug 
administration aortic AIx, aortic AIx@75 and RAIx were, respectively, on average 
3%, 2% and 4% lower with sildenafil alone, 16%, 15% and 22% lower with ISMN 
alone and 18%, 17% and 26% lower with combined sildenafil and ISMN. 
 
The data for central BP, HR and CF-PWV are shown in Figure 7.4. Sildenafil alone, 
ISMN alone and the combination all reduced central systolic BP and central diastolic 
BP compared to placebo. Central systolic BP was reduced more by ISMN alone than 
by sildenafil alone, although the effects of the 2 drugs given alone were not 
significantly different for central diastolic BP. The combination of sildenafil and 
ISMN produced a greater fall in central systolic BP than either drug given alone and 
a greater fall in central diastolic BP than sildenafil alone. The effect of the 
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combination on central diastolic BP was not significantly different to the effect of 
ISMN alone. Compared to placebo, from 1 to 3 hours after drug administration 
central BP was on average 15/10 mmHg lower with sildenafil alone, 28/14 mmHg 
lower with ISMN alone and 36/19 mmHg lower with combined sildenafil and ISMN. 
There was an early trend to a small increase in HR with sildenafil alone and the 
combination of sildenafil and ISMN compared to either placebo or ISMN alone, but 
there was no overall significant difference between any of the study phases. There 
was no effect on CF-PWV of either sildenafil alone, ISMN alone, or the combination 
of sildenafil and ISMN.  
 
7.3.3 Side effects 
Two subjects experienced transient side effects. One experienced flushing, headache 
and dizziness with the combination of sildenafil and ISMN and the other a headache 



































































Figure 7.2. Effects on peripheral BP and MAP. 
Data expressed as mean changes from baseline. Error bars are SEMs. Effects at each 
time point on the left and AUCs of these curves on the right. Placebo in black, 
sildenafil in blue, ISMN in green and combined sildenafil and ISMN in red. The 
dotted lines represent the sum of the effects of sildenafil alone and ISMN alone at 
each time point. 
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Figure 7.3. Effects on arterial wave reflection. 
Data expressed as mean changes from baseline. Error bars are SEMs. Effects at each 
time point on the left and AUCs of these curves on the right. Placebo in black, 
sildenafil in blue, ISMN in green and combined sildenafil and ISMN in red. The 
dotted lines represent the sum of the effects of sildenafil alone and ISMN alone at 
each time point. 
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Figure 7.4. Effects on central BP, HR and CF-PWV. 
Data expressed as mean changes from baseline. Error bars are SEMs. For central BP, 
effects at each time point are on the left and AUCs of these curves on the right. 
AUCs are not shown for HR or PWV because none of the comparisons were not 
statistically significant for these parameters. Placebo in black, sildenafil in blue, 
ISMN in green and combined sildenafil and ISMN in red. The dotted lines represent 





7.4.1 Main findings 
The main findings from the present study are that in patients with TRH who were 
maintained on their usual antihypertensives both sildenafil and ISMN given alone 
acutely reduced BP and there was additional BP reduction when these drugs were 
given in combination. 
 
7.4.2 The effect of placebo 
During the placebo phase of the study there was a general trend to an increase in BP 
throughout the monitoring period. Subjects took their usual antihypertensives on 
waking, generally a couple of hours before starting the study. Thus, it is likely that 
baseline measures were made at around the time of the peak effect of their normal 
regimens. The subsequent increase in BP with placebo may, therefore, be the result 
of waning of this peak effect. In keeping with this, HR tended to decline with time, 
which might be expected as a baroreceptor-mediated response to increasing BP. The 
alternative explanation, that the subjects became increasingly restless, seems less 
likely because HR would be expected to increase under these circumstances.  
 
7.4.3 The effects of sildenafil, ISMN and combined sildenafil and ISMN 
7.4.3.1 Peripheral BP 
The effect of PDE5 inhibition on BP in patients with TRH has not been investigated 
previously. The observed acute reduction in BP with sildenafil of around 13/10 
mmHg compared to placebo would likely be of real clinical benefit if it were 
sustained with regular treatment. Given that sildenafil alone reduces BP in 
uncomplicated hypertensives when taken regularly (chapter 6), it seems likely that it 
would also continue to reduce BP with regular treatment in TRH, although this 
would have to be investigated specifically.  
 
Once daily extended-release ISMN has recently been shown to reduce systolic BP, 
but not diastolic BP, in patients with treatment-resistant systolic hypertension 
(Stokes et al., 2005). In the present study, in addition to reducing systolic BP, ISMN 
 
 174 
also reduced diastolic BP, suggesting that the benefit of organic nitrates may not be 
restricted to systolic BP when a more heterogeneous TRH population is studied. 
Compared to placebo, ISMN reduced BP acutely by around 18/14 mmHg and this 
was achieved at a very low dose of 10 mg. Whether this effect can be sustained with 
regular treatment warrants further investigation. With chronic treatment the 
development of nitrate tolerance might attenuate the degree of BP reduction that can 
be achieved. However, nitrate tolerance can be avoided by ensuring that there is a 
regular nitrate-free or nitrate-low period in each 24-hours (Thadani et al., 1992). 
Indeed, a preparation that allowed for this was used in the study that demonstrated 
chronic efficacy in resistant systolic hypertension. The downside of requiring a 
nitrate-free or nitrate-low period is that, during this time, BP may be less well 
controlled. However, reducing BP for a substantial portion of the day may be 
preferable to not reducing it at all. Further advantages of organic nitrates are that 
they are very familiar to physicians, being widely used in CAD, and that they are 
relatively inexpensive. 
 
The primary aim of the present study was to investigate the effect of combined 
sildenafil and ISMN on BP in TRH. When given together these drugs substantially 
reduced BP, by around 26/18 mmHg compared to placebo. The effect on systolic BP 
was significantly greater than the effect of either drug given alone and the effect on 
diastolic BP was significantly greater than sildenafil alone. There was also a trend to 
a greater reduction in diastolic BP than with ISMN alone, and the lack of statistical 
significance is probably due the small size of the study. As can be seen in Figure 7.2, 
the effect of the combination on BP was no greater than would be expected from the 
sum of the effects of each drug given individually. Indeed, the effects in comparison 
to placebo appear to be less than additive (reductions of 13/10 mmHg with sildenafil 
and 18/14 with ISMN compared to 26/18 mmHg with the combination). The lack of 
any synergism in the interaction of these drugs on BP may indicate that they could be 
used to reduce BP in TRH in a controlled manner. However, while the present study 
demonstrates the potential of an organic nitrate and PDE5 inhibitor combination to 
reduce BP in TRH, further research is needed to establish the longer-term efficacy 
and safety of such an approach. 
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The rationale for investigating the effect of combined sildenafil and ISMN on BP in 
TRH was that the unique antihypertensive potency of this drug combination might be 
useful in reducing BP in this therapeutically challenging population. However, as 
discussed above, while these drugs produced substantial reduction in BP when given 
together, they also each significantly reduced BP when given alone. This is 
interesting because neither drug alone is considered to be a particularly powerful 
antihypertensive, at least in the doses used, yet clinically significant BP reductions 
occurred even though subjects were treatment-resistant and were also taking at least 
3 other antihypertensives. One possible explanation for this is that the NO-cGMP 
pathway is not the primary target of any of the usual antihypertensives that the 
subjects were taking. As a consequence, the potential for BP reduction with drugs 
that act on this pathway might be greater than with drugs that act on pathways that 
are already targeted by other drugs. It should also be borne in mind that the term 
“resistant hypertension” refers to a failure to reach a target BP rather than necessarily 
a general insensitivity to the effects of antihypertensives. For example, a patient with 
a BP of 210/110 mmHg which is reduced to 160/95 mmHg with 3 antihypertensives 
may be defined as treatment-resistant even though there has been a substantial drug-
related BP reduction. Thus, even though the patients recruited had TRH, there was 
no particular reason to suppose that they would necessarily be relatively insensitive 
to drugs targeting the NO-cGMP pathway as part of a more generalised insensitivity 
to antihypertensives. The administration of the study drugs several hours after the 
patients had taken their usual antihypertensives may have had the consequence of 
maximising the observed effects on BP, in that the potential for BP reduction may 
have been greater if the effects of the regular drugs had passed their peaks, whereas 
if all drugs had been administered simultaneously there may have been less scope for 
additional BP reduction. Although this is speculative, if it proved to be correct it 
would suggest that staggering administration times throughout the day might provide 
better overall control of BP in TRH.  
 
7.4.3.2 Arterial wave reflection, central BP and PWV 
While ISMN alone had a slightly greater effect on BP than did sildenafil alone, 
ISMN substantially reduced arterial wave reflection whereas sildenafil had very little 
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effect. In addition, there was very little additional effect on wave reflection when 
sildenafil was given with ISMN. These data further support the concept (discussed in 
section 6.4.7) that PDE5 inhibitors are not “nitrate-like” in their haemodynamic 
action, even though they act on the same biochemical pathway. ISMN 10 mg most 
likely dilated peripheral conduit arteries, as well as resistance arterioles, whereas 
sildenafil probably mainly dilated arterioles.  
 
Sildenafil alone had a similar effect on central systolic BP (reduction of ~13 mmHg 
vs placebo) as it did on peripheral systolic BP (reduction of ~15 mmHg vs placebo). 
In contrast, the effect of ISMN alone on systolic BP was greater centrally (reduction 
of ~28 mmHg vs placebo) than peripherally (reduction of ~18 mmHg vs placebo). 
Given that peripheral systolic BP was greater than central systolic BP at baseline, the 
proportional difference in the effect of ISMN between the 2 sites was even larger. As 
central systolic BP is augmented by the arterial pressure wave returning from the 
periphery, this finding is expected given the observed effects on arterial wave 
reflection. There is recent evidence that reducing central BP may be more important 
than reducing peripheral BP in the preventing cardiovascular events (Williams et al., 
2006). Therefore, the substantial effect of ISMN on central systolic BP in TRH may 
be of particular benefit if it were sustained with regular treatment. Even further 
benefit might be gained with the addition of sildenafil, given that the combination 
reduced central systolic BP by ~36 mmHg. 
 
Even though BP is considered to be a major confounding factor of arterial stiffness, 
PWV was unaffected by any treatment in the current study, despite very substantial 
acute changes in BP. Sildenafil alone also did not affect PWV acutely when given to 
untreated hypertensives, although the effects of BP were milder than in the present 
study (see sections 6.3.6 and 6.4.4). As discussed in section 6.4.4, these findings are 
consistent with the possibility that, at least in hypertension, structural changes to 
large arteries occur such that the stiffness of their walls remains relatively constant 





There were no significant changes in HR during any phase of the study despite 
significant reductions in BP, especially with the combination of sildenafil and ISMN. 
Four of the subjects were taking a ß-blocker and this may have limited any increase 
in HR that might otherwise have occurred. In addition, the subjects remained rested 
supine throughout the study and it is possible that HR might have increased if the 
subjects had been ambulatory. Nevertheless, the lack of any increase in HR is 
encouraging in terms of potential clinical use, especially when compared to the 
vasodilator minoxidil which, although often used for TRH, must be prescribed with a 
ß-blocker to prevent reflex tachycardia.  
 
7.4.3.4 Side effects  
Few side effects were experienced, even with the combination of sildenafil and 
ISMN. However, this was a small single dose study and the subjects were kept 
supine, which may have limited symptoms of hypotension. Any future study 
investigating the potential of combined PDE5 inhibitor and organic nitrate should 
closely monitor for side effects. 
 
7.4.4 Summary 
In patients with TRH maintained on their usual antihypertensives sildenafil given 
alone and ISMN given alone both acutely reduce BP. There is additional BP 


















8.1 NON-INVASIVE ASSESSMENT OF ENDOTHELIAL VASOMOTOR 
FUNCTION 
 
8.1.1 The appropriate dose of GTN to use as an endothelium-independent 
control  
Relatively low doses of sublingual GTN, in the order of 8 to 50 µg, are generally 
equivalent to the effects of the endothelium-dependent stimuli that are used to assess 
endothelial vasomotor function non-invasively. For FMD, the dose of sublingual 
GTN that is equivalent to the effect of post-reactive hyperaemia-induced increased 
shear stress on brachial artery diameter is between 8 and 35 µg. Given that values for 
FMD in normal healthy subjects vary in the published literature, it is not possible to 
define a dose that is precisely equivalent to the normal FMD response in different 
populations. However, the dose-response data clearly indicate that 400 µg, a dose 
still used by many investigators (Pena et al., 2004; Woodman et al., 2004; Wu et al., 
2004; Zilkens et al., 2003), dilates the brachial artery to a much greater extent than 
does post-reactive hyperaemia-induced increased shear stress. Moreover, this dose 
causes significant systemic haemodynamic changes and may not even be sufficient 
to cause maximum NO-mediated dilatation. Therefore, it seems rational to use a 
lower dose of GTN in FMD studies and 25 µg, already used by some investigators 
(Bennett-Richards et al., 2002; Cross et al., 2003; Ghiadoni et al., 2001; Ghiadoni et 
al., 2003), would generally be appropriate.  
 
The dose-response study data suggested that the dose of GTN that was equivalent to 
the effect of salbutamol 400 µg on aortic AIx was 50 µg. This was based on 
previously published data in which the mean maximum change in aortic AIx with 
salbutamol was ~11% in healthy subjects (Wilkinson et al., 2002a). When this dose 
was used in the study investigating the effect of age and gender on salbutamol 
responses, it resulted in a greater effect on aortic AIx that did salbutamol (-14% vs -
6%), suggesting that a smaller dose would have been more appropriate. GTN also 
had a much greater effect on RAIx (-18% vs -8% with salbutamol). In contrast to 
FMD, which has been used extensively the last 10 to 15 years, there is currently little 
published data on the effect of salbutamol on arterial wave reflection, However, it is 
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likely that the methodology will be used with increasing frequency and as further 
data are published there will be greater appreciation of the range of normal 
responses. It will then be possible, by referring to the dose-response relationships 
characterised here, to choose with greater confidence an appropriate dose of GTN to 
use as a control for the effects of salbutamol. 
 
8.1.2 Reduction in arterial wave reflection with salbutamol: the effects of age, 
gender and correlation with FMD 
There were no effects of either age or gender on the degree of reduction in arterial 
wave reflection with inhaled salbutamol. Given the well-documented age-related 
decline in both FMD and muscarinic agonist-induced vasodilatation in the forearm, 
the lack of any effect of age on salbutamol responses is of particular interest and is 
well worthy of further investigation. Although the study reported here was a 
reasonable size overall, in any given decade of age (20s, 30s etc) there were only 
around 10 subjects. Moreover, there were only 3 subjects in their 60s and 1 subject in 
their 70s. A similar study recruiting greater numbers of healthy subjects of different 
ages, especially over 60 years, would be of value. Consideration should also be given 
to controlling for aerobic fitness in such a study. Given the evidence that the age-
related decline in endothelium-dependent vasomotor function is agonist-specific 
(DeSouza et al., 2002), the effect of age on salbutamol-induced vasodilatation in the 
forearm of healthy subjects should be investigated. If there is no effect of age on 
salbutamol-induced vasodilatation, this would be consistent with the data on 
systemic salbutamol responses. If, on the other hand, there is a decline in salbutamol-
induced vasodilatation in the forearm with age, this would suggest that measurement 
of arterial wave reflection is not sufficiently sensitive to detect this effect.  
 
There was no correlation between brachial artery FMD and the extent of reduction in 
arterial wave reflection with salbutamol in healthy subjects. Although this may 
initially seem surprising, because both are measures of NO-dependent vasodilatation, 
it is in keeping with recent data from the much larger PIVUS study (Lind et al., 
2005). The possibility that measurement of resistance artery endothelial vasomotor 
function might provide information on cardiovascular risk that is additional to 
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information obtained by measuring conduit artery endothelial vasomotor function is 
intriguing. In this respect, the longitudinal data from the PIVUS study will be very 
interesting. Other prospective studies on the value of measuring the effect of inhaled 
salbutamol on arterial wave reflection will determine the potential of this 
methodology for cardiovascular risk assessment. These studies will also generate 
data on baseline arterial wave reflection and should resolve whether additional 
prognostic information can be gained from the derived central waveform over the 
directly-measured peripheral waveform. Moreover, it will also be possible to 
determine whether challenge with salbutamol provides additional prognostic 
information over simple measurement of baseline arterial wave reflection.  
 
 
8.2 ENDOTHELIAL FUNCTION IN HEALTHY SMOKERS AND THE EFFECT 
OF SILDENAFIL 
Compared to non-smokers, there was a reduced systemic vascular response to 
inhaled salbutamol in smokers. While this is consistent with previous studies that 
have demonstrated that smoking is associated with impaired endothelium-dependent 
vasomotor function, the reduced effect of salbutamol was only shown when the 
response was quantified as the AUC of the change in aortic AIx. This may indicate 
that the AUC of the change in aortic AIx is more sensitive for the detection for 
endothelial vasomotor dysfunction than the maximum change in aortic AIx or either 
the AUC of the change or the maximum change in RAIx, in which there were 
statistically non-significant trends to reduced responses with salbutamol in smokers. 
Future studies using this methodology, in smokers and in other at risk populations, 
should address this question.  
 
There was a trend to an improvement in the response to salbutamol in smokers with 
sildenafil. If this was a real effect the study was underpowered to detect it with 
statistical confidence. Therefore, a larger study would be required to definitely 
address this question. Power calculations suggested that around 60 smokers would be 
needed for such a study. It is possible that subjects with a more extensive smoking 
history would exhibit greater impairment of salbutamol responses at baseline and 
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also greater improvement in salbutamol responses with sildenafil. Therefore, 
recruiting subjects with a more extensive smoking history might reduce the required 
sample size. A similar study in which endothelial vasomotor function was also 
measured by other methodologies, such as brachial artery FMD or response to ACh 
in the foreman, would allow for a comparison between methodologies in the 
assessment of both baseline endothelium-dependent vasomotor function and the 
effect on this of treatment with sildenafil.  
 
 
8.3 THE TIME COURSE OF THE HYPOTENSIVE INTERACTION BETWEEN 
SILDENAFIL AND GTN 
In men with stable angina the interaction on BP reduction between sildenafil 100 mg 
and GTN 400 µg lasted for at least 8 hours after sildenafil administration, but was, 
on average, no more than additive from 6 hours after sildenafil. These data have 
direct clinical relevance in that they will inform clinical judgement on whether GTN 
could be considered for a patient with angina who has taken sildenafil more than 6 
hours previously. Importantly, the study does not exclude the possibility of 
significant hypotension if GTN is administered between 6 and 8 hours after sildenafil 
but suggests that this would be substantially less likely than if it were given within 6 
hours of sildenafil. Therefore, if GTN is considered appropriate it should be used 
cautiously in patients who are haemodynamically stable and closely monitored. A 
much larger study would be required to determine with some confidence the 
frequency with which significant hypotension occurs when GTN is given more than 
6 hours after sildenafil. However, it is not likely that such a study will be performed. 
GTN is also frequently given intravenously when patients are admitted to hospital 
with acute angina. The data on the time course of the interaction with sublingual 
GTN may not easily be extrapolated to GTN given intravenously, but a similar study 
to that reported here could be performed with intravenous GTN. 
 
The time course of the hypotensive interactions between GTN and the other PDE5 
inhibitors in clinical use have not been characterised in detail in patients with CAD. 
Unpublished data in healthy subjects have apparently shown that vardenafil 10 mg 
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does not potentiate the BP lowering effect of sublingual GTN 400 µg given after 1 to 
24 hours, but that vardenafil 20 mg does potentiate the BP lowering effect of 
sublingual GTN 400 µg given after 1 and 4 hours, though not after 24 hours 
(Summary of product characteristics for Levitra, 2005). Vardenafil has a similar 
pharmacokinetic profile to sildenafil (see Table 1.1) and it is possible that the time 
course of its interaction with sublingual GTN in angina patients would also be 
similar to that with sildenafil. However, this would need to be investigated directly. 
Tadalafil has a much longer duration of action than sildenafil and in 166 men, mostly 
healthy but some of whom were diabetic or hypertensive, an interaction with 
sublingual GTN 400 µg was evident at 24 hours but not at 48 hours after tadalafil 
administration (Kloner et al., 2003a). 
 
 
8.4 THE EFFECT OF PDE5 INHIBITION IN HYPERTENSION 
 
8.4.1 PDE5 inhibitors for the initial treatment of hypertension 
In otherwise untreated hypertensives sildenafil given 3 times daily for 16 days 
reduced daytime ambulatory BP by 10/6 mmHg compared to placebo. This is the 
first study to investigate the effects of chronic PDE5 inhibition on BP in 
hypertension and indicates that PDE5 inhibitors have potential in the long-term 
treatment of this condition. While there was some attenuation of the acute effect on 
BP, this was relatively small and the persistent hypotensive effect at 16 days suggests 
that the effects on BP will be maintained in the long term. However, longer studies 
would be needed to confirm this. 
 
Sildenafil did not reduce arterial wave reflection to any greater extent than would be 
expected from its effects on BP. However, the trend to an improvement in CF-PWV 
after 16 days of regular sildenafil is worth investigating further. Specifically, does 
longer treatment with a PDE5 inhibitor reduce PWV? Given the strong relationship 
between PWV and cardiovascular events, reduction in PWV may be an important 
mechanism through which treatment improves clinical outcome. The dissociation 
between the effect of sildenafil on BP and its potential effect on PWV may suggest a 
 
 184 
progressive reduction in the intrinsic stiffness of large arteries. This, itself, might be 
a result of chronic reduction in BP, although reduction in PWV has not been shown 
consistently with chronic treatment with antihypertensives of different classes 
(Oliver et al., 2003). 
 
Sildenafil also had no effect on conduit artery endothelium-dependent vasomotor 
function, measured as brachial artery FMD, in hypertensives. This finding does not 
discount the possibility that PDE5 inhibition would improve endothelium-dependent 
vasomotor function in other vascular territories. For example, the effects of chronic 
treatment with a PDE5 inhibitor on endothelium-dependent vasomotion in the 
forearm vascular bed or on the systemic vascular response to salbutamol could be 
investigated in future studies.  
 
Drugs with a duration of action long enough to allow once-daily administration are 
preferred in the management of hypertension (or, indeed, any condition requiring 
chronic treatment) to maximise patient convenience and adherence to treatment. In 
this respect sildenafil, which has a relatively short duration action and must be given 
3 times daily, is not ideal. However, tadalafil might be more suitable as an 
antihypertensive, given that it has a much longer duration of action and can be given 
once daily. Therefore, wherever possible, tadalafil should probably be used in future 
studies investigating the potential of PDE5 inhibitors for the treatment of 
hypertension. Alternatively, if modified release preparations of sildenafil or 
vardenafil were developed these might also be suitable. A priority for further 
research on the role of PDE5 inhibitors as treatments for hypertension is to 
characterise appropriate dosing strategies for use in regular therapy. For example, 
what are the smallest doses that reduce BP and how much additional hypotensive 
effect can be achieved by increasing dose? Subsequently, studies comparing both 
antihypertensive efficacy and tolerability of PDE5 inhibitors with established 
antihypertensives would help to determine their place in clinical practice.  
 
Side effects were reported relatively commonly with regular sildenafil administration 
and these might limit the potential for widespread clinical use in hypertension. Given 
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that tadalafil is likely to be the most suitable PDE5 inhibitor for the chronic treatment 
of hypertension, at least of those currently available, any future chronic studies using 
this drug should carefully evaluate its side effect profile. There is a suggestion from 
the literature that back pain and myalgia may be more common with tadalafil 
(Govier et al., 2003; Hatzimouratidis et al., 2005; Setter et al., 2005) and future 
studies should monitor plasma creatine kinase concentrations. Dyspepsia was 
reported relatively commonly with regular sildenafil. If the PDE5 inhibitors are 
pursued as treatments for hypertension there should be very careful evaluation of 
their chronic effects on the lower oesophagus. The possibility of chronic reflux 
oesophagitis should be taken very seriously given the possibility of an increased risk 
in oesophageal neoplasia.  
 
 
8.4.2 PDE5 inhibitors and organic nitrates for TRH 
In patients with TRH who were maintained on their usual antihypertensives, a 
combination of sildenafil and ISMN produced substantial acute reduction in BP. 
However, each of these drugs given alone also significantly reduced BP, albeit to a 
lesser degree than in combination. Although this study was very small the clear 
effects on BP that were demonstrated provide a sufficient base from which to 
progress to regular dosing studies. Further investigation of the effects of a PDE5 
inhibitor alone or a long-acting nitrate alone on BP in TRH could be performed 
relatively easily in an outpatient-based study. For further investigation of the effects 
of combined PDE5 inhibitor and organic nitrate, one possible study design would be 
to give patients with TRH either regular sildenafil or regular ISMN alone initially 
and, if BP is not controlled, to then also give the alternative drug. Given the potential 
for substantial BP reduction with the combination, subjects would need to be 
monitored closely. The relatively short duration of action of sildenafil would make it 
suitable for such initial chronic dosing studies, because profound hypotension might 
last substantially longer if a longer acting drug, such as tadalafil, were used. 
However, after these studies, the effect of tadalafil in combination with an organic 




There are certain groups of patients in whom BP control is considered particularly 
important but often more difficult to achieve, including patients with diabetes or 
renal failure. Moreover, because of their increased cardiovascular risk, target BPs are 
lower for these patients than for hypertensives in general (Williams et al., 2004). 
Aggressive BP lowering therapy in the form of combined PDE5 inhibitor and 
organic nitrate could be particularly useful in these situations and studies specifically 
recruiting renal failure or diabetes patients should be considered. 
 
If future research confirms the potential of combined PDE5 inhibitor and organic 
nitrate in TRH, the substantial BP reduction that might be achieved may even allow 
for cessation of other antihypertensives. This would allow for simplification of 
medication regimens, but would have to be investigated directly. 
 
The antihypertensive drug nebivolol is a ß1-adrenoreceptor antagonist that also acts 
as a vasodilator by stimulating the production of endothelial NO (Dessy et al., 2005; 
Mason et al., 2005). By virtue of this action, PDE5 inhibitors might be expected to 
potentiate nebivolol’s effects on BP. There are no published data on the combined 
effects of PDE5 inhibitors and nebivolol on BP, but the potential of such a drug 
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2005;77(4):335-8 Letters to the Editor 337ose-response relationship of sublingual
itroglycerin with brachial artery dilatation and
hange in central and peripheral
ugmentation index
o the Editor:
Flow-mediated dilatation (FMD) of the brachial artery
BA)1 and arterial pressure waveform analysis are used to
ssess nitric oxide (NO)–mediated endothelial vasomotor
unction noninvasively, the latter by measuring the change in
ugmentation index after inhaled albuterol (INN, salbutamol),
t either the central aorta (AAIx)2 or the radial artery (RAIx).3
o differentiate impaired endothelial function from general-
zed vascular dysfunction, the endothelium-dependent re-
ponses are usually compared with the effects of sublingual
itroglycerin (NTG), an endothelium-independent vasodila-
or. In FMD studies 400 g NTG has been used most com-
only, although lower doses, which may dilate the BA to an
xtent similar to the shear stress stimulus, may be more
ppropriate.4 However, the dose-response relationships of
ublingual NTG to change in BA diameter, AAIx, and RAIx
re not known. To help define the doses of NTG that should
e used, we characterized these dose-response relationships.
In this 9-way, double-blind, randomized, crossover study,
7 healthy men, with a mean age of 40 years (SEM, 4 years),
eceived sublingual 80-L solutions of placebo (water on 2
ccasions) and 7 doses of NTG (5-400 g). BA diameter was
easured continuously by ultrasound, and AAIx and RAIx
ere assessed by use of the SphygmoCor system (AtCor
edical, West Ryde, New South Wales, Australia). Subjects
ere seen on 3 separate days. On each day, FMD was
easured first, followed by the responses to 3 separate doses
f NTG or placebo, each given 2 hours apart. After drug
dministration, the BA was scanned for 5 minutes and the
eak change in diameter was recorded. Heart rate and blood
ressure were measured after 4 minutes, and AAIx and RAIx
ere measured after 5 minutes.
At baseline, the mean values were as follows, with SEM in
arentheses: blood pressure, 124 mm Hg (3 mm Hg)/77 mm
g (3 mm Hg); FMD, 3.9% (0.6%); AAIx, 14% (2%); and
AIx, 64% (3%). Fig 1 illustrates the dose-response relation-
ig 1. Log dose-response relationships of sublingual nitro-
lycerin (NTG) to change in heart rate (HR) (A), systolic and
iastolic blood pressure (BP) (B), central aorta augmentation
ndex (AAIx) (C), radial artery augmentation index (RAIx)
D), and brachial artery diameter (E). Data are given as mean
hanges (95% confidence intervals). For AAIx and RAIx,
he NTG doses that are equivalent to the normal responses to
lbuterol are indicated. For brachial artery diameter, the
anges of NTG doses that are equivalent to the normal flow-
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338 Letters to the Editor APRIL 2005hips. The dose range of NTG that yielded vasodilatation
quivalent to that of an accepted normal BA FMD of
pproximately 4% to 10% was approximately 8 to 35 g.
he doses equivalent to the effects of 400 g albuterol on
AIx and RAIx were approximately 50 g (absolute
hange in AAIx of approximately 11%)2 and approxi-
ately 25 g (percentage change in RAIx of approxi-
ately 12%).3
Thus relatively low doses of NTG, in the range from 8 to
0 g, change BA diameter, AAIx, and RAIx to a degree
imilar to that of the endothelium-dependent stimuli in
ealthy subjects. Therefore, with the use of these doses, if a
roup of subjects has an impaired response to the
ndothelium-dependent stimulus but not to NTG, one can
onclude that the defect lies at the level of the endothelium.
f the NTG response is also reduced, more generalized vas-
ular dysfunction is likely. Using higher NTG doses, on the
lateau of the dose-response relationship, would theoretically
ssess the maximum capacity for NO-mediated dilatation, a
ifferent measure of vascular function and potential damage.
ndeed, lower doses are not appropriate for assessing maximal
esponsiveness to NO. Of note, however, is that even with
00 g NTG there was no evidence that a maximum response
f change in BA diameter, AAIx, or RAIx was approached.
herefore assessing maximum NO-mediated dilatation would
ikely be confounded by the systemic hemodynamic effects of
igher doses of NTG. dJames J. Oliver, MRCP
Amie Bowler, BSc(Hons)
Querine Beudeker, BSc
Thomas ten Cate, BSc
David J. Webb, MD
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Effect of Regular Phosphodiesterase Type 5 Inhibition
in Hypertension
James J. Oliver, Vanessa P. Melville, David J. Webb
Abstract—There are no published controlled clinical trials of regular phosphodiesterase type 5 inhibitor therapy as a
long-term treatment of hypertension. In a randomized, double-blind, 2-way crossover study, 25 otherwise untreated
hypertensive subjects were administered 50 mg of sildenafil or matched placebo 3 times daily for 16 days, and the
effects on ambulatory blood pressure (BP), clinic BP, arterial wave reflection, carotid-femoral pulse wave velocity, and
brachial artery flow-mediated dilatation were assessed. Three subjects were withdrawn because of adverse effects, and
the data from the remaining 22 subjects were analyzed. Sildenafil reduced ambulatory BP (mean [SE] change from
baseline for average daytime BP: systolic 8 [2] mm Hg versus 2 [2] mm Hg with placebo, P0.01; diastolic 6
[1] mm Hg versus 0 [1] mm Hg, P0.01) and clinic BP (change from baseline to 1 hour after drug administration on
day 16: systolic 5 [2] mm Hg versus 4 [2] mm Hg, P0.01; diastolic 5 [1] mm Hg versus 2 [2] mm Hg, P0.01).
Compared with baseline, sildenafil, but not placebo, reduced arterial wave reflection both acutely and after chronic
treatment, but the chronic change in arterial wave reflection was not statistically different from the chronic change with
placebo. Sildenafil did not affect pulse wave velocity or flow-mediated dilatation. The main adverse effects of sildenafil,
which were generally transient and rated as mild or moderate in severity, were dyspepsia, headache, and myalgia. In
conclusion, regular sildenafil constitutes effective antihypertensive therapy. Further studies are warranted to evaluate the
role of longer-acting phosphodiesterase type 5 inhibitors as antihypertensive agents in clinical practice. (Hypertension.
2006;48:622-627.)
Key Words: phosphodiesterase 5  sildenafil  hypertension  blood pressure  arterial stiffness
NO causes vasodilatation by stimulating vascular smoothmuscle soluble guanylate cyclase to convert guanosine
5-triphosphate to cGMP,1 which leads to a reduction in
intracellular calcium concentration.2 cGMP is degraded by
cGMP-specific, cGMP-binding phosphodiesterase 5 (PDE5),
and intracellular concentrations of cGMP are tightly con-
trolled by this enzyme via a number of negative feedback
mechanisms.3
Inhibitors of PDE5 increase the intracellular concentration
of cGMP, with the consequence that NO-mediated cellular
responses, such as vascular smooth muscle relaxation, are
promoted. By stimulating vascular relaxation within the
corpora cavernosa during sexual stimulation, inhibitors of
PDE5 promote penile erection and are effective treatments of
male erectile dysfunction.4 PDE5 inhibition also causes
vasodilatation in the pulmonary vascular bed, and in pulmo-
nary arterial hypertension the PDE5 inhibitor sildenafil sub-
stantially reduces pulmonary artery blood pressure (BP) and
improves functional capacity.5
PDE5 inhibitors are also vasodilators in the systemic
circulation.6 In healthy subjects, single doses of sildenafil
have been found to reduce BP acutely in some6,7 but not
all8–10 studies. Similarly, some studies have found that sil-
denafil reduces BP acutely in patients with coronary artery
disease (CAD),6,11,12 whereas others have found no effect.11,13
In hypertensive patients, acute reduction in BP with sildenafil
has been demonstrated consistently, although only in studies
in which other antihypertensive drugs were also being taken
by the participants.14–16 Although enhancement of the effects
of endogenous NO through PDE5 inhibition may reduce
BP in hypertension, the potential of regular PDE5 inhibitor
therapy for the chronic treatment of hypertension has not
been investigated previously in a controlled clinical trial.
Endothelium-dependent vasomotor function is generally
assessed in vivo by methodologies that are essentially surro-
gate measures of endothelial NO generation. As a result,
PDE5 inhibitors might be expected to improve these re-
sponses. Although this would not constitute an improvement
in endothelial function as such, because release of NO and
other elements of endothelial function would not be expected
to change, it might nevertheless be of clinical benefit, given
the general vasculoprotective actions of NO, which are
predominantly mediated through simulation of cGMP.17 Sil-
denafil has been found to improve endothelium-dependent
vasodilatation in some previous studies11,18–21 but not in
all.9–11,22 There are no published studies on the effect of
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Phosphodiesterase Inhibition
PDE5 inhibition on endothelium-dependent vasomotor func-
tion in hypertension.
In single dose studies, sildenafil has been found to reduce
central augmentation index (CAIx), a measure of the effect of
peripheral arterial wave reflection on the pressure waveform
of the central aorta, in treated hypertensives,14 hypertensive
cardiac transplant patients,19 and patients with CAD.23 It also
acutely reduced carotid-femoral pulse wave velocity (CF-
PWV), a measure of central arterial stiffness, in patients with
CAD23 and heart failure.24 However, the effects of chronic
PDE5 inhibition on arterial stiffness and arterial wave reflec-
tion have not been investigated previously. The aim of this
study was to investigate the effects of chronic treatment with
sildenafil on BP (the primary outcome measure), endotheli-
um-dependent vasomotor function, arterial stiffness, and ar-
terial wave reflection in otherwise untreated hypertensives.
Methods
The study was of randomized, placebo-controlled, double-blind,
2-way crossover design. It was approved by a local research ethics
committee, was performed in accordance with the Declaration of
Helsinki, and written informed consent was obtained from all of
the subjects.
Subjects
Subjects were identified from primary care and hospital hypertension
clinics. The inclusion criteria were: male or female, 3 separate
clinic measurements of systolic BP 160 mm Hg or diastolic BP
100 mm Hg, not taking antihypertensives; hypertension confirmed
on ambulatory BP monitoring (average daytime systolic BP
145 mm Hg or diastolic BP 95 mm Hg), within 3 months of the
screening visit; and subjects with “borderline” hypertension (defined
as an average awake systolic BP 135 and 145 mm Hg or diastolic
BP 85 and 95 mm Hg) if their calculated 10-year risk of
cardiovascular disease was 20% or they had evidence of target
organ damage. The exclusion criteria were: history of other major
cardiac, respiratory, neurologic, or renal disease; systolic BP consis-
tently 210 mm Hg or diastolic BP consistently 120 mm Hg;
current alcohol abuse; diabetes; taking any vasoactive drugs; previ-
ous serious drug allergy; and pregnancy.
Potentially suitable subjects attended a screening visit at which a
medical history was taken and a physical examination and 12-lead
ECG were performed. A nonfasting blood sample was also taken. A
24-hour ambulatory BP monitor was fitted if ambulatory monitoring
had not been performed within 3 months.
Measurements
Clinic BP and heart rate (HR) were recorded, with an appropriate
sized cuff, using a validated oscillometric sphygmomanometer, the
Omron HEM-705CP.25 Ambulatory BP was recorded at the brachial
artery using a validated Spacelabs 90217 ambulatory BP monitor.26
Measurements were taken every 30 minutes for 24 hours. BP
variability was calculated as the within-subject SD of all of the
systolic and diastolic daytime readings.
Radial artery waveforms, calibrated to brachial BP, were mea-
sured by applanation tonometry and the SphygmoCor apparatus. The
radial augmentation index (RAIx) was derived from averaged radial
artery waveforms. CAIx, CAIx adjusted to a standard HR of 75 bpm
(CAIx@75), and central aortic BP were calculated from central
aortic waveforms, which were derived by applying a generalized
transfer function to the directly measured radial waveforms. True
mean arterial BP was derived from integration of the radial wave-
form. The SphygmoCor apparatus was also used to measure CF-
PWV. Brachial artery flow-mediated dilatation (FMD) was used to
assess endothelium-dependent vasomotor function.27 FMD was
quantified both as the peak change from baseline and as the area
under the curve of the change from baseline in brachial artery
diameter after 5 minutes of forearm ischemia. The response to
nitroglycerin, an endothelium-independent control, was not assessed
because of the potential for significant hypotension when given with
sildenafil.28 Full details of the methodologies used are available in an
online supplement at http://hyper.ahajournals.org.
Protocol
Subjects refrained from alcohol for 24 hours and caffeinated
drinks, food, and smoking for 12 hours before each visit. Studies
were conducted in a quiet room kept at 22°C to 24°C.
The study was composed of 2 periods that, except for the
treatment received (sildenafil or placebo), were identical. On day 1,
subjects attended the research unit at 8:00 AM. After 30 minutes,
supine rest baseline measurements of BP and HR, radial waveforms,
CF-PWV, and FMD were recorded in that order. Sildenafil 50 mg or
matched placebo (both obtained from Pfizer, United Kingdom) was
then administered orally, and the same measurements were repeated
1 hour after dose. Subjects were discharged with a supply of the
same tablets to take 3 times daily (morning, early afternoon, and
evening). An ambulatory BP monitor was fitted at 8:00 AM on day
15. On day 16, this was removed, and further measurements were
made before and 1 hour after sildenafil or placebo, as on day 1. There
was a washout period of 6 days between the periods. For all of the
measures, except FMD, duplicate recordings were made and mean
values entered into the analyses.
Subjects recorded the time they took each tablet on a diary card.
During each period, they were provided with 46 tablets, 2 more than
required, and were asked to return all of the unused tablets. Subjects
were also issued with cards on which they were asked to rate any
symptoms as mild, moderate, or severe.
Analyses
Data are given as means and SEs. Means were compared by paired
Student t tests. Correlation coefficients were calculated using the
Pearson method. The screening ambulatory BP was used as the
baseline for both phases of the study.
Results
Subjects
Thirty-six subjects underwent screening (34 from primary
care and 2 from the hospital clinic). Of those screened, 10 did
not meet the entry criteria, and 1 withdrew before starting the
study. Of the 25 subjects who started the study, 3 were
withdrawn because of adverse effects. Analyses were per-
formed on the data from the remaining 22 subjects. The
baseline characteristics of the subjects are given in Table 1.
At baseline, there was a nocturnal reduction of 10% in both
systolic BP and diastolic BP in all of the subjects (ie, there
were no nocturnal nondippers).
Vascular Effects
There were no differences in baseline measures of any
parameter between placebo and sildenafil phases of the study.
Sildenafil significantly reduced both systolic and diastolic
ambulatory 24-hour, daytime, and nighttime BPs compared
with both baseline and placebo (Table 2). Higher baseline
ambulatory systolic BP but not diastolic BP was associated
with a greater reduction with sildenafil (24-hour: r0.55,
P0.01; daytime: r0.52, P0.05; nighttime: r0.51,
P0.05). There was no effect of either sildenafil or placebo
on BP variability (systolic: 13.8 [0.6] mm Hg at baseline,
13.2 [0.6] mm Hg after placebo, and 13.2 [0.6] mm Hg after
sildenafil; diastolic: 9.4 [0.6] mm Hg at baseline, 9.1
[0.7] mm Hg after placebo, and 9.1 [0.5] mm Hg after
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sildenafil; comparisons with baseline and between placebo
and sildenafil are all statistically nonsignificant).
The effects of sildenafil and placebo on clinic BP, arterial
wave reflection, CF-PWV, central BP, and FMD are shown in
Table 3. Sildenafil reduced clinic systolic BP, diastolic BP,
and mean arterial BP acutely (1 hour after administration),
but by day 16, the magnitude of this reduction in BP was less
than that on day 1. On day 16, BP was generally slightly
lower 1 hour after sildenafil administration (time of peak
effect) than just before sildenafil administration (time of
trough effect). Sildenafil did not affect clinic pulse pressure
or HR, either acutely or chronically (data not shown).
Sildenafil reduced CAIx, CAIx@75, and RAIx acutely but,
as with the effects on clinic BP, the magnitude of these effects
on day 16 were reduced compared with those on day 1. When
recorded before sildenafil administration on day 16, these
measures were not significantly different from baseline, but
when recorded 1 hour after sildenafil administration on day 16,
they were significantly lower than at baseline. The changes from
baseline in CAIx, CAIx@75, and RAIx with sildenafil were
significantly different from placebo on day 1 but were not
significantly different from placebo either before or after silde-
nafil administration on day 16. Compared with baseline, silde-
nafil reduced central systolic BP and central diastolic BP, both at
1 hour and after 16 days of regular treatment. However, the
changes in these parameters were not significantly different from
the changes observed with placebo when measured before
sildenafil administration on day 16. Sildenafil reduced central
pulse pressure acutely but not after chronic treatment.
CF-PWV and FMD were unaffected by sildenafil, both
acutely and chronically. Sildenafil also did not affect baseline
brachial artery diameter or the extent of reactive hyperemia at
any point (data not shown).
Adverse Effects
Two subjects were withdrawn while taking sildenafil, 1
because of severe headache (after 3 days) and the other
because of back pain and feeling generally unwell (after 6
days), and 1 subject was withdrawn while taking placebo,
because of joint pains, nausea, and headache (after 11 days).
For a full summary of the symptoms experienced see the
online supplement. Dyspepsia occurred in 10 subjects with
sildenafil and lasted 5 days. Headaches occurred in 8
subjects and were generally mild and transient. Low back/
buttock/leg muscle ache occurred in 7 subjects, was usually
responsive to simple analgesia, and tended to settle within a
few days. Plasma creatine kinase concentrations were mea-
sured in 4 of the subjects who experienced these symptoms,
and all were within the normal laboratory reference range. Six
of the 18 men in the study reported increased penile erection,
which occurred only with sildenafil.
Discussion
Sildenafil reduced BP both acutely and after 16 days of
regular administration. The reduction in average daytime BP
was 8/6 mm Hg compared with baseline and 10/6 mm Hg
compared with placebo. This degree of BP reduction is
similar to the effect of other, commonly used antihyperten-
sive drugs when they are given as monotherapy in hyperten-
sion.29 The correlation between baseline systolic BP and the
extent of reduction in systolic BP with sildenafil suggests that
in a more hypertensive population, a greater absolute effect
on BP may occur.
When given as 50 mg 3 times daily, sildenafil accumulates
in the plasma. The accumulation ratio, based on the area
under the curve of the plasma concentration versus time curve
of 0 to 8 hours, is 1.59 in healthy subjects (Baerbel Wittke,
unpublished data, 2006). Despite this, although there was a
persistent hypotensive effect of sildenafil for 16 days, the
clinic BP data show that there was some attenuation of the
acute effect. This may be the result of neurohormonal
counterregulatory mechanisms, such as stimulation of the
renin–angiotensin system, after the initial vasodilatation-
mediated reduction in BP. On day 16 of treatment, clinic BP
was higher before the administration of sildenafil than at 1
hour afterward. Although average nighttime BP was reduced,
this suggests that the overnight dose interval was sufficiently







Age, y 60 (3) 60 (10)
Weight, kg 89 (3) 87 (7)




Plasma glucose, mmol/L 5.3 (0.1) 5.9 (0.7)
Serum triglyceride, mmol/L 2.0 (0.3) 1.6 (0.1)
Serum cholesterol
Total, mmol/L 5.4 (0.2) 5.9 (0.1)
LDL, mmol/L 3.2 (0.1) 3.9 (0.2)
HDL, mmol/L 1.3 (0.1) 1.3 (0.2)
Total:HDL ratio 4.5 (0.3) 5.0 (0.8)
For continuous variables data are means (SEs). BMI indicates body mass
index; LDL, low-density lipoprotein; HDL, high-density lipoprotein.





Baseline Sildenafil Placebo Sildenafil Placebo
24-h
Systolic BP 144 (1.5) 138 (1.7)* 147 (1.5) 7 (1.9) 3 (2.1)*
Diastolic BP 85 (1.4) 80 (1.9)* 87 (2.2) 5 (1.1) 1 (1.3)*
Daytime
Systolic BP 153 (1.7) 145 (1.8)* 155 (1.5) 8 (2.0) 2 (2.0)*
Diastolic BP 92 (1.4) 86 (1.8)* 92 (2.2) 6 (1.1) 0 (1.3)*
Nighttime
Systolic BP 124 (1.9) 119 (1.9)† 129 (2.1) 5 (1.9) 5 (2.6)†
Diastolic BP 71 (1.6) 68 (2.0)† 74 (2.4) 4 (1.3) 3 (1.7)†
For absolute values, comparisons are against baseline, and for changes from
baseline, comparisons are between sildenafil and placebo.
*P0.01; †P0.05.
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long for the antihypertensive effect to begin to wane, which
may be of clinical relevance given that the early morning
surge in BP may be an important trigger of cardiovascular
events.30 The use of a modified-release preparation of silde-
nafil (not currently available) or a longer-acting PDE5 inhib-
itor might afford better protection at this time. A more stable
steady-state plasma concentration that would occur with
either a modified-release preparation or a longer acting agent
might also result in a greater cumulative reduction in BP.
Despite reducing BP, HR was not affected by sildenafil. This
has been reported previously and is consistent with an
influence on baroreflex regulation.6
Sildenafil reduced arterial wave reflection, whether mea-
sured as CAIx, CAIx@75, or RAIx and did so in a manner
that was similar to the effect on clinic BP, with a greater
reduction acutely than was evident after 16 days. However,
this effect was relatively small and was no more than would
be expected as a simple consequence of the reduction in
systemic BP,31 suggesting that sildenafil did not act specifi-
cally to reduce large artery stiffness. This conclusion may
also be supported by the lack of effect of sildenafil on
CF-PWV, a more direct measure of large artery stiffness.
However, although the effects were not statistically signifi-
cant, there was a trend to a progressive reduction in CF-PWV
(0.2 m/s at 1 hour, 0.5 m/s on day 16 before sildenafil,
and 0.8 m/s on day 16 after sildenafil), and the possibility
of a real effect on CF-PWV should not be dismissed; a larger
sample size or a longer treatment period may have demon-
strated a significant effect. With chronic treatment, sildenafil
reduced central BP to an extent similar to its effect on
peripheral BP. Measurement of central BP did not, therefore,
provide any additional information on the antihypertensive
action of sildenafil over and above the measurement of
peripheral BP.
TABLE 3. Effects on Peripheral Clinic BP, Arterial Wave
Reflection, Central BP, CF-PWV, and FMD
Measure
Absolute Values Changes From Baseline
Sildenafil Placebo Sildenafil Placebo
Systolic BP, mm Hg
Baseline 150 (2.6) 154 (3.3)
1 h 141 (2.8)* 155 (3.2) 10 (2.2) 1 (1.9)*
Day 16, predose 146 (2.8) 152 (3.1) 4 (2.4) 2 (1.8)
Day 16, postdose 145 (2.8)† 158 (3.9) 5 (2.3) 4 (2.1)*
Diastolic BP, mm Hg
Baseline 88 (1.5) 89 (1.6)
1 h 82 (1.9)* 90 (1.7) 6 (1.2) 2 (1.2)*
Day 16, predose 85 (1.5)* 88 (1.8) 3 (1.0) 0 (1.1)
Day 16, postdose 83 (1.6)* 90 (2.0) 5 (1.0) 2 (1.5)*
MAP (mm Hg)
Baseline 111 (1.7) 113 (2.2)
1 h 102 (2.3)* 113 (2.2) 8 (1.5) 1 (1.5)*
Day 16, predose 107 (1.9)* 112 (2.2) 4 (1.3) 1 (1.3)
Day 16, postdose 105 (2.0)* 115 (2.6) 5 (1.4) 2 (1.7)*
CAIx, %
Baseline 32 (1.9) 32 (2.0)
1 h 28 (2.1)* 33 (1.9) 4 (0.9) 1 (0.9)*
Day 16, predose 30 (2.0) 31 (2.3) 2 (1.1) 1 (1.1)
Day 16, postdose 30 (2.0)† 31 (2.3) 2 (0.8) 1 (1.1)
CAIx@75, %
Baseline 25 (1.7) 25 (1.9)
1 h 22 (1.8)* 24 (1.8) 3 (0.8) 1 (0.6)†
Day 16, predose 23 (1.8) 24 (2.2) 2 (0.9) 1 (0.9)
Day 16, postdose 23 (1.8)* 23 (2.0)† 1 (0.7) 2 (0.8)
RAIx, %
Baseline 88 (2.7) 89 (3.0)
1 h 82 (2.9)* 90 (2.7) 6 (1.2) 1 (1.4)*
Day 16, predose 85 (2.8) 87 (3.2) 3 (1.6) 2 (1.6)
Day 16, postdose 84 (2.8)* 88 (3.0) 4 (1.2) 1 (1.9)
Central systolic BP,
mm Hg
Baseline 142 (3.1) 145 (3.7)
1 h 130 (3.2)* 148 (3.6) 12 (2.2) 2 (1.9)*
Day 16, predose 137 (3.1)† 144 (3.6) 5 (2.2) 2 (1.8)
Day 16, postdose 136 (3.4)† 149 (4.4) 6 (2.1) 4 (2.3)*
Central diastolic BP,
mm Hg
Baseline 89 (1.5) 90 (1.6)
1 h 82 (2.0)* 90 (2.1) 6 (1.2) 0 (1.7)*
Day 16, predose 86 (1.5)* 89 (1.8) 3 (1.0) 0 (1.1)
Day 16, postdose 84 (1.6)* 91 (2.0) 5 (1.1) 1 (1.5)*
Central pulse pressure,
mm Hg
Baseline 53 (2.9) 55 (3.0)
1 hour 48 (2.3)* 57 (3.4) 5 (1.7) 2 (1.7)*
Day 16, predose 51 (2.6) 54 (3.1) 2 (1.8) 1 (1.3)




Absolute Values Changes From Baseline
Sildenafil Placebo Sildenafil Placebo
CF-PWV, m/s
Baseline 10.4 (0.49) 10.2 (0.63)
1 h 10.2 (0.47) 10.4 (0.55) 0.2 (0.20) 0.2 (0.18)
Day 16, predose 9.9 (0.55) 10.7 (0.62)† 0.5 (0.28) 0.5 (0.20)†
Day 16, postdose 9.6 (0.56)‡ 10.3 (0.53) 0.8 (0.38) 0.1 (0.18)
FMD (peak dilatation, %)
Baseline 2.6 (0.38) 2.1 (0.39)
1 h 2.1 (0.44) 2.8 (0.47) 0.4 (0.30) 0.7 (0.39)
Day 16, predose 2.7 (0.38) 2.2 (0.36) 0.1 (0.32) 0.1 (0.41)
Day 16, postdose 2.6 (0.63) 3.2 (0.48)† 0.0 (0.62) 1.1 (0.46)
FMD (AUC, AU)
Baseline 7.1 (1.91) 5.6 (2.00)
1 h 7.4 (2.35) 4 (3.14) 0.3 (2.91) 0.3 (2.96)
Day 16, predose 7.3 (2.22) 6.9 (1.91) 0.3 (2.85) 0.5 (2.97)
Day 16, postdose 7.9 (2.53) 6.4 (2.28) 0.8 (3.40) 0.3 (2.64)
For absolute values, comparisons are against baseline, and for changes from
baseline, comparisons are between sildenafil and placebo.
*P0.01; †P0.05; ‡P0.063.
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Sildenafil had no effect on FMD, indicating that it did not
modulate endothelium-dependent vasomotion, either acutely
or after chronic treatment. There are conflicting data on the
acute effects of sildenafil on endothelium-dependent vasomo-
tor responses, with some reports of an improvement and other
reports showing no effect. Although these previous studies
have recruited different patients and used different method-
ologies, there are no apparent consistent differences to ex-
plain the different effects observed. For example, there are
positive and negative studies that used forearm plethysmog-
raphy20,22 or FMD9,11,21 and that recruited smokers9,21 or
patients with CAD.11,22 It should be noted that the use of a
clamp to hold the ultrasound probe in place, as well as
computerized analysis of arterial images, represent best prac-
tice in FMD studies, maximizing our confidence that the
finding is truly negative.
Given that FMD is largely NO mediated, it would seem
logical that sildenafil, by preserving NO-stimulated cGMP,
would improve FMD. However, this might only be expected
in subjects with impaired endothelium-dependent vasomotor
function at baseline. Although we did not include a normo-
tensive control group in the present study, in a further
(unpublished) study in our department, mean baseline FMD
was 5.6% (0.4%) in 44 healthy men and women with mean
age 42 years. Thus, endothelium-dependent vasomotion was
most likely impaired in the hypertensive subjects, even if this
was partly because they were, on average, older. A possible
explanation for the lack of effect of sildenafil on FMD in the
present study is that, compared with healthy subjects,32 NO
contributes relatively little to shear stress-induced vasodila-
tation at the brachial artery in hypertensive subjects. In
support of this hypothesis, it has been shown previously that
although vasodilatation to bradykinin in the forearm is NO
mediated in healthy subjects, in hypertensive subjects it is not
only reduced but is also mediated by a different pathway,
possibly involving endothelium-dependent hyperpolariza-
tion.33 Although not investigated previously, if similar
changes occur in the brachial artery, sildenafil may be
expected to have little or no effect on FMD in hypertension.
The relevance of an improvement in FMD to cardiovascu-
lar prognosis in hypertension is not clear. Although there is
evidence that prognosis is better in patients that demonstrate
improvements in FMD after treatment,34 FMD is not consis-
tently improved by antihypertensive drugs of different classes
although, with the possible exception of -blockers,35 these
drugs are substantially equivalent in reducing cardiovascular
events.36 Therefore, the lack of effect of sildenafil on FMD
should not, in itself, detract from its potential as an antihy-
pertensive in clinical practice.
Adverse effects from regular sildenafil treatment were
relatively common but generally transient and of mild-to-
moderate severity. Headache was experienced with a similar
frequency to that seen in other studies, but dyspepsia was
slightly more frequent.5 Myalgia (reported as an aching
sensation of the low back, buttocks, or legs) has generally
been reported to occur in 5% of men taking single doses37
but seems to occur more frequently with repeated adminis-
tration, for example, in 28% of subjects in the present study
and in 14% of subjects with pulmonary arterial hypertension.5
The lack of any rise in plasma creatine kinase in 4 of our
subjects with myalgia suggests that these symptoms were not
because of an underlying myositis.
As a consequence of the range of outcome measures and
assessment of these at multiple time points, a large number of
statistical comparisons have been made, presenting the pos-
sibility of type 1 statistical errors. However, this possibility is
of least concern for the data on the effect on ambulatory BP,
the primary outcome measure, because ambulatory BP was
only assessed at baseline and at the end of each treatment
period. Moreover, the effect of sildenafil on both 24-hour and
daytime BPs was highly statistically significant (P0.01).
Perspectives
This is the first controlled clinical trial to demonstrate the
potential of regular PDE5 inhibition in the chronic treatment
of hypertension. Although sildenafil effectively reduced BP,
its use in clinical practice is limited by its relatively short
duration of action, requiring it to be administered 3 times
daily. A modified-release preparation of sildenafil may over-
come this problem but is not currently available. Alterna-
tively, a longer acting PDE5 inhibitor, such as tadalafil, may
be more suitable for further studies on PDE5 inhibition in
hypertension. Assuming that such an agent is also shown to
reduce BP when administered chronically, characterization of
its adverse effect profile and an appropriate dosing strategy
for chronic use would be research priorities. Clarification of
the effects of chronic PDE5 inhibition on CF-PWV would
also be of interest. Studies comparing both antihypertensive
efficacy and tolerability of PDE5 inhibitors with established
antihypertensives would help to determine their place in
clinical practice. A potentially valuable indication for the
use of PDE5 inhibitors as antihypertensives is in men with
erectile dysfunction. However, it would be necessary to
demonstrate that the effect of PDE5 inhibition on erectile
function is maintained in the long term with the regular
dosing pattern that would be required for the treatment of
hypertension.
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